Updated on 2024/10/05

Information

 

写真a

 
FUKUDA HARUHISA
 
Organization
Faculty of Medical Sciences Department of Basic Medicine Associate Professor
Faculty of Medical Sciences Center for Cohort Studies(Concurrent)
Graduate School of Medical Sciences Department of Medicine(Concurrent)
Graduate School of Medical Sciences Department of Health Care Administration and Management(Concurrent)
Title
Associate Professor
Contact information
メールアドレス
Tel
0926426960
Profile
自治体が保有する保健・医療・介護・行政等の健康関連データを住民単位で統合したデータベースを構築し,今後20年間に渡り追跡評価することで,ライフコース健康学を創出する研究(LIFE Study)を実施している.健康の関連要因・健康の波及効果の解明,データサイエンスに立脚したEvidence-Based Health Policyの変革,ヘルスケア産業における開発プロセス革新などを通じて,健康寿命延伸と健康格差解消に向けた研究成果を産出することをめざしている.
External link

Research Areas

  • Life Science / Hygiene and public health

  • Life Science / Medical management and medical sociology

Degree

  • Ph.D

Research History

  • 九州大学科学技術イノベーション政策教育研究センター 協力教員

    2024.6 - Present

      More details

  • 大学共同利用機関法人 情報・システム研究機構 統計数理研究所 医療健康データ科学研究センター 客員准教授

    2023.4 - Present

      More details

  • Kyushu University Faculty of Medical Sciences Associate Professor

    2013.4 - Present

      More details

  • 一般財団法人 医療経済研究・社会保険福祉協会 医療経済研究機構

    一般財団法人 医療経済研究・社会保険福祉協会 医療経済研究機構

  • 東海大学(非常勤講師) 埼玉県立大学(非常勤講師)

Research Interests・Research Keywords

  • Research theme:医療経済評価

    Keyword:医療経済評価

    Research period: 2024

  • Research theme:医療政策

    Keyword:医療政策

    Research period: 2024

  • Research theme:医療の質

    Keyword:医療の質

    Research period: 2024

  • Research theme:ライフコース疫学

    Keyword:ライフコース疫学

    Research period: 2024

  • Research theme:データベース疫学

    Keyword:データベース疫学

    Research period: 2024

  • Research theme:Longevity Improvement & Fair Evidence Study:LIFE Study

    Keyword:healthy Longevity, lifecourse, database epidemiology, claims data, prevention

    Research period: 2019.4

  • Research theme:Healthcare Manage-Metrics

    Keyword:Healthcare management, quantitative analysis

    Research period: 2013.4 - 2019.3

  • Research theme:Regulatory science of medical devices

    Keyword:medical reimbursement system, device lag

    Research period: 2013.4 - 2015.3

  • Research theme:Economic and Epidemiological Research into Healthcare-Acquired Infections

    Keyword:surgical site infection, multi resistant infection, ventilator associated pneumonia, central line associated bloodstream infection, catheter-associated urinary tract infection, cost, antimicrobial drug

    Research period: 2011.4 - 2023.3

  • Research theme:Cost-Effectiveness Analysis of drug, device, and treatment

    Keyword:health technology assessment, cost of illness

    Research period: 2011.4 - 2022.3

Awards

  • 科学技術賞(開発部門)

    2024.4   文部科学省  

     More details

  • 文部科学大臣表彰「科学技術賞」(開発部門)

    2024.4   文部科学省   自治体と協働した健康データベース研究基盤の開発

     More details

    本開発では、自治体が保有する保健・医療・介護・行政データを住民単位で統合し、住民一人ひとりを20 年以上追跡し、ライフコースに渡る健康づくりに貢献可能な汎用的なデータベース研究基盤(LIFE Study)を開発した。
    本開発により、全国の研究者がデータを迅速かつ効果的に利用可能になり、我が国における健康データベース研究拠点が新たに創出された。具体的には、本研究拠点において、予防接種台帳・医療情報・感染症発生情報が統合解析され、新型コロナウイルスワクチンの有効性と安全性に関する多数のエビデンスが発信された。
    本成果は、我が国のEBPM を実践する上で、必須でありながらも欠落してきたデータベースをアカデミア主導で開発することで、健康寿命の延伸と健康格差の解消に向けた科学的エビデンスの創出に寄与している。

  • 第 25 回学術集会若⼿奨励最優秀賞

    2021.12   日本ワクチン学会  

  • 第25回日本ワクチン学会学術集会若手奨励最優秀賞

    2021.12   第25回日本ワクチン学会学術集会   第25回日本ワクチン学会学術集会の一般演題の発表内容が最も優れた演者に授与される賞

  • 第9回日本環境感染学会賞

    2013.3   日本環境感染学会  

  • 日本環境感染学会賞

    2013.3   日本環境感染学会  

  • 第11回日本クリニカルパス学会学術集会 優秀賞

    2010.12   日本クリニカルパス学会  

  • 日本クリニカルパス学会学術集会 優秀賞

    2010.12   日本クリニカルパス学会  

▼display all

Papers

  • Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS Study. Reviewed

    Fukuda H, Maeda M, Murata F

    Vaccine   in press   2023.3

     More details

    Language:Others  

  • Development of a Data Platform for Monitoring Personal Health Records in Japan: The Sustaining Health by Integrating Next-generation Ecosystems (SHINE) Study Reviewed

    Fukuda H, Murata F, Azuma S, Fujimoto M, Kudo S, Kobayashi Y, Saho K, Nakahara K, Ono R

    Plos One   18 ( 2 )   e0281512   2023.2

     More details

    Language:Others  

  • Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged ≥75 years in Japan: LIFE-VENUS Study. Reviewed International journal

    40 ( 34 )   5023 - 5029   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Risk of cardiovascular events leading to hospitalization after Streptococcus pneumoniae infection: A retrospective cohort LIFE study. BMJ Open Invited Reviewed International journal

    Nishimura N, Fukuda H.

    BMJ Open   in press   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Effectiveness of mRNA vaccines against SARS-CoV-2 infections during the periods of Delta and Omicron variant predominance in Japan: The VENUS Study. Reviewed International journal

    Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H.

    International Journal of Infectious Disease   in press   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijid.2022.10.001

  • Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study. Invited Reviewed International journal

    Fukuda H, Maeda M, Murata F, Murata Y.

    Journal of Alzheimer's Disease   in press   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3233/JAD-220200

  • Comparative risk of fracture in community-dwelling older adults initiating suvorexant versus Z-drugs: Results from LIFE Study. Reviewed International journal

    Adomi M, Maeda M, Murata F, Fukuda H.

    Journal of the American Geriatrics Society   in press   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jgs.18068

  • Development and Application of a Japanese Vaccine Database for Comparative Assessments in the Post-Authorization Phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. Reviewed International journal

    Ishiguro C, Mimura W, Murata F, Fukuda H.

    Vaccine   40 ( 42 )   6179 - 6186   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • The Longevity Improvement & Fair Evidence (LIFE) Study: Overview of the Study Design and Baseline Participant Profile. Reviewed

    Fukuda H, Ishiguro C, Ono R, Kiyohara K

    Journal of Epidemiology   33 ( 8 )   428 - 437   2022.3

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

  • NDB解析用データセットテーブルの開発 Reviewed

    福田治久, 佐藤大介, 白岩健, 福田敬

    保健医療科学   68 ( 2 )   2019.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    目的
    2011年度より第三者提供が開始されたレセプト情報・特定健診等情報データベース(NDB)の研究利用が不十分な状況にある.学術研究を加速化させ,エビデンスに基づいた医療政策を推進するためには,NDBの活用可能性を高めていく必要がある.本研究の目的は,臨床疫学研究および医療経済研究を行うのに有用性が高く,かつ,データ容量の効率性が高いNDB解析用データセットを構築することである.
    方法
    2009年4月から2016年12月の間の医科入院レセプトおよびDPCレセプトにおいて1度でも出現したことのある解析用患者IDを全データから無作為に25%分を抽出し,当該解析用患者IDの全期間における全診療行為情報を含む全レセプトデータを格納したNDBを用いた.臨床疫学研究および医療経済研究を行うのに有用性の高い解析用データセットテーブルに必要な変数について検討した.また,医科レセプトにおいては退院年月日情報が含まれていないことから,レセプトデータを用いた補完的な退院年月日を付加する方法について検討した.本検討では,退院年月日情報が含まれるDPCレセプトを用いて,入院年月日と診療実日数を用いる場合と,診療行為発生日を用いる場合のそれぞれの方法で退院年月日を算出し,実際のDPCレセプトに記載されている退院年月日との一致状況について検証した.
    結果
    NDBに含まれるレコード識別情報を有機的に連結させた解析用データセットテーブルとして,以下の11テーブルを開発した:患者(KAN),レセプト(REC),傷病名(SYO),診療行為(SIN),薬剤(IYA),特定器材(TOK),調剤(TYO),調剤加算料等(TKA),DPC診断群分類(BUD),医療機関(IRK),入院(ADM).医療機関(IRK)を除く各テーブルは解析用患者IDによって相互に突合することができる.また,医科レセプトにおける補完退院年月日は,診療行為(SI),医薬品(IY),特定器材(TO),コーディングデータ(CD)の各レコードにおける診療行為年月日の最終日情報を用いることで,99.83%の入院症例において正しい退院年月日を付加することができた.
    結論
    本研究において開発した解析用データセットテーブルを用いることで,NDBを用いた臨床疫学研究および医療経済研究を即座に実施可能な環境をもたらすことができる.

  • 手術部位感染発生率の病院間比較手法の検証:JANISデータを用いた全国多施設研究 Reviewed

    福田 治久

    日本環境感染学会誌   28 ( 2 )   63 - 73   2013.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • JANIS/DPC統合データベース構築による胃手術における手術部位感染発生による追加的医療資源の推定 Reviewed

    福田 治久

    日本環境感染学会誌   27 ( 6 )   389 - 396   2012.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    背景:
    医療政策に費用対効果の視点を導入する議論は,感染制御領域においても例外ではない.しかしながら,費用対効果の検証に不可欠な,我が国における疾病費用に関する検証は十分に実施されていない.本研究の目的は胃手術の実施症例に対する手術部位感染(SSI)発生による追加的医療資源を推定することである.
    方法:
    2007年7月から2010年12月の間に6病院において胃手術を実施した症例を解析対象に定めた.使用データは,JANISデータとDPCデータを突合して構築したJANIS/DPC統合データベースである.推定には,従属変数を術後在院日数および術後医療費(出来高換算)に定め,曝露変数をSSIの有無および深さに定めた一般化線形モデルを用いた.
    結果:
    解析対象症例数は857症例であり,感染者数は42症例であった.SSI発生による術後在院日数の延長および術後医療費の増加は,表層切開創SSIでは6.6日および206千円,深部切開創SSIでは12.8日および398千円,臓器/体腔SSIでは18.3日および1,021千円と推定された.
    結論:
    本研究は,JANISデータとDPCデータという既存データを突合するJANIS/DPC統合データベースを構築するとともに,6施設を対象に胃手術症例におけるSSI発生による追加的医療資源を推定した.本推定値は,感染制御方策の費用対効果の検証に活用可能である.

  • Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Reviewed International journal

    Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    Human vaccines & immunotherapeutics   20 ( 1 )   2350091 - 2350091   2024.12   ISSN:2164-5515 eISSN:2164-554X

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    Although previous studies have shown no increased mortality risk after the primary series of COVID-19 mRNA vaccines, reports on booster doses are lacking. This study aimed to evaluate mortality risk after the mRNA vaccine boosters in addition to the primary series. This nested case-control study included two age-specific cohorts (18-64 and ≥65 years as of February 1, 2021) in two municipalities. All deaths were identified and matched five controls for each case at each date of death (index date) with risk set sampling according to municipality, age, and sex. The adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for mRNA vaccines (first to fifth doses) were estimated by comparing with no vaccination within 21 and 42 days before the index date using a conditional logistic regression model. The 18-64-years cohort comprised 431 cases (mean age, 57.0 years; men, 58.2%) and 2,155 controls (mean age, 56.0; men, 58.2%), whereas the ≥65-years cohort comprised 12,166 cases (84.0; 50.2%) and 60,830 controls (84.0, 50.2%). The aORs (95% CI) in 0-21 days after the third and fourth doses in the 18-64-years cohort were 0.62 (0.24, 1.62) and 0.38 (0.08, 1.84), respectively. The aORs (95% CI) after the third to fifth doses in the ≥65 years cohort were 0.36 (0.31, 0.43), 0.30 (0.25, 0.37), and 0.26 (0.20, 0.33), respectively. In conclusion, booster doses of mRNA vaccines do not increase mortality risk. These findings could help subsequent vaccine campaigns and alleviate vaccine hesitancy.

    DOI: 10.1080/21645515.2024.2350091

    Web of Science

    Scopus

    PubMed

    researchmap

  • Statin use and risk of Parkinson’s Disease among older adults in Japan: A nested case-control study using the LIFE study. Reviewed

    Ge S, Zha L, Kimura Y, Narii N, Okita Y, Shimoura Y, Komatsu M, Gon Y, Komukai S, Murata F, Maeda M, Kiyohara K, Sobue T, Kitamura T, Fukuda H.

    Brain Communications   6 ( 3 )   fcae195   2024.9

     More details

    Authorship:Last author  

  • Protective effects of 23-valent pneumococcal polysaccharide vaccination against mortality: The VENUS Study. Reviewed

    Murata F, Maeda M, Fukuda H.

    Open Forum Infectious Diseases   11 ( 9 )   ofae530   2024.9

     More details

    Authorship:Last author, Corresponding author  

  • Post-discharge functional outcomes in older patients with sepsis.

    Ge S, Tanaka A, Zha L, Narii N, Shimomura Y, Komatsu M, Komukai S, Murata F, Maeda M, Kiyohara K, Kitamura T, Fukuda H.

    Critical Care   28   281   2024.9

     More details

    Authorship:Last author  

  • Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin Ⅱ receptor blockers: a retrospective cohort study using LIFE Study data. Reviewed

    Uemura R, Hieda M, Maeda M, Murata F, Fukuda H.

    Hypertension Research   47 ( 9 )   2275 - 2283   2024.9

     More details

    Authorship:Last author, Corresponding author  

  • Association of statin use with dementia risk among older adults in Japan: A nested case-control study using the LIFE study. Reviewed

    Ge S, Kitamura T, Narii N, Okita Y, Zha L, Komatsu M, Komukai S, Murata F, Maeda M, Gon Y, Kimura Y, Kiyohara K, Sobue T, Fukuda H.

    Journal of Alzheimer's Disease   100 ( 3 )   987 - 998   2024.9

     More details

    Authorship:Last author  

  • Evaluation of antimicrobial selective pressure using the multicenter semiautomatic surveillance system, Japan Surveillance for Infection Prevention and Healthcare Epidemiology. Reviewed

    Hayakawa K, Asai Y, Tajima T, Endo M, Kawabata J, Fujii N, Sakaguchi M, Ishioka H, Tsuzuki S, Matsunaga N, Ohmagari N, Fukuda H.

    Journal of Infection and Public Health   17   102474   2024.9

     More details

    Authorship:Last author  

  • Evaluation of antimicrobial selective pressure using the multicenter semiautomatic surveillance system Japan surveillance for infection prevention and healthcare epidemiology

    Hayakawa, K; Asai, Y; Tajima, T; Endo, M; Kawabata, J; Fujii, N; Sakaguchi, M; Ishioka, H; Tsuzuki, S; Matsunaga, N; Ohmagari, N; Fukuda, H

    JOURNAL OF INFECTION AND PUBLIC HEALTH   17 ( 8 )   102474   2024.8   ISSN:1876-0341 eISSN:1876-035X

     More details

    Language:English   Publisher:Journal of Infection and Public Health  

    Background: Evaluating the selective pressure of antimicrobials on bacteria is important for promoting antimicrobial stewardship programs (ASPs). The aim of this study was to assess the selective pressure of antimicrobials by evaluating their use (carbapenem [CBP] and CBP-sparing therapy) over time and the detection status of CBP-resistant organisms using multicenter data. Methods: Among the facilities whose data were registered in the Japan Surveillance for Infection Prevention and Healthcare Epidemiology from 2017 to 2020, those that had data on the use of CBP and CBP-sparing therapy (fluoroquinolones [FQs], cefmetazole [CMZ], piperacillin–tazobactam [PIP/TAZ], ampicillin–sulbactam [ABPC/SBT], ceftriaxone/cefotaxime [CTRX/CTX], CAZ (ceftazidime), cefepime [CFPM], and aminoglycosides [AGs]) as well as on CBP-resistant Enterobacterales (CRE) and CBP-resistant Pseudomonas aeruginosa (CRPA) detection were included. Alcohol-based hand rubbing (ABHR) usage was also analyzed. Regression analyses, including multivariable regression analysis, were performed to evaluate trends. The association of antimicrobial use density (AUD) with CRE and CRPA detection rates was evaluated. Results: In 28 facilities nationwide, CBP, FQ, CAZ, AG, and PIP/TAZ use decreased over the 3-year period, whereas the use of CMZ, ABPC/SBT, CTRX/CTX, CFPM, and ABHR as well as the rates of CRE and CRPA detection increased. The average AUD did not significantly correlate with CRE and CRPA detection rates. The multivariable regression analysis did not reveal any significant correlation between each AUD or ABHR and CRE or CRPA detection. Conclusion: CBP and ABHR use showed a decreasing and an increasing trend, respectively, while CRPA and CRE detection rates exhibited a gradual increase. The considerably low CRE and CRPA detection rates suggest that slight differences in numbers may have been observed as excessive trend changes. Further investigation is warranted to evaluate selective pressure while considering the characteristics of ASP and the mechanisms underlying resistance.

    DOI: 10.1016/j.jiph.2024.102474

    Web of Science

    Scopus

    PubMed

  • Postdischarge functional outcomes in older patients with acute heart failure in Japan: the Longevity Improvement & Fair Evidence study. Reviewed International journal

    Nobuhiro Narii, Tetsuhisa Kitamura, Atsushi Hirayama, Yoshimitsu Shimomura, Ling Zha, Masayo Komatsu, Sho Komukai, Yohei Sotomi, Katsuki Okada, Yasushi Sakata, Fumiko Murata, Megumi Maeda, Kosuke Kiyohara, Tomotaka Sobue, Haruhisa Fukuda

    Age and ageing   53 ( 7 )   afae152   2024.7   ISSN:0002-0729 eISSN:1468-2834

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The association between care needs level (CNL) at hospitalisation and postdischarge outcomes in older patients with acute heart failure (aHF) has been insufficiently investigated. METHODS: This population-based cohort study was conducted using health insurance claims and CNL data of the Longevity Improvement & Fair Evidence study. Patients aged ≥65 years, discharged after hospitalisation for aHF between April 2014 and March 2022, were identified. CNLs at hospitalisation were classified as no care needs (NCN), support level (SL) and CNL1, CNL2-3 and CNL4-5 based on total estimated daily care time as defined by national standard criteria, and varied on an ordinal scale between SL&CNL1 (low level) to CNL4-5 (fully dependent). The primary outcomes were changes in CNL and death 1 year after discharge, assessed by CNL at hospitalisation using Cox proportional hazard models. RESULTS: Of the 17 724 patients included, 7540 (42.5%), 4818 (27.2%), 3267 (18.4%) and 2099 (11.8%) had NCN, SL&CNL1, CNL2-3 and CNL4-5, respectively, at hospitalisation. One year after discharge, 4808 (27.1%), 3243 (18.3%), 2968 (16.7%), 2505 (14.1%) and 4200 (23.7%) patients had NCN, SL&CNL1, CNL2-3, CNL4-5 and death, respectively. Almost all patients' CNLs worsened after discharge. Compared to patients with NCN at hospitalisation, patients with SL&CNL1, CNL2-3 and CNL4-5 had an increased risk of all-cause death 1 year after discharge (hazard ratio [95% confidence interval]: 1.19 [1.09-1.31], 1.88 [1.71-2.06] and 2.56 [2.31-2.84], respectively). CONCLUSIONS: Older patients with aHF and high CNL at hospitalisation had a high risk of all-cause mortality in the year following discharge.

    DOI: 10.1093/ageing/afae152

    Web of Science

    Scopus

    PubMed

    researchmap

  • Association of Statin Use with Dementia Risk Among Older Adults in Japan: A Nested Case-Control Study Using the LIFE Study. International journal

    Sanyu Ge, Tetsuhisa Kitamura, Ling Zha, Masayo Komatsu, Sho Komukai, Fumiko Murata, Megumi Maeda, Yasufumi Gon, Yasuyoshi Kimura, Kosuke Kiyohara, Tomotaka Sobue, Haruhisa Fukuda

    Journal of Alzheimer's disease : JAD   100 ( 3 )   987 - 998   2024.7   ISSN:13872877

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Previous studies have shown a possible association between statin use and a decreased risk of dementia, but the association has not been sufficiently established, especially in the super-aging society of Japan. OBJECTIVE: This study aimed to determine the association between statin use and the risk of dementia among Japanese participants aged> =65 years old. METHODS: Data from the Longevity Improvement and Fair Evidence (LIFE) Study were utilized, including medical and long-term care (LTC) claim data from 17 municipalities between April 2014 and December 2020. A nested case-control study was conducted with one case matched to five controls based on age, sex, municipality, and year of cohort entry. We used a conditional logistic regression model to calculate the odds ratios (ORs) and 95% confidence intervals (95% CIs). RESULTS: This study included 57,302 cases and 283,525 controls, with 59.7% of the participants being woman. After adjusting for potential confounders, statin use was associated with a lower risk of dementia (OR, 0.70; 95% CI: 0.68-0.73) and Alzheimer's disease (OR: 0.66; 95% CI: 0.63-0.69). Compared with non-users, the ORs of dementia were as follows: 1.42 (1.34-1.50) for 1-30 total standardized daily dose (TSDD), 0.91 (0.85-0.98) for 31-90 TSDD, 0.63 (0.58-0.69) for 91-180 TSDD, and 0.33 (0.31-0.36) for >180 TSDD in dose-analysis. CONCLUSIONS: Statin use is associated with a reduced risk of dementia and Alzheimer's disease among older Japanese adults. A low cumulative statin dose is associated with an increased risk of dementia, whereas a high cumulative statin dose is a protective factor against dementia.

    DOI: 10.3233/JAD-240113

    Scopus

    PubMed

    researchmap

  • Validity of Vaccination Information in the COVID-19 Surveillance System in Japan: Implications for Developing Efficient and Highly Valid Data Collection Systems in Future Pandemics. Reviewed

    Horie Y, Ishiguro C, Mimura W, Maeda M, Murata, Fukuda H

    GHM Open   in press   2024.7

     More details

    Authorship:Last author  

    researchmap

  • Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin II receptor blockers: a retrospective cohort study using LIFE Study data

    Uemura, R; Hieda, M; Maeda, M; Murata, F; Fukuda, H

    HYPERTENSION RESEARCH   2024.6   ISSN:0916-9636 eISSN:1348-4214

     More details

    Language:English   Publisher:Hypertension Research  

    There is insufficient evidence that angiotensin-converting enzyme inhibitors (ACEIs) can reduce pneumonia by inducing a dry cough that confers a protective effect on the airway. To increase the evidence base on the clinical use of ACEIs for pneumonia prevention, this retrospective cohort study aimed to comparatively examine the risk of pneumonia-related hospitalization between ACEI initiators and angiotensin II receptor blocker (ARB) initiators using claims data from two Japanese municipalities. We identified persons who were newly prescribed any ACEI or ARB as their first antihypertensive agent between April 2016 and March 2020. The Fine-Gray method was applied to a Cox proportional hazards model to estimate the subdistribution hazard ratio (HR) of ACEI use (reference: ARB use) for pneumonia-related hospitalization, with death treated as a competing risk. Sex, age, comorbidities, medications, and pneumococcal immunization were included as covariates. The analysis was conducted on 1421 ACEI initiators and 9040 ARB initiators, and the adjusted subdistribution HR of ACEI use was estimated to be 1.21 (95% confidence interval: 0.89–1.65; P = 0.22). ACEI initiation did not demonstrate any significant preventive effect against pneumonia-related hospitalization relative to ARB initiation. There remains a lack of strong evidence on the protective effects of ACEIs, and further research is needed to ascertain the benefits of their use in preventing pneumonia. (Figure presented.)

    DOI: 10.1038/s41440-024-01768-7

    Web of Science

    Scopus

    PubMed

  • Statin use and risk of Parkinson’s disease among older adults in Japan: a nested case-control study using the longevity improvement and fair evidence study Reviewed

    Sanyu Ge, Ling Zha, Yasuyoshi Kimura, Yoshimitsu Shimomura, Masayo Komatsu, Yasufumi Gon, Sho Komukai, Fumiko Murata, Megumi Maeda, Kosuke Kiyohara, Tomotaka Sobue, Tetsuhisa Kitamura, Haruhisa Fukuda

    Brain Communications   6 ( 3 )   fcae195   2024.6   eISSN:2632-1297

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    Abstract

    The association between statin use and the risk of Parkinson’s disease remains inconclusive, particularly in Japan’s super-aging society. This study aimed to investigate the potential association between statin use and the risk of Parkinson’s disease among Japanese participants aged ≥65 years. We used data from the Longevity Improvement and Fair Evidence Study, which included medical and long-term care claims data from April 2014 to December 2020 across 17 municipalities. Using a nested case-control design, we matched one case to five controls based on age, sex, municipality, and cohort entry year. A conditional logistic regression model was used to estimate the odds ratios with 95% confidence intervals. Among the 56,186 participants (9,397 cases and 46, 789 controls), 53.6% were women. The inverse association between statin use and Parkinson’s disease risk was significant after adjusting for multiple variables (odds ratio: 0.61; 95% confidence interval: 0.56–0.66). Compared with non-users, the dose analysis revealed varying odds ratios: 1.30 (1.12–1.52) for 1–30 total standard daily doses, 0.77 (0.64–0.92) for 31-90 total standard daily doses, 0.62 (0.52–0.75) for 91–180 total standard daily doses, and 0.30 (0.25–0.35) for >180 total standard daily doses. Statin use among older Japanese adults was associated with a decreased risk of Parkinson’s disease. Notably, lower cumulative statin doses were associated with an elevated risk of Parkinson’s disease, whereas higher cumulative doses exhibited protective effects against Parkinson’s disease development.

    DOI: 10.1093/braincomms/fcae195

    Web of Science

    Scopus

    PubMed

    researchmap

  • Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database. Reviewed International journal

    Satoshi Yamate, Chieko Ishiguro, Haruhisa Fukuda, Satoshi Hamai, Yasuharu Nakashima

    PloS one   19 ( 6 )   e0305320   2024.6   ISSN:1932-6203

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Rebamipide has been widely co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) in Japan for decades. This study aimed to evaluate the effectiveness of rebamipide in preventing upper gastrointestinal bleeding in new users of NSAIDs without risk factors of NSAID-induced ulcers other than age. METHODS: A nested case-control study was conducted using medical claims data of 1.66 million inhabitants of 17 municipalities participating in Japan's Longevity Improvement & Fair Evidence study. The cohort entry (t0) corresponded to a new user of NSAIDs for osteoarthritis or low back pain. Patients with risk factors of NSAID-induced ulcers other than age were excluded. Cases were defined as patients who underwent gastroscopy for upper gastrointestinal bleeding (occurrence date was defined as index date). A maximum of 10 controls were selected from non-cases at the index date of each case by matching sex, age, follow-up time, and type and dosage of NSAIDs. Exposure to rebamipide was defined as prescription status from t0 to index date: Non-user (rebamipide was not co-prescribed during the follow-up period), Continuous-user (rebamipide was co-prescribed from t0 with the same number of tablets as NSAIDs), and Irregular-user (neither Non-user nor Continuous-user). Conditional logistic regression analysis was conducted to estimate each category's odds ratio compared to non-users. FINDINGS: Of 67,561 individuals who met the inclusion criteria, 215 cases and 1,516 controls were selected. Compared with that of Non-users, the odds ratios and 95% confidence interval were 0.65 (0.44-0.96) for Continuous-users and 2.57 (1.73-3.81) for Irregular-users. CONCLUSIONS: Continuous co-prescription of rebamipide significantly reduced the risk of upper gastrointestinal bleeding in an Asian cohort of new users of NSAIDs with osteoarthritis or low back pain without risk factors other than age.

    DOI: 10.1371/journal.pone.0305320

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

    Mimura Wataru, Ishiguro Chieko, Terada-Hirashima Junko, Matsunaga Nobuaki, Sato Shuntaro, Kawazoe Yurika, Maeda Megumi, Murata Fumiko, Fukuda Haruhisa

    Journal of Epidemiology   34 ( 6 )   278 - 285   2024.6   ISSN:09175040 eISSN:13499092

     More details

    Language:English   Publisher:Japan Epidemiological Association  

    <p><b>Background:</b> We evaluated the effectiveness of the BNT162b2 vaccine against infection, symptomatic infection, and hospitalization in older people during the Delta-predominant period (July 1 to September 30, 2021).</p><p><b>Methods:</b> We performed a population-based cohort study in an older adult population aged ≥65 years using data from the Vaccine Effectiveness, Networking, and Universal Safety Study conducted from January 1, 2019, to September 30, 2021, in Japan. We matched BNT162b2-vaccinated and -unvaccinated individuals in a 1:1 ratio on the date of vaccination of the vaccinated individual. We evaluated the effectiveness of the vaccine against infection, symptomatic infection, and coronavirus disease (COVID-19)-related hospitalization by comparing the vaccinated and unvaccinated groups. We estimated the risk ratio and risk difference using the Kaplan–Meier method with inverse probability weighting. The vaccine effectiveness was calculated as (1 − risk ratio) × 100%.</p><p><b>Results:</b> The study included 203,574 matched pairs aged ≥65 years. At 7 days after the second dose, the vaccine effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization was 78.1% (95% confidence interval [CI], 65.2–87.8%), 79.1% (95% CI, 64.6–88.9%), and 93.5% (95% CI, 83.7–100%), respectively.</p><p><b>Conclusion:</b> BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan’s older adult population aged ≥65 years during the Delta-predominant period.</p>

    DOI: 10.2188/jea.je20230106

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged ≥65 years during the Delta variant predominance in Japan: The VENUS Study. Reviewed

    Mimura W, Ishiguro C*, Terada-Hirashima J, Matsunaga N, Sato S, Kawazoe Y, Maeda M, Murata F, Fukuda H.

    Journal of Epidemiology   34 ( 6 )   278 - 285   2024.6

     More details

    Authorship:Last author  

  • Analysis of post-extraction bleeding in patients taking antithrombotic therapy using data from the longevity improvement and fair evidence study

    Nakamura, J; Nakatsuka, K; Uchida, K; Akisue, T; Maeda, M; Murata, F; Fukuda, H; Ono, R

    GERODONTOLOGY   41 ( 2 )   269 - 275   2024.6   ISSN:0734-0664 eISSN:1741-2358

     More details

    Language:English   Publisher:Gerodontology  

    Background: Several studies have investigated post-extraction bleeding in patients on antithrombotic therapy, but most included a small sample size. Objective: This study aimed to analyse post-extraction bleeding in patients on antithrombotic therapy using data from a large database. Materials and Methods: Claims data of National Health Insurance and Late-Stage Elderly Healthcare System enrollees who underwent tooth extraction between October 2014 and March 2019 (n = 107 767) in a large multiregional cohort study (Longevity Improvement and Fair Evidence study) were included. Antithrombotic therapy was determined based on the drug codes used at the time of tooth extraction (classified into six groups: no antithrombotic, single antiplatelet, dual antiplatelet, Direct Oral Anticoagulant, warfarin and combined antiplatelet and anticoagulant therapies). The outcome was defined as the presence of “post-extraction bleeding” as a receipt disease name in the same month as tooth extraction. To examine the association between antithrombotic therapy and post-extraction bleeding in detail, multiple logistic regression analysis was performed with post-extraction bleeding as the objective variable; each antithrombotic therapy as the explanatory variable; and age, sex and comorbidities as adjustment variables. Results: Antithrombotic therapy was administered in 14 343 patients (13.3%), and post-extraction bleeding was observed in 419 patients (0.4%). The rate of post-extraction bleeding was significantly lower in the no antithrombotic therapy and single antiplatelet groups than that in the other groups (odds ratio: 2.00–9.02). Conclusion: The frequency of post-extraction bleeding is high in patients on anticoagulation or dual antithrombotic therapy. Therefore, careful preparation before extraction is necessary in these patients.

    DOI: 10.1111/ger.12703

    Web of Science

    Scopus

    PubMed

  • Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged≧65 Years During the Delta Variant Predominance in Japan: The VENUS Study(タイトル和訳中)

    Mimura Wataru, Ishiguro Chieko, Terada-Hirashima Junko, Matsunaga Nobuaki, Sato Shuntaro, Kawazoe Yurika, Maeda Megumi, Murata Fumiko, Fukuda Haruhisa

    Journal of Epidemiology   34 ( 5-6 )   278 - 285   2024.6   ISSN:0917-5040

     More details

    Language:English   Publisher:(一社)日本疫学会  

  • Investigating the epidemiology and outbreaks of scabies in Japanese households, residential care facilities, and hospitals using claims data: the Longevity Improvement & Fair Evidence (LIFE) study

    Yamaguchi, Y; Murata, F; Maeda, M; Fukuda, H

    IJID REGIONS   11   100353   2024.6   eISSN:2772-7076

     More details

    Language:English   Publisher:IJID Regions  

    Objectives: This study aimed to characterize the epidemiology of scabies and its outbreaks in Japanese households, residential care facilities (RCFs), and hospitals using claims data. Methods: This descriptive epidemiological study was conducted using claims data from eight municipalities in Japan. Scabies cases were identified using a combination of recorded diagnoses and administered medications. The study period was from April 2015 to March 2019. Outbreaks were defined as ≥2 cases of scabies occurring within a calendar month at a single household, RCF, or hospital. Results: We identified 857 scabies cases for analysis. The annual prevalence of scabies ranged from 40 to 67 per 100,000 beneficiaries. The annual attack rate of scabies was found to be highest in RCFs (21 per 1000 RCFs), followed by hospitals (11 per 1000 hospitals) and households (0.25 per 1000 households). The annual outbreak attack rate was also highest in RCFs (4.0 per 1000 RCFs), followed by hospitals (1.6 per 1000 hospitals) and household (0.027 per household). The patterns of outbreaks varied widely among the RCFs. Conclusions: The study showcases the potential of claims data for detecting infectious disease outbreaks, which could provide valuable insight for the future management and prevention of scabies. Infection control of scabies in RCFs is crucial in aging societies.

    DOI: 10.1016/j.ijregi.2024.03.008

    Web of Science

    Scopus

    PubMed

  • Incidence of post-COVID psychiatric disorders according to the periods of SARS-CoV-2 variant dominance: The LIFE study

    Murata, F; Maeda, M; Murayama, K; Nakao, T; Fukuda, H

    JOURNAL OF PSYCHIATRIC RESEARCH   174   12 - 18   2024.6   ISSN:0022-3956 eISSN:1879-1379

     More details

    Language:English   Publisher:Journal of Psychiatric Research  

    This retrospective cohort study examined the incidence of post-COVID psychiatric disorders in older adults according to hospitalization status and SARS-CoV-2 variant period in Japan. Claims data, COVID-19 case-related information, and vaccination records were obtained from three Japanese municipalities. We identified individuals aged ≥65 years who had COVID-19 or other respiratory tract infection (RTI) between March 2021 and December 2022. Participants were categorized into non-hospitalized and hospitalized patients, and the study period was divided into the Alpha (March to May 2021), Delta (June to December 2021), Omicron BA.1/BA.2 (January to June 2022), and Omicron BA.5 (July to December 2022) periods. Modified Poisson regression analyses were performed to estimate the incidence rate ratios (IRRs) for the occurrence of psychiatric disorders (organic mental disorders, psychotic disorders, mood disorders, anxiety disorders, and insomnia) three months after COVID-19 (reference: other RTI). For overall psychiatric disorders, we analyzed 19,489 non-hospitalized patients (COVID-19: 6,728, Other RTI: 12,761) and 2925 hospitalized patients (COVID-19: 1,036, Other RTI: 1889). When compared with other RTI cases, COVID-19 cases had significantly lower IRRs for overall psychiatric disorders in both non-hospitalized (IRR: 0.59, P < 0.001) and hospitalized cases (IRR: 0. 83, P = 0.045) during the Omicron BA.1/BA.2 period, but only in non-hospitalized cases (IRR: 0.45, P < 0.001) during the Omicron BA.5 period. The incidences of the individual post-COVID psychiatric disorders varied according to disorder type, hospitalization status, and SARS-CoV-2 variant period. These findings provide a foundation for further research to explore these variations and improve the provision of psychiatric care in future epidemics.

    DOI: 10.1016/j.jpsychires.2024.04.010

    Web of Science

    Scopus

    PubMed

  • Validity of claims-based definition of number of remaining teeth in Japan: Results from the Longevity Improvement and Fair Evidence Study

    Tamada, Y; Kusama, T; Ono, S; Maeda, M; Murata, F; Osaka, K; Fukuda, H; Takeuchi, K

    PLOS ONE   19 ( 5 )   e0299849   2024.5   ISSN:1932-6203

     More details

    Language:English   Publisher:PLoS ONE  

    Background Secondary healthcare data use has been increasing in the dental research field. The validity of the number of remaining teeth assessed from Japanese dental claims data has been reported in several studies, but has not been tested in the general population in Japan. Objectives To evaluate the validity of the number of remaining teeth assessed from Japanese dental claims data and assess its predictability against subsequent health deterioration. Methods We used the claims data of residents of a municipality that implemented oral health screening programs. Using the number of teeth in the screening records as the reference standard, we assessed the validity of the claims-based number of teeth by calculating the mean differences. In addition, we assessed the association between the claims-based number of teeth and pneumococcal disease (PD) or Alzheimer’s disease (AD) in adults aged ≥65 years using Cox proportional hazards analyses. Results Of the 10,154 participants, the mean number of teeth assessed from the claims data was 20.9, that in the screening records was 20.5, and their mean difference was 0.5. During the 3-year follow-up, PD or AD onset was observed in 10.4% (3,212/30,838) and 5.3% (1,589/ 30,207) of participants, respectively. Compared with participants with ≥20 teeth, those with 1–9 teeth had a 1.29 (95% confidence interval [CI]: 1.17–1.43) or 1.19 (95% CI: 1.04–1.36) times higher risk of developing PD or AD, respectively. Conclusion High validity of the claims-based number of teeth was observed. In addition, the claims-based number of teeth was associated with the risk of PD and AD.

    DOI: 10.1371/journal.pone.0299849

    Web of Science

    Scopus

    PubMed

  • Incidence of post-COVID psychiatric disorders according to the periods of SARS-CoV-2 variant dominance: The LIFE Study. Reviewed

    Murata F, Maeda M, Murayama K, Nakao T, Fukuda H

    Journal of Psychiatric Research   174   12 - 18   2024.4

     More details

    Authorship:Last author, Corresponding author   Language:Others   Publishing type:Research paper (scientific journal)  

  • Effect of participation in a surgical site infection surveillance programme on hospital performance in Japan: a retrospective study

    Kawabata, J; Fukuda, H; Morikane, K

    JOURNAL OF HOSPITAL INFECTION   146   183 - 191   2024.4   ISSN:0195-6701 eISSN:1532-2939

     More details

    Language:English   Publisher:Journal of Hospital Infection  

    Background: The effect of hospital participation in the Japan Nosocomial Infection Surveillance (JANIS) programme on surgical site infection (SSI) prevention is unknown. Aim: To determine if participation in the JANIS programme improved hospital performance in SSI prevention. Methods: This retrospective before–after study analysed Japanese acute care hospitals that joined the SSI component of the JANIS programme in 2013 or 2014. The study participants comprised patients who had undergone surgeries targeted for SSI surveillance at JANIS hospitals between 2012 and 2017. Exposure was defined as the receipt of an annual feedback report 1 year after participation in the JANIS programme. The changes in standardized infection ratio (SIR) from 1 year before to 3 years after exposure were calculated for 12 operative procedures: appendectomy, liver resection, cardiac surgery, cholecystectomy, colon surgery, caesarean section, spinal fusion, open reduction of long bone fracture, distal gastrectomy, total gastrectomy, rectal surgery, and small bowel surgery. Logistic regression models were used to analyse the association of each post-exposure year with the occurrence of SSI. Findings: In total, 157,343 surgeries at 319 hospitals were analysed. SIR values declined after participation in the JANIS programme for procedures such as liver resection and cardiac surgery. Participation in the JANIS programme was significantly associated with reduced SIR for several procedures, especially after 3 years. The odds ratios in the third post-exposure year (reference: pre-exposure year) were 0.86 [95% confidence interval (CI) 0.79–0.84] for colon surgery, 0.72 (95% CI 0.56–0.92) for distal gastrectomy, and 0.77 (95% CI 0.59–0.99) for total gastrectomy. Conclusion: Participation in the JANIS programme was associated with improved SSI prevention performance in several procedures in Japanese hospitals after 3 years.

    DOI: 10.1016/j.jhin.2023.02.018

    Web of Science

    Scopus

    PubMed

  • 生活保護受給開始前後での医科・歯科医療費の変化 LIFE Study

    塩田 千尋, 竹内 研時, 玉田 雄大, 草間 太郎, 福田 治久, 小坂 健

    口腔衛生学会雑誌   74 ( 増刊 )   112 - 112   2024.4   ISSN:0023-2831

     More details

    Language:Japanese   Publisher:(一社)日本口腔衛生学会  

    researchmap

  • 歯周病と新規糖尿病発症の併存と年間医療費との関連 LIFE Study

    衣川 安奈, 竹内 研時, 玉田 雄大, 草間 太郎, 佐藤 美寿々, 福田 治久, 小坂 健

    口腔衛生学会雑誌   74 ( 増刊 )   122 - 122   2024.4   ISSN:0023-2831

     More details

    Language:Japanese   Publisher:(一社)日本口腔衛生学会  

    researchmap

  • 日本人高齢者におけるClaimed-based frailty index LIFE Study(Claims-based Frailty Index in Japanese Older Adults: A Cohort Study Using LIFE Study Data)

    Nakatsuka Kiyomasa, Ono Rei, Murata Shunsuke, Akisue Toshihiro, Fukuda Haruhisa

    Journal of Epidemiology   34 ( 3-4 )   112 - 118   2024.4   ISSN:0917-5040

     More details

    Language:English   Publisher:(一社)日本疫学会  

    <Highlight>●本研究の目的は、医療レセプトデータベースからフレイルを判定するClaimed-based frailty index(CFI)が、日本人高齢者にも適用できるかを、有害事象の予測を通して検討することである。●2014年4月から2019年3月に、ある12市町村の国民健康保険後期高齢者医療制度に加入している高齢者を対象にした。●CFIによるprefrail、frail群はrobust群と比較して、有意に要介護認定・死亡が起こりやすいことが明らかとなった。●本研究は、要介護認定・死亡の予測を通して、日本人高齢者におけるレセプトデータベースでも、CFIが適用できることを明らかにした。(著者抄録)

  • Medication adherence and associated factors in newly diagnosed hypertensive patients in Japan: the LIFE study

    Sagara, K; Goto, K; Maeda, M; Murata, F; Fukuda, H

    JOURNAL OF HYPERTENSION   42 ( 4 )   718 - 726   2024.4   ISSN:0263-6352 eISSN:1473-5598

     More details

    Language:English   Publisher:Journal of Hypertension  

    Hypertension is the leading cardiovascular risk factor worldwide. However, in Japan, only 30% of patients have their blood pressure controlled under 140/90 mmHg, and nonadherence to antihypertensives is thought to be a reason for the poor control of hypertension. We therefore sought to assess the adherence to hypertension treatment and to evaluate factors influencing patients’ adherence in a large, representative sample of the Japanese population. To this end, we analyzed claims data from the LIFE Study database, which includes 112 506 Japanese adults with newly diagnosed hypertension. Medication adherence was measured for a year postdiagnosis using the proportion of days covered (PDC) method. Factors associated with adherence to antihypertensives were also assessed. Among the total 112 506 hypertensive patients, the nonadherence rate (PDC ≤ 80%) for antihypertensives during the first year after initiation of the treatment was 26.2%. Younger age [31 – 35 years: odds ratio (OR), 0.15; 95% confidence interval (95% CI), 0.12 – 0.19 compared with 71 – 74-year-old patients], male gender, monotherapy, and diuretics use [OR, 0.87; 95% CI, 0.82 – 0.91 compared with angiotensin II receptor blockers (ARBs)] were associated with poor adherence in the present study. Cancer comorbidity (OR, 0.84; 95% CI, 0.79 – 0.91 compared with no comorbidity), prescription at a hospital, and living in a medium-sized to regional city were also associated with poor adherence. Our present findings showing the current status of adherence to antihypertensive medications and its associated factors using claims data in Japan should help to improve adherence to antihypertensives and blood pressure control.

    DOI: 10.1097/HJH.0000000000003661

    Web of Science

    Scopus

    PubMed

  • Incidence of post-COVID psychiatric disorders according to the periods of SARS-CoV-2 variant dominance: The LIFE Study. Reviewed

    Murata F, Maeda M, Murayama K, Nakao T, Fukuda H

    Journal of Psychiatric Research   174   12 - 18   2024.4

     More details

    Authorship:Last author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study

    Maeda, M; Murata, F; Fukuda, H

    VACCINE   42 ( 7 )   1542 - 1548   2024.3   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publisher:Vaccine  

    Objectives: Although COVID-19 no longer constitutes a Public Health Emergency of International Concern, vaccination remains an important tool for reducing disease burden and mitigating future outbreaks. However, little is known about the impact of vaccination on medical expenditures and hospitalization duration after breakthrough infection. This study aimed to examine this impact during the Delta wave in Japan. Methods: This retrospective study was conducted using medical care claims data, vaccination records, and COVID-19-related information. COVID-19 cases in three municipalities were categorized into two age groups: 20–64 years and ≥65 years. For each group, we constructed linear regression models with a generalized estimating equation. We calculated the risk ratios (RRs) and 95% confidence intervals (CIs) of COVID-19 vaccination for total medical expenditures and hospitalization duration after adjusting for sex, comorbidities, and municipality. Results: We analyzed 618 cases aged 20-64 years (mean age: 38.4 years, women: 45.1%) and 208 cases aged ≥65 years (76.4 years, 53.8%). The RRs (95% CIs) of vaccination for total medical expenditures were 0.53 (0.44–0.64) in the 20-64 years age group and 0.51 (0.39–0.66) in the ≥65 years age group. Next, the RRs (95% CIs) of vaccination for hospitalization duration were 0.59 (0.42–0.83) in the 20–64 years age group and 0.69 (0.49–0.98) in the ≥65 years age group. Conclusions: COVID-19 vaccination was associated with lower total medical expenditures and hospitalization duration after breakthrough infection, with a more pronounced effect in older persons.

    DOI: 10.1016/j.vaccine.2024.01.082

    Web of Science

    Scopus

    PubMed

  • Investigating the Epidemiology and Outbreaks of Scabies in Japanese Households, Residential Care Facilities, and Hospitals Using Claims Data: The LIFE Study. Reviewed

    Yamaguchi Y, Murata F, Maeda M, Fukuda H

    IJID Regions   11   100353   2024.3

     More details

    Authorship:Last author, Corresponding author   Language:Others  

  • Changes in the utilization of outpatient and visiting dental care and per-attendance care cost by age groups during COVID-19 pandemic waves in Japan: A time-series analysis from LIFE study. Reviewed

    Kusama T, Tamada Y, Kiuchi S, Maeda M, Murata F, Osaka K, Fukuda H, Takeuchi K

    Journal of Epidemiology   in press   2024.3

     More details

    Language:Others  

  • Associations between COVID-19 vaccination and incident psychiatric disorders after breakthrough SARS-CoV-2 infection: The VENUS Study Reviewed

    Fumiko Murata, Megumi Maeda, Keitaro Murayama, Tomohiro Nakao, Haruhisa Fukuda

    Brain, Behavior, and Immunity   117   521 - 528   2024.3   ISSN:0889-1591 eISSN:1090-2139

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.bbi.2024.02.018

    Web of Science

    Scopus

    PubMed

    researchmap

  • Changes in the utilization of outpatient and visiting dental care and per-attendance care cost by age groups during COVID-19 pandemic waves in Japan: A time-series analysis from LIFE study. Reviewed

    Kusama T, Tamada Y, Kiuchi S, Maeda M, Murata F, Osaka K, Fukuda H, Takeuchi K

    Journal of Epidemiology   in press   2024.3

     More details

  • Investigating the Epidemiology and Outbreaks of Scabies in Japanese Households, Residential Care Facilities, and Hospitals Using Claims Data: The LIFE Study. Reviewed

    Yamaguchi Y, Murata F, Maeda M, Fukuda H

    IJID Regions   in press   2024.3

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study

    Murata, F; Maeda, M; Ono, R; Fukuda, H

    VACCINE   42 ( 6 )   1268 - 1274   2024.2   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publisher:Vaccine  

    Background: Little is known about the impact of physical activity (PA) and PPSV23 vaccination on pneumonia-related hospitalizations. This study examined the association between regular PA and pneumonia-related hospitalization according to PPSV23 vaccination status in older adults. Methods: This retrospective cohort study was conducted using health checkup data, medical care claims data, and vaccination records from two Japanese municipalities. Residents aged ≥65 years who had undergone a health checkup between April 2016 and March 2021 were categorized into a PPSV23 vaccinated or unvaccinated cohort. Each cohort was further divided into a PA group and no PA group. The hazard ratio (HR) of PA for pneumonia-related hospitalization was calculated for each cohort while adjusting for sex, age, comorbidities, and metabolic syndrome. Results: The vaccinated cohort comprised 16,295 participants (no PA: 5,139, PA: 11,156), and the unvaccinated cohort comprised 7,998 participants (no PA: 2,671, PA: 5,327). In the vaccinated cohort, the PA group had a significantly lower hazard for pneumonia-related hospitalization than the no PA group (adjusted HR: 0.58, P = 0.004). However, PA was not associated with pneumonia-related hospitalization in the unvaccinated cohort (adjusted HR: 0.70, P = 0.270). Conclusions: PA can reduce the risk of pneumonia-related hospitalization in vaccinated persons. Interventions that increase both vaccination rates and PA habits may help to reduce these hospitalizations in older adults.

    DOI: 10.1016/j.vaccine.2024.01.060

    Web of Science

    Scopus

    PubMed

  • Validity of Claims-based Definition of Number of Remaining Teeth in Japan: Results from the Longevity Improvement and Fair Evidence Study. Reviewed

    Tamada Y, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H, Takeuchi K

    Plos One   19 ( 5 )   e0299849   2024.2

     More details

    Language:Others  

  • Validity of Claims-based Definition of Number of Remaining Teeth in Japan: Results from the Longevity Improvement and Fair Evidence Study. Reviewed

    Tamada Y, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H, Takeuchi K

    Plos One   in press   2024.2

     More details

  • Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy

    Moriyama Shohei, Hieda Michinari, Kisanuki Megumi, Kawano Shotaro, Yokoyama Taku, Fukata Mitsuhiro, Kusaba Hitoshi, Maruyama Toru, Baba Eishi, Akashi Koichi, Fukuda Haruhisa

    Circulation Journal   88 ( 2 )   217 - 225   2024.1   ISSN:13469843 eISSN:13474820

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b> Hypertension is a frequent adverse event caused by vascular endothelial growth factor signaling pathway (VSP) inhibitors. However, the impact of hypertension on clinical outcomes during VSP inhibitor therapy remains controversial.</p><p><b><i>Methods and Results:</i></b> We reviewed 3,460 cancer patients treated with VSP inhibitors from the LIFE Study database, comprising Japanese claims data between 2016 and 2020. Patients were stratified into 3 groups based on the timing of hypertension onset: (1) new-onset hypertension (n=569; hypertension developing after VSP inhibitor administration); (2) pre-existing hypertension (n=1,790); and (3) no hypertension (n=1,101). Time to treatment failure (TTF) was used as the primary endpoint as a surrogate for clinical outcomes. The median (interquartile range) TTF in the new-onset and pre-existing hypertension groups was 301 (133–567) and 170 (72–358) days, respectively, compared with 146 (70–309) days in the non-hypertensive group (P<0.001 among all groups). In an adjusted Cox proportional hazard model, new-onset (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.50–0.68; P<0.001) and pre-existing (HR 0.85; 95% CI 0.73–0.98; P=0.026) hypertension were independent factors for prolonged TTF. The TTF of new-onset hypertension was longer than that of pre-existing hypertension (HR 0.68; 95% CI 0.62–0.76; P<0.001).</p><p><b><i>Conclusions:</i></b> This study highlighted that new-onset hypertension induced by VSP inhibitors was an independent factor for favorable clinical outcomes. Pre-existing hypertension before VSP inhibitor initiation was also a significant factor.</p>

    DOI: 10.1253/circj.cj-22-0628

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • Comparison design and evaluation power in cohort and self-controlled case series designs for post-authorization vaccine safety studies

    Shuntaro Sato, Yurika Kawazoe, Tomohiro Katsuta, Haruhisa Fukuda

    PeerJ   12   e16780 - e16780   2024.1   ISSN:2167-8359 eISSN:2167-8359

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PeerJ  

    Background

    Post-authorization safety studies (PASSs) of vaccines are important. PASSs enable the evaluation of association between vaccination and adverse events following immunization through common study designs. Clinical trials during vaccine development typically include a few thousand to 10,000 participants while a PASS might aim to detect a few adverse events per 100,000 vaccine recipients. While all available data may be utilized, prior consideration of power analyses are nonetheless crucial for interpretation in cases where statistically significant differences are not found.

    Methods

    This research primarily examined cohort study design and self-controlled case series (SCCS) design, estimating the power of a PASS under plausible conditions.

    Results

    Both the cohort study and SCCS designs necessitated large sample sizes or high event counts to guarantee adequate power. The SCCS design is particularly suited to evaluating rare adverse events. However, extremely rare events may not yield sufficient occurrences, thereby resulting in low power. Although the SCCS design can more efficiently control for time-invariant confounding in principle, it solely estimates relative measures. A cohort study design might be preferred if confounding can be adequately managed as it also estimates absolute measures. It may be an easy decision to use all the data at hand for either design. We found it necessary to estimate the sample size and number of events to be used in the study based on a priori information and anticipated results.

    DOI: 10.7717/peerj.16780

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://peerj.com/articles/16780.xml

  • Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study

    Yamada, N; Nakatsuka, K; Tezuka, M; Murata, F; Maeda, M; Akisue, T; Fukuda, H; Ono, R

    VACCINE   42 ( 2 )   239 - 245   2024.1   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publisher:Vaccine  

    Purpose: To investigate individual and environmental vaccination-related factors among the older adults in Japan, using administrative data. Methods: We conducted a cohort study and included people who reached the relevant age (≥65 years) for routine pneumococcal vaccination of older adults between April 2015 and March 2020. Monthly data of residents in the two municipalities from April 2014 to March 2020 and vaccination records from April 2015 to March 2020 were used. We defined five cohorts according to the year in which routine vaccinations were available. Each cohort was followed for a total of two years, with the first year being the “baseline period” and second year being the “vaccine follow-up period.” Pneumococcal vaccination data was extracted from vaccination records at “first dose.” Age, sex, socioeconomic status, comorbidities, hospital visit history, hospitalization history, Specific Health Check-ups participation, and information on contracted hospitals for pneumococcal vaccination were used as covariates. A multivariate logistic regression model was used to investigate the relationship between pneumococcal vaccination and vaccination-related factors. Odds ratios (OR) and 95 % confidence intervals (95 % CI) were calculated. Results: Analysis included 17,991 patients. Vaccination coverage was 33.6 % for all subjects. Multivariate analysis found the following as significant vaccination-related factors: female (OR: 1.18, 95 % CI: 1.11–1.26), not low income (1.76, 1.17–2.76), hospital visits: ≥once/month (1.27, 1.19–1.35), and Specific Health Check-ups participation (2.10, 1.95–2.27). No significant results were found for hospitals that contracted pneumococcal vaccination. Conclusions: Individual factors, such as sex and Specific Health Check-ups participation, were found to be important factors affecting pneumococcal vaccination among older adults in Japan. Environmental factors, such as the characteristics of residential areas, should be evaluated in further investigations.

    DOI: 10.1016/j.vaccine.2023.12.009

    Web of Science

    Scopus

    PubMed

  • Immune thrombocytopenic purpura and Guillain-Barr<acute accent>e syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study

    Sato, S; Katsuta, T; Kawazoe, Y; Takahashi, M; Murata, F; Maeda, M; Fukuda, H; Kamidani, S

    VACCINE   42 ( 1 )   4 - 7   2024.1   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publisher:Vaccine  

    Background: To address the lack of an active vaccine safety surveillance system in Japan, the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study was initiated in 2021 as a pilot system using existing health insurance claims data and vaccination records. Methods: This study evaluated the value of the VENUS study by assessing the incidence of immune thrombocytopenic purpura (ITP) and Guillain-Barré syndrome (GBS) following vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) using a self-controlled case series (SCCS) design. Results: Incidence rate ratios for ITP during 28-day and 42-day risk periods were 0.89 (95% confidence interval [CI], 0.12–6.4), and 0.58 (95% CI, 0.081–4.2), respectively. Neither was statistically significant. Incidence rate ratios could not be estimated for GBS due to the limited sample size. Conclusion: The VENUS study can provide valuable insights to facilitate the establishment of an advanced vaccine monitoring system in Japan.

    DOI: 10.1016/j.vaccine.2023.11.053

    Web of Science

    Scopus

    PubMed

  • Association between reduced posterior occlusal contact and Alzheimer’s disease onset in older Japanese adults: results from the LIFE Study. Reviewed

    Miyano T, Ayukawa Y, Anada T, Takahashi I, Furuhashi H, Tokunaga S, Hirata A, Nakashima N, Kato K, Fukuda H.

    Journal of Alzheimer's Disease   97   871 - 881   2024.1

     More details

    Authorship:Last author, Corresponding author  

  • Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed

    Sato S, Katsuta T, Kawazoe Y, Takahashi M, Murata F, Maeda M, Fukuda H, Kamidani S.

    Vaccine   42 ( 1 )   4 - 7   2024.1

  • The Age-Specific Impact of COVID-19 Vaccination on Medical Expenditures and Hospitalization Duration After Breakthrough Infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. Reviewed

    Maeda M, Murata F, Fukuda H

    Vaccine   42 ( 7 )   1542 - 1548   2024.1

     More details

    Authorship:Last author, Corresponding author   Language:Others  

  • Both new-onset and pre-existing hypertension are favorable indicators of clinical outcomes in patients treated with vascular endothelial growth factor inhibitors. Reviewed

    Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, AkashiK, Fukuda H

    Circulation Journal   88 ( 2 )   217 - 225   2024.1

     More details

    Authorship:Last author   Language:Others   Publishing type:Research paper (scientific journal)  

    Both new-onset and pre-existing hypertension are favorable indicators of clinical outcomes in patients treated with vascular endothelial growth factor inhibitors.

  • Association Between Regular Physical Activity and Pneumonia-Related Hospitalization According to Pneumococcal Vaccination Status: The VENUS Study. Reviewed

    Murata F, Maeda M, Ono R, Fukuda H

    Vaccine   42 ( 6 )   1268 - 1274   2024.1

     More details

    Authorship:Last author, Corresponding author   Language:Others  

  • Bivalent mRNA Vaccine Effectiveness and Hybrid Immunity against COVID-19 among Older Adults in Japan: A Test-negative Study from the VENUS Study. Reviewed

    Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H

    BMC Infectious Diseases   24 ( 1 )   135   2024.1   eISSN:1471-2334

     More details

    Authorship:Last author   Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study
    Abstract

    Background

    Bivalent COVID-19 vaccines have been implemented worldwide since the booster vaccination campaigns of autumn of 2022, but little is known about their effectiveness. Thus, this study holistically evaluated the effectiveness of bivalent vaccines against infection in older adults in Japan.

    Methods

    We adopted the test-negative design using COVID-19 test data of individuals, aged ≥ 65 years, residing in three municipalities in Japan, who underwent tests in medical institutions between October 1 and December 30, 2022. Logistic regression analyses were conducted to estimate the odds of testing positive according to vaccination status. Vaccine effectiveness was defined as (1 − odds ratio) × 100&#37;.

    Results

    A total of 3,908 positive and 16,090 negative results were included in the analyses. Receiving a bivalent dose in addition to ≥ 2 monovalent doses was 33.6&#37; (95&#37; confidence interval [CI]: 20.8, 44.3&#37;) more effective than receiving no vaccination, and 18.2&#37; (95&#37; CI: 9.4, 26.0&#37;) more effective than receiving ≥ 2 monovalent doses but not receiving a bivalent vaccination. In addition, the effectiveness peaked at 14–20 days after administration and then gradually declined over time. Furthermore, a bivalent booster dose provided 18.6&#37; (95&#37; CI: 9.9, 26.5&#37;) additional protection among those vaccinated with ≥ 2 monovalent doses, in the absence of a previous infection history. However, we did not find sufficient evidence of effectiveness of bivalent vaccines among previously infected older adults.

    Conclusions

    Bivalent vaccines are effective against COVID-19 infections among older adults without a history of infection.

    DOI: 10.1186/s12879-024-09035-3

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1186/s12879-024-09035-3/fulltext.html

  • Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed

    in press   2024.1

     More details

    Language:Others  

  • Impact of Concurrent Visual and Hearing Impairment on Incident Alzheimer’s Disease: The LIFE Study. Reviewed

    Journal of Alzheimer’s Disease   98 ( 1 )   197 - 207   2024.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Medication Adherence and Associated Factors in Newly Diagnosed Hypertensive Patients in Japan: The LIFE Study. Reviewed

    Sagara K, Goto K, Maeda M, Murata F, Fukuda H

    Journal of Hypertension   42 ( 4 )   718 - 726   2024.1

     More details

    Authorship:Last author   Language:Others  

  • Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study. Reviewed

    Yamada N, Nakatsuka K, Tezuka M, Murata F, Maeda M, Akisue T, Fukuda H, Ono R

    Vaccine   42 ( 2 )   239 - 245   2024.1

     More details

    Language:Others  

  • Comparison design and evaluation power in cohort and self- controlled case series designs for post-authorization vaccine safety studies. Reviewed

    Sato S, Kawazoe Y, Katsuta T, Fukuda H.

    PeerJ   12   e16780   2024.1

     More details

    Authorship:Last author  

  • Impact of Concurrent Visual and Hearing Impairment on Incident Alzheimer’s Disease: The LIFE Study. Reviewed

    Kim S, Maeda M, Murata F, Fujii T, Ueda E, Ono R, Fukuda H.

    Journal of Alzheimer’s Disease   98 ( 1 )   197 - 207   2024.1

     More details

    Authorship:Last author, Corresponding author  

  • Association Between Regular Physical Activity and Pneumonia-Related Hospitalization According to Pneumococcal Vaccination Status: The VENUS Study. Reviewed

    Murata F, Maeda M, Ono R, Fukuda H

    Vaccine   42 ( 6 )   1268 - 1274   2024.1

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy(タイトル和訳中)

    Moriyama Shohei, Hieda Michinari, Kisanuki Megumi, Kawano Shotaro, Yokoyama Taku, Fukata Mitsuhiro, Kusaba Hitoshi, Maruyama Toru, Baba Eishi, Akashi Koichi, Fukuda Haruhisa

    Circulation Journal   88 ( 2 )   217 - 225   2024.1   ISSN:1346-9843

     More details

    Language:English   Publisher:(一社)日本循環器学会  

  • Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed

    Sato S, Katsuta T, Kawazoe Y, Takahashi M, Murata F, Maeda M, Fukuda H, Kamidani S

    Vaccine   in press   2024.1

     More details

  • The Age-Specific Impact of COVID-19 Vaccination on Medical Expenditures and Hospitalization Duration After Breakthrough Infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. Reviewed

    Maeda M, Murata F, Fukuda H

    Vaccine   42 ( 7 )   1542 - 1548   2024.1

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study. Reviewed

    Yamada N, Nakatsuka K, Tezuka M, Murata F, Maeda M, Akisue T, Fukuda H, Ono R

    Vaccine   in press   2024.1

     More details

  • Medication Adherence and Associated Factors in Newly Diagnosed Hypertensive Patients in Japan: The LIFE Study. Reviewed

    Sagara K, Goto K, Maeda M, Murata F, Fukuda H

    Journal of Hypertension   42 ( 4 )   718 - 726   2024.1

     More details

    Authorship:Last author  

    researchmap

  • Impact of Concurrent Visual and Hearing Impairment on Incident Alzheimer’s Disease: The LIFE Study. Reviewed

    Kim S, Maeda M, Murata F, Fujii T, Ueda E, Ono R, Fukuda H

    Journal of Alzheimer’s Disease   98 ( 1 )   197 - 207   2024.1

     More details

    Authorship:Last author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Validity of Vaccination Information in the COVID-19 Surveillance System in Japan: Implications for Developing Efficient and Highly Valid Data Collection Systems in Future Pandemics. Reviewed

    Horie Y, Ishiguro C, Mimura W, Maeda M, Murata, Fukuda H.

    GHM Open   2024

     More details

    Authorship:Last author  

  • Validation study of the claims-based algorithm using the International Classification of Diseases codes to identify patients with coronavirus disease in Japan from 2020 to 2022: The VENUS study. Reviewed

    Chikamochi T, Ishiguro C*, Mimura W, Maeda M, Murata F, Fukuda H.

    Pharmacoepidemiology and Drug Safety   2024

     More details

    Authorship:Last author  

  • Factors Associated with Hospitalization, Length of Stay, and Hospital Expenditures for Respiratory Syncytial Virus Infection in Japanese Infants and Children According to Palivizumab-Indicated Underlying Conditions: The LIFE Study. Reviewed

    Inoue M, Maeda M, Murata F, Fukuda H.

    The Pediatric Infectious Disease Journal   2024

     More details

    Authorship:Last author, Corresponding author  

  • Public periodontal screening increases subsequent regular dental visits: the LIFE Study. Reviewed

    Tamada Y, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H, Takeuchi K

    JDR Clinical & Translational Research   2024

  • Association Between Reduced Posterior Occlusal Contact and Alzheimer's Disease Onset in Older Japanese Adults: Results from the LIFE Study

    Miyano, T; Ayukawa, Y; Anada, T; Takahashi, I; Furuhashi, H; Tokunaga, S; Hirata, A; Nakashima, N; Kato, K; Fukuda, H

    JOURNAL OF ALZHEIMERS DISEASE   97 ( 2 )   871 - 881   2024   ISSN:1387-2877 eISSN:1875-8908

     More details

    Language:English   Publisher:Journal of Alzheimer's Disease  

    Background: An association between poor oral health and cognitive decline has been reported. Most of these studies have considered the number of teeth as a criterion, only a few studies have analyzed the relationship between occlusal status and Alzheimer’s disease (AD). Objective: To elucidate whether posterior occlusal contact is associated with AD, focusing on the Eichner classification, among an older population aged 65 years or older in Japan. Methods: This study used monthly claims data of National Health Insurance in Japan from April 2017 to March 2020. The outcome was newly diagnosed AD defined according to ICD-10 code G30. The number of teeth was estimated by dental code data, and occlusal contact was divided into three categories, namely A, B, and C, according to the Eichner classification. Multivariate Cox proportional hazards models were used to analyze the association between a new diagnosis of AD and the Eichner classification. Results: A total of 22,687 participants were included, 560 of whom had newly diagnosed AD during a mean follow-up period of 12.2 months. The AD participants had a lower proportion of Eichner A and a higher proportion of Eichner C. After adjusting for covariates, hazard ratios (95% confidence intervals) with Eichner B and C were 1.34 (1.01–1.77) and 1.54 (1.03–2.30), respectively. Conclusions: In older people aged ≥ 65 years old, reduced posterior occlusal contact as well as tooth loss have an impact on AD. This study emphasizes the importance of paying attention to occlusal contacts to reduce the risk of AD.

    DOI: 10.3233/JAD-230449

    Web of Science

    Scopus

    PubMed

  • Impact of Concurrent Visual and Hearing Impairment on Incident Alzheimer's Disease: The LIFE Study

    Kim, SA; Maeda, M; Murata, F; Fujii, T; Ueda, E; Ono, R; Fukuda, H

    JOURNAL OF ALZHEIMERS DISEASE   98 ( 1 )   197 - 207   2024   ISSN:1387-2877 eISSN:1875-8908

     More details

    Language:English   Publisher:Journal of Alzheimer's Disease  

    Background: The prevalence of Alzheimer's disease (AD) is increasing in Japan due to population aging. The association between sensory impairment and incident AD remains unclear. Objective: This study aimed to investigate the impact of sensory impairment on incident AD. Methods: We analyzed residents of five municipalities participating in the Longevity Improvement Fair Evidence (LIFE) Study. The participants comprised individuals who had newly applied for long-term care needs certification between 2017 and 2022 and had no cognitive impairment upon application or AD diagnosis within the preceding six months. Participants were classified according to sensory impairment status: visual impairment (VI), hearing impairment (HI), neither sensory impairment (NSI), and dual sensory impairment (DSI). The month succeeding the certification application was set as the index month, and the interval from that month until AD onset was assessed. Multivariable Cox proportional hazards analysis was performed to calculate the risk of AD onset according to sensory impairment status while adjusting for sex, age, dependence level, self-reliance level, and comorbidities. Results: Among 14,186 participants, we identified 1,194 (8.4%) who developed AD over a median follow-up period of 22.6 months. VI and HI only were not associated with incident AD. However, DSI conferred a significantly higher risk (HR: 1.6, CI: 1.1-2.2, p = 0.008) of AD onset than NSI. Conclusions: Individuals with concurrent DSI have a higher risk of developing AD than those with single or NSI. Preventing and treating sensory impairment may not only improve functional outcomes, but could also help to reduce the future risk of AD.

    DOI: 10.3233/JAD-230806

    Web of Science

    Scopus

    PubMed

  • Validity of vaccination information in the COVID-19 surveillance system in Japan: Implications for developing efficient and highly valid data collection systems in future pandemics

    Horie Yuki, Ishiguro Chieko, Mimura Wataru, Maeda Megumi, Murata Fumiko, Fukuda Haruhisa

    GHM Open   advpub ( 0 )   2024   ISSN:2436293X eISSN:24362956

     More details

    Language:English   Publisher:National Center for Global Health and Medicine  

    <p>Japan's government developed the Health Center Real-time Information-sharing System on COVID-19 (HER-SYS), the national COVID-19 surveillance system, which relies on manual data entry. Following the COVID-19 vaccination campaign, physicians were mandated to report COVID-19 cases with vaccination history <i>via</i> HER-SYS. However, concerns have arisen regarding the accuracy of this vaccination history. This study aimed to assess the validity of vaccination history recorded in HER-SYS. We used data from HER-SYS provided by three municipalities. The study cohort comprised COVID-19 cases registered in HER-SYS from February 2021 to March 2022. The validity of vaccination history in HER-SYS was assessed by cross-referencing with the Vaccination Record System (VRS) of these municipalities. We calculated sensitivity to gauge the extent of missing data in HER-SYS, and positive predictive value (PPV) to evaluate the accuracy of data entered into HER-SYS. Of the 19,260 COVID-19 cases included in the study cohort, HER-SYS and VRS identified 3,257 and 8,323 cases, respectively, as having the first-dose vaccination history. Cross-referencing identified 3,093 cases as true positives in HER-SYS. The sensitivity was 37.2% (95% confidence interval [CI]: 36.1−38.2) and the PPV was 95.0% (95% CI: 94.2−95.7). Collection of vaccination data by HER-SYS was found to be inadequate to obtain information on vaccination history of COVID-19 cases. This suggests that real-time data linkage across different systems such as HER-SYS and VRS would reduce the burden of manual data entry during the pandemic and lead to appropriate infection control measures based on more accurate information. </p>

    DOI: 10.35772/ghmo.2024.01007

    CiNii Research

  • Changes in the Utilization of Outpatient and Visiting Dental Care and Per-attendance Care Cost by Age Groups During COVID-19 Pandemic Waves in Japan: A Time-series Analysis From the LIFE Study

    Kusama Taro, Tamada Yudai, Maeda Megumi, Murata Fumiko, Osaka Ken, Fukuda Haruhisa, Takeuchi Kenji

    Journal of Epidemiology   advpub ( 0 )   2024   ISSN:09175040 eISSN:13499092

     More details

    Language:English   Publisher:Japan Epidemiological Association  

    <p><b>Background:</b> The influence of the coronavirus disease 2019 (COVID-19) pandemic on dental care utilization may have differed according to individual characteristics or type of dental care provision. This study aimed to evaluate the changes in dental care utilization and per-attendance costs by age group and type of dental care during the COVID-19 pandemic in Japan.</p><p><b>Methods:</b> This time-series study used healthcare insurance claims data from 01/07/2019 to 09/27/2021 (143 weeks) from nine municipalities in Japan. Dental care utilization rate per week and average dental care cost per attendance by age groups (0–19 years/20–64 years/65–74 years/≥75 years) and types of dental care (outpatient/visiting) were used as outcome variables. COVID-19 pandemic waves in Japan were used as predictors: 1<sup>st</sup> (03/23/2020–05/17/2020), 2<sup>nd</sup> (06/22/2020–09/27/2020), 3<sup>rd</sup> (10/26/2020–02/21/2021), 4<sup>th</sup> (02/22/2021–06/07/2021), and 5<sup>th</sup> (07/05/2021–09/13/2021) waves. Fixed-effects models were employed to estimate the proportional changes.</p><p><b>Results:</b> In the fixed-effects model, we observed large declines in dental care utilization during the 1<sup>st</sup> (17.0–22.0%) and 2<sup>nd</sup> waves (3.0–13.0%) compared to the non-pandemic wave period in all age groups. In contrast, the average dental care cost per attendance increased in all age groups by 5.2–8.6% during the 1<sup>st</sup> wave.</p><p><b>Conclusion:</b> During the initial wave of the COVID-19 pandemic in Japan, dental care utilization decreased in all age groups, whereas the average dental care cost per attendance increased. The COVID-19 pandemic may have changed the dental care provision pattern towards less frequent and more concentrated dental care to avoid the risk of infection.</p>

    DOI: 10.2188/jea.je20230323

    Web of Science

    PubMed

    CiNii Research

  • Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-16 to 2020-21 seasons: from the VENUS study

    Tsuzuki, S; Murata, F; Maeda, M; Asai, Y; Koizumi, R; Ohmagari, N; Fukuda, H

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY   78 ( 12 )   2976 - 2982   2023.12   ISSN:0305-7453 eISSN:1460-2091

     More details

    Language:English   Publisher:Journal of Antimicrobial Chemotherapy  

    Background: Seasonal influenza vaccination might be considered an antimicrobial resistance (AMR) countermeasure because it can reduce unnecessary antimicrobial use for acute respiratory infection by mitigating the burden of such diseases. Objectives: To examine the association between seasonal influenza vaccination and antimicrobial use (AMU) in Japan at the community level and to examine the impact of influenza vaccination on the frequency of unnecessary antimicrobial prescription for upper respiratory infection. Methods: For patients who visited any healthcare facility in one of the 23 wards of Tokyo, Japan, due to upper respiratory infection and who were aged 65 years or older, we extracted data from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study database, which includes all claims data and vaccination records from the 2015–16 to 2020–21 seasons. We used the average treatment effect (ATE) with 1:1 propensity score matching to examine the association of vaccination status with frequency of antibiotic prescription, frequency of healthcare facility consultation, risk of admission and risk of death in the follow-up period of the same season (from 1 January to 31 March). Results: In total, 244 642 people were enrolled. Matched data included 101 734 people in each of the unvaccinated and vaccinated groups. The ATE of vaccination was −0.004 (95% CI −0.006 to −0.002) for the frequency of antibiotic prescription, −0.005 (−0.007 to −0.004) for the frequency of healthcare facility consultation, −0.001 (−0.002 to −0.001) for the risk of admission and 0.00 (0.00 to 0.00) for the risk of death. Conclusions: Our results suggest that seasonal influenza vaccination is associated with lower frequencies of unnecessary antibiotic prescription and of healthcare facility consultation.

    DOI: 10.1093/jac/dkad340

    Web of Science

    Scopus

    PubMed

  • Association of anticholinergic drug exposure with the risk of dementia among older adults in Japan: The LIFE Study

    Okita, Y; Kitamura, T; Komukai, S; Zha, L; Komatsu, M; Narii, N; Murata, F; Megumi, M; Gon, Y; Kimura, Y; Kiyohara, K; Sobue, T; Fukuda, H

    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY   38 ( 12 )   e6029   2023.12   ISSN:0885-6230 eISSN:1099-1166

     More details

    Language:English   Publisher:International Journal of Geriatric Psychiatry  

    Objectives: Several studies have investigated that anticholinergic drugs cause cognitive impairment. However, the risk of dementia associated with anticholinergics has not been extensively investigated in the super-aging society of Japan. We conducted this study to assess the association between anticholinergic drugs and the risk of dementia in older adults in Japan. Methods: This nested case-control study used data from the Longevity Improvement & Fair Evidence Study, which includes claim data in Japan from 2014 to 2020. We included 66,478 cases of diagnosed dementia and 328,919 matched controls aged ≥65 years, matched by age, sex, municipality, and cohort entry year. Primary exposure was the total cumulative anticholinergic drugs prescribed from cohort entry date to event date or matched index date, which was the total standardized daily doses for each patient, calculated by adding the total dose of different types of anticholinergic drugs in each prescription, divided by the World Health Organization-defined daily dose values. Odds ratios for dementia associated with cumulative exposure to anticholinergic drugs were calculated using conditional logistic regression adjusted for confounding variables. Results: The mean (standard deviation) age at index date was 84.3 (6.9), and the percentage of women was 62.1%. From cohort entry date to event date or matched index date, 18.8% of the case patients and 13.7% of the controls were prescribed at least one anticholinergic drug. In the multivariable-adjusted model, individuals with anticholinergic drugs prescribed had significantly higher odds of being diagnosed with dementia (adjusted odds ratio, 1.50 [95% confidence interval, 1.47–1.54]). Among specific types of anticholinergic drugs, a significant increase in risk was observed with the use of antidepressants, antiparkinsonian drugs, antipsychotics, and bladder antimuscarinics in a fully multivariable-adjusted model. Conclusions: Several types of anticholinergic drugs used by older adults in Japan are associated with an increased risk of dementia. These findings suggest that the underlying risks should be considered alongside the benefits of prescribing anticholinergic drugs to this population.

    DOI: 10.1002/gps.6029

    Web of Science

    Scopus

    PubMed

  • Association of anticholinergic drug exposure with the risk of dementia among older adults in Japan: the LIFE study. Reviewed

    Okita Y, Kitamura T, Komukai S, Zha L, Komatsu M, Narii N, Murata F, Maeda M, Gon Y, Kimura Y, Kiyohara K, Sobue T, Fukuda H

    International Journal of Geriatric Psychiatry   38 ( 12 )   e6029   2023.11

     More details

    Language:Others  

  • Association between reduced posterior occlusal contact and Alzheimer’s disease onset in older Japanese adults: results from the LIFE Study. Reviewed

    in press   2023.11

     More details

    Language:Others  

  • Association of anticholinergic drug exposure with the risk of dementia among older adults in Japan: the LIFE study. Reviewed

    Okita Y, Kitamura T, Komukai S, Zha L, Komatsu M, Narii N, Murata F, Maeda M, Gon Y, Kimura Y, Kiyohara K, Sobue T, Fukuda H

    International Journal of Geriatric Psychiatry   in press   2023.11

     More details

    Authorship:Last author  

    researchmap

  • Association between reduced posterior occlusal contact and Alzheimer’s disease onset in older Japanese adults: results from the LIFE Study. Reviewed

    Miyano T, Ayukawa Y, Anada T, Takahashi I, Furuhashi H, Tokunaga S, Hirata A, Nakashima N, Kato K, Fukuda H

    Journal of Alzheimer's Disease.   in press   2023.11

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • The association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-2016 to 2020-2021 seasons: from the VENUS study. Reviewed

    Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H

    Journal of Antimicrobial Chemotherapy   78 ( 12 )   2976 - 2982   2023.10

     More details

    Authorship:Last author   Language:Others  

  • Bivalent vaccine effectiveness among older adults aged ≥65 years during the BA.5 predominant period in Japan: the VENUS Study. Reviewed

    10 ( 10 )   ofad475   2023.10

     More details

    Language:Others  

  • Bivalent vaccine effectiveness among older adults aged ≥65 years during the BA.5 predominant period in Japan: the VENUS Study. Reviewed

    Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Maeda M, Murata F, Fukuda H

    Open Forum Infectious Diseases   10 ( 10 )   ofad475   2023.10

     More details

    Authorship:Last author  

    researchmap

  • Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS study

    Mimura, W; Ishiguro, C; Murata, F; Maeda, M; Fukuda, H

    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY   32   187 - 187   2023.10   ISSN:1053-8569 eISSN:1099-1557

     More details

  • Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS study

    Ishiguro, C; Mimura, W; Maeda, M; Murata, F; Fukuda, H

    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY   32   183 - 183   2023.10   ISSN:1053-8569 eISSN:1099-1557

     More details

  • The association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-2016 to 2020-2021 seasons: from the VENUS study. Reviewed

    Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H

    Journal of Antimicrobial Chemotherapy   in press   2023.10

     More details

    Authorship:Last author  

    researchmap

  • Bivalent vaccine effectiveness among older adults aged ≥65 years during the BA.5 predominant period in Japan: the VENUS Study. Reviewed

    Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Maeda M, Murata F, Fukuda H.

    Open Forum Infectious Diseases   10 ( 10 )   ofad475   2023.10

     More details

    Authorship:Last author  

  • Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study. International journal

    Wataru Mimura, Chieko Ishiguro, Junko Terada-Hirashima, Nobuaki Matsunaga, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    Open forum infectious diseases   10 ( 10 )   ofad475   2023.9   ISSN:2328-8957

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 became prevalent in July 2022 in Japan. Bivalent messenger RNA (mRNA) vaccines were approved as booster doses for individuals who received the primary series or booster dose by monovalent vaccines. We aimed to assess the effectiveness of bivalent vaccines in Japanese adults aged ≥65 years. METHODS: We conducted a population-based cohort study using data collected from January 2019 to February 2023 in Japan. We included individuals aged ≥65 years in a municipality who received the first or second booster dose of monovalent mRNA vaccines. We estimated the effectiveness of the second or third booster dose of bivalent mRNA vaccines during the Omicron BA.5-predominant period (July-December 2022), compared with ≥90 days after the booster dose of monovalent vaccines. We used a Cox proportional hazard regression model with vaccination status as a time-dependent covariate. RESULTS: A total of 81 977 individuals aged ≥65 years (mean [standard deviation] age, 78.3 [7.4] years; 33 487 male [40.8%]) were included in the study cohort. Among them, 57 396 were vaccinated with the second or third dose of bivalent vaccines (BA.1 or BA.4/5). The effectiveness against coronavirus disease 2019 (COVID-19) was estimated to be 57.9% (95% confidence interval, 52.7%-62.5%) for ≥14 days after the second or third bivalent booster dose, compared with 90 days after the first or second monovalent booster dose. CONCLUSIONS: The study showed that the bivalent mRNA vaccines as the second and third doses would provide protection against COVID-19 among adults ≥65 years in Japan.

    DOI: 10.1093/ofid/ofad475

    Web of Science

    Scopus

    PubMed

    researchmap

  • 連載 医療システムの質・効率・公正--医療経済学の新たな展開・Vol.9 ワクチンデータベースを用いたワクチンの有効性・安全性の科学的検証

    福田 治久

    医学のあゆみ   286 ( 11 )   921 - 927   2023.9   ISSN:00392359

     More details

    Publisher:医歯薬出版  

    DOI: 10.32118/ayu28611921

    CiNii Research

  • Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged ≥65 years during the Delta variant predominance in Japan: The VENUS Study. Reviewed

    in press   2023.9

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. International journal

    Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases   134   200 - 206   2023.9   ISSN:1201-9712 eISSN:1878-3511

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ijid.2023.06.017

    Web of Science

    Scopus

    PubMed

  • Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged ≥65 years during the Delta variant predominance in Japan: The VENUS Study. Reviewed

    Mimura W, Ishiguro C, Terada-Hirashima J, Matsunaga N, Sato S, Kawazoe Y, Maeda M, Murata F, Fukuda H

    Journal of Epidemiology   in press   2023.9

     More details

    Authorship:Last author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study

    Tamada, Y; Takeuchi, K; Kusama, T; Maeda, M; Murata, F; Osaka, K; Fukuda, H

    VACCINE   41 ( 37 )   5447 - 5453   2023.8   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publisher:Vaccine  

    Background: Although the effectiveness of coronavirus disease 2019 (COVID-19) vaccines is a crucial public health concern, evidence from Western Pacific countries is limited, including Japan. This study aimed to estimate the COVID-19 vaccines effectiveness (VE) against infection during the Delta variant predominance (July–September 2021) in Japan. Methods: We performed a test-negative study using COVID-19 test data of ≥20-year-old residents in four municipalities who were tested in medical institutions between July 1 and September 30, 2021. We extracted COVID-19 test data from healthcare claims data, and the vaccination status at the testing date was ascertained using the Vaccination Record System data. Confirmed positive cases were identified using data from the national system for COVID-19, Health Center Real-time Information-sharing System on COVID-19. Logistic regression analyses were conducted to estimate the odds of testing positive according to vaccination status. VE was calculated as (1 − odds ratio) × 100%. Results: This study included 530 positive and 15,650 negative results. Adjusted manufacturer-unspecified VE was 4.1% (95% confidence interval [CI], −36.5–32.6) at 0–13 days after the first dose, 45.2% (95% CI, 13.4–65.3) at ≥14 days after the first dose, 85.2% (95% CI, 69.9–92.7) at 0–13 days after the second dose, and 79.6% (95% CI, 72.6–84.8) at ≥14 days after the second dose. In addition, the VE after the second dose was highest at 14–34 days after the dose (VE, 89.1%; 95% CI, 80.5–93.9). Conclusions: High real-world effectiveness of COVID-19 vaccines, especially two doses, against infection during the Delta variant predominance in Japan was confirmed.

    DOI: 10.1016/j.vaccine.2023.07.035

    Web of Science

    Scopus

    PubMed

  • LIFE Study 研究デザインと参加者のベースラインプロファイル(The Longevity Improvement & Fair Evidence(LIFE) Study: Overview of the Study Design and Baseline Participant Profile)

    Fukuda Haruhisa, Ishiguro Chieko, Ono Rei, Kiyohara Kosuke

    Journal of Epidemiology   33 ( 7-8 )   428 - 437   2023.8   ISSN:0917-5040

     More details

    Language:English   Publisher:(一社)日本疫学会  

    2019年にスタートした「Longevity Improvement & Fair Evidence(LIFE)Study」は、多地域を対象にした住民コホート型のデータベースプロジェクトである。LIFE Studyは、日本における健康寿命の延伸と健康格差の是正に向けたエビデンスの創出を目指している。現時点で、4都道府県18市町村の住民142万人の健康関連データなどを蓄積している。全年齢層および全疾患をカバーしており、日本発のリアル・ワールド・エビデンスを創出可能なプラットフォームになることが期待される。(著者抄録)

  • Effectiveness of COVID-19 Vaccines against Infection in Japan: A Test-Negative Study from the VENUS Study. Reviewed

    Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H

    Vaccine   41 ( 37 )   5447 - 5453   2023.7

     More details

    Authorship:Last author   Language:Others   Publishing type:Research paper (scientific journal)  

  • Multiregional population-based cohort study for evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: the VENUS Study. Reviewed

    Ishiguro C, Mimura W, Uemura Y, Maeda M, Murata F, Fukuda H

    Open Forum Infectious Diseases   10 ( 7 )   ofad274   2023.7

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Effect of COVID-19 Vaccination on Household Transmission of SARS-CoV-2 in the Omicron Era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed

    Maeda M, Murata F, Fukuda H

    International Journal of Infectious Diseases   134   200 - 206   2023.7

     More details

    Authorship:Last author, Corresponding author   Language:Others   Publishing type:Research paper (scientific journal)  

  • Disease burden and progression in patients with new-onset mild cognitive impairment and Alzheimer’s disease identified from Japanese claims data: Evidence from the LIFE Study. Reviewed

    in press   2023.7

     More details

    Language:Others  

  • Associations between income changes and the risk of herpes zoster: LIFE study

    Onizuka, H; Fukuda, H

    SOCIAL SCIENCE & MEDICINE   328   115981   2023.7   ISSN:0277-9536 eISSN:1873-5347

     More details

    Language:English   Publisher:Social Science and Medicine  

    Economic stability is thought to be associated with health outcomes. Income changes may affect the occurrence of herpes zoster (HZ), which is a neurocutaneous disease caused by the varicella-zoster virus. This retrospective cohort study aimed to examine the associations between annual income changes and incident HZ in a Japanese population. The analysis was conducted using a database of public health insurance claims data linked with administrative data containing income levels. The study population comprised 48,317 middle-aged persons aged 45–64 years from five municipalities, and participants were followed-up from April 2016 until March 2020. Income changes were categorized as income unchanged (income in the year of interest remained within 50% of income in the previous year), income rise (income increased by more than 50% from the previous year to the year of interest), and income drop (income decreased by more than 50% from the previous year to the year of interest). Cox proportional hazards regression analyses were performed to calculate the hazard ratios of HZ for income drop and income rise (reference: income unchanged) as time-varying variables. Covariates included age, sex, and immune-related conditions. The results showed that income drop was significantly associated with a higher hazard ratio (1.15, 95% confidence interval: 1.00–1.31) for HZ. In contrast, income rise was not associated with HZ. A subgroup analysis revealed that the lowest baseline income group had a significantly higher risk of HZ when experiencing an income drop (HR: 1.56, 95% CI: 1.13–2.15). As zoster vaccination is voluntary and vaccination coverage in middle-aged persons is low in Japan, our findings indicate that it may be advantageous to promote and subsidize voluntary vaccinations for middle-aged people with low baseline income who have experienced substantial income reductions in order to reduce the risk of HZ.

    DOI: 10.1016/j.socscimed.2023.115981

    Web of Science

    Scopus

    PubMed

  • Disease burden and progression in patients with new-onset mild cognitive impairment and Alzheimer’s disease identified from Japanese claims data: Evidence from the LIFE Study. Reviewed

    Fukuda H, Kanzaki H, Murata F, Maeda M, Ikeda M

    Journal of Alzheimer's Disease   in press   2023.7

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • Effectiveness of COVID-19 Vaccines against Infection in Japan: A Test-Negative Study from the VENUS Study. Reviewed

    Tamada Y, Takeuchi K, Kusama T, Maeda M, Murata F, Osaka K, Fukuda H

    Vaccine   41 ( 37 )   5447 - 5453   2023.7

     More details

    Authorship:Last author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Effect of COVID-19 Vaccination on Household Transmission of SARS-CoV-2 in the Omicron Era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed

    Maeda M, Murata F, Fukuda H

    International Journal of Infectious Diseases   134   200 - 206   2023.7

     More details

    Authorship:Last author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Analysis of post-extraction bleeding in antithrombotic therapy patients: The Longevity Improvement and Fair Evidence Study. Reviewed

    Nakamura J, Nakatsuka K, Uchida K, Akisue T, Fukuda H, Ono R

    Gerodontology   41 ( 2 )   269 - 275   2023.6

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Analysis of post-extraction bleeding in antithrombotic therapy patients: The Longevity Improvement and Fair Evidence Study. Reviewed

    Nakamura J, Nakatsuka K, Uchida K, Akisue T, Fukuda H, Ono R

    Gerodontology   in press   2023.6

     More details

    Publishing type:Research paper (scientific journal)  

    researchmap

  • Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study

    Fukuda H., Maeda M., Murata F.

    Vaccine   41 ( 23 )   3556 - 3563   2023.5   ISSN:0264410X

     More details

    Language:English   Publisher:Vaccine  

    Background: There are currently no COVID-19 vaccine assessment systems in Japan that allow for the active surveillance of both vaccinated and unvaccinated persons. Herein, we describe the development of Japan's first COVID-19 vaccine effectiveness and safety assessment system with active surveillance capabilities. Methods: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study was developed as a multi-source database that links four data types at the individual resident level: Basic Resident Register (base population information), Vaccination Record System (vaccination-related information), Health Center Real-time Information-sharing System on COVID-19 (HER-SYS; information on COVID-19 occurrence), and health care claims data (information on diagnoses, hospitalizations, diagnostic tests, and treatments). These data were obtained from four municipalities. Individual residents were linked across the data types using five matching algorithms based on names, birth dates, and sex; the data were anonymized after linkage. To ascertain the viability of the VENUS Study's database for COVID-19 vaccine assessments, we examined the trends in COVID-19 vaccinations, COVID-19 cases, and polymerase chain reaction (PCR) test numbers. We also evaluated the linkage rates across the data types. Results: Our multi-source database was able to monitor COVID-19 vaccinations, COVID-19 cases, and PCR test numbers throughout the pandemic. Using the five algorithms, the data linkage rates between the COVID-19 occurrence information in the HER-SYS and the Basic Resident Register ranged from 85·4% to 91·7%. Conclusion: If used judiciously with an understanding of each data source's characteristics, the VENUS Study can provide a viable data platform that facilitates active surveillance and comparative analyses for population-based research on COVID-19 vaccine effectiveness and safety in Japan.

    DOI: 10.1016/j.vaccine.2023.03.059

    Scopus

    PubMed

  • Multiregional population-based cohort study for evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: the VENUS Study Reviewed

    Chieko Ishiguro, Wataru Mimura, Yukari Uemura, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    Open Forum Infectious Diseases   10 ( 7 )   ofad274   2023.5   ISSN:2328-8957 eISSN:2328-8957

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    Abstract

    Background

    This study was performed to assess the increased risk of herpes zoster (HZ) associated with mRNA vaccines for coronavirus disease 2019.

    Methods

    This population-based cohort study was conducted in 4 municipalities in Japan. Individuals covered under public health insurance systems without a history of HZ were followed from October 1, 2020 to November 30, 2021. Incidence rates of HZ within 28 days of BNT162b2 or mRNA-1273 vaccination were compared. Adjusted incidence rate ratios (IRR) and 95% confidence intervals (CI) were estimated using a Poisson regression model, including vaccination status as a time-dependent covariate. Subgroup analyses by sex, age, and municipality were also conducted.

    Results

    A total of 339 548 individuals (median age, 74 years) were identified. During follow up, 296 242 individuals (87.2%) completed the primary series, among whom 289 213 and 7019 individuals received homologous BNT162b2 and mRNA-1273 vaccines, respectively. The adjusted IRRs of the first and second BNT162b2 vaccinations were 1.05 (95% CI, 0.84–1.32) and 1.09 (95% CI, 0.90–1.32), respectively. No cases of HZ were observed after mRNA-1273 vaccination. In subgroup analysis, the adjusted IRR of the second BNT162b2 vaccination was 2.94 (95% CI, 1.41–6.13) in individuals aged &amp;lt;50 years old.

    Conclusions

    No increased risk of HZ was found after BNT162b2 vaccination in the overall study population. However, an increased risk was observed in the younger subgroup.

    DOI: 10.1093/ofid/ofad274

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://academic.oup.com/ofid/article-pdf/10/7/ofad274/51009557/ofad274.pdf

  • Associations between income changes and the risk of herpes zoster: LIFE Study. Reviewed

    Onizuka H, Fukuda H

    Social Science & Medicine   in press   2023.5

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Associations between income changes and the risk of herpes zoster: LIFE Study. Reviewed

    Onizuka H, Fukuda H

    Social Science & Medicine   in press   2023.5

     More details

    Authorship:Last author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Survey of psychiatric symptoms among inpatients with COVID-19 using the Diagnosis Procedure Combination data and medical records in Japan

    Nakao, T; Murayama, K; Fukuda, H; Eto, N; Fujita, K; Igata, R; Ishikawa, K; Isomura, S; Kawaguchi, T; Maeda, M; Mitsuyasu, H; Murata, F; Nakamura, T; Nishihara, T; Ohashi, A; Sato, M; Yoshida, Y; Kawasaki, H; Ozone, M; Yoshimura, R; Tatebayashi, H

    BRAIN, BEHAVIOR, & IMMUNITY - HEALTH   29   100615   2023.5   ISSN:2666-3546

     More details

    Language:English   Publisher:Brain, Behavior, and Immunity - Health  

    Physical symptoms such as fatigue and muscle weakness, and psychiatric symptoms like depression and anxiety are considered as complications and sequelae of COVID-19. This epidemiological study investigated the actual status of psychiatric symptoms and disorders caused by COVID-19, from four major university hospitals and five general hospitals in Fukuoka Prefecture, Japan, having a population of 5 million. We conducted a survey of psychiatric disorders associated with COVID-19 using Diagnosis Procedure Combination (DPC) data and the psychiatric records of the hospitals. In the study period from January 2019 to September 2021, 2743 COVID-19 admissions were determined from DPC data across the nine sites. These subjects had significantly more anxiety, depression, and insomnia, and were receiving higher rates of various psychotropic medications than controls influenza and respiratory infections. A review of psychiatric records revealed that the frequency of organic mental illness with insomnia and confusion was proportional to the severity of COVID-19 infection and that anxiety symptoms appeared independent of infection severity. These results indicate that COVID-19 is more likely to produce psychiatric symptoms such as anxiety and insomnia than conventional infections.

    DOI: 10.1016/j.bbih.2023.100615

    Web of Science

    Scopus

    PubMed

  • Effect of participation in a surgical site infection surveillance program on hospital performance in Japan: a retrospective study. Reviewed

    Kawabata J, Morikane K, Fukuda H

    Journal of Hospital Infection   146   183 - 191   2023.4

     More details

    Authorship:Last author, Corresponding author   Language:Others  

  • Association between metabolic syndrome and participation in colorectal cancer screening in Japan: A retrospective cohort analysis using LIFE study data

    Murata, F; Maeda, M; Fukuda, H

    CANCER EPIDEMIOLOGY   83   102335   2023.4   ISSN:1877-7821 eISSN:1877-783X

     More details

    Language:English   Publisher:Cancer Epidemiology  

    Background: People with metabolic syndrome have an elevated risk of developing colorectal cancer (CRC), and are recommended to undergo cancer screening. This study examined the association between metabolic syndrome and CRC screening participation in Japan. Methods: This retrospective cohort study was conducted using insurance claims data, health checkup data, and cancer screening data from a Japanese city. The study population comprised persons aged 40–74 years who had undergone health checkups between fiscal years (FY) 2016 and 2019. The exposure was metabolic syndrome risk (high risk, moderate risk, and no risk) as determined during health checkups. The outcome was CRC screening participation. Logistic regression analyses were performed to examine the associations between metabolic syndrome risk and CRC screening participation. Results: We analyzed 20,558 people in the FY2016 cohort, 19,065 people in the FY2017 cohort, 17,496 people in the FY2018 cohort, and 15,647 people in the FY2019 cohort. The odds of CRC screening participation were significantly lower in the moderate-risk group (P < 0.05) in all FYs except FY2019 and the high-risk group (P < 0.001) in all FYs when compared with the no-risk group. When analyzed according to age group, older persons aged 65–74 years generally had significantly lower odds of CRC screening participation than persons aged 40–49 years across all metabolic syndrome risk groups. Conclusion: This is the first study from Japan to show that people with metabolic syndrome, especially older persons aged 65–74 years, are less likely to undergo CRC screening than people without metabolic syndrome. These findings indicate a need to develop and implement age-specific measures to increase cancer screening uptake among persons with metabolic syndrome.

    DOI: 10.1016/j.canep.2023.102335

    Web of Science

    Scopus

    PubMed

  • Effect of participation in a surgical site infection surveillance program on hospital performance in Japan: a retrospective study. Reviewed

    Kawabata J, Morikane K, Fukuda H

    Journal of Hospital Infection   in press   2023.4

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • National trends in the outcomes of subarachnoid haemorrhage and the prognostic influence of stroke centre capability in Japan: retrospective cohort study

    Kurogi, R; Kada, A; Ogasawara, K; Nishimura, K; Kitazono, T; Iwama, T; Matsumaru, Y; Sakai, N; Shiokawa, Y; Miyachi, S; Kuroda, S; Shimizu, H; Yoshimura, S; Osato, T; Horie, N; Nagata, I; Nozaki, K; Date, I; Hashimoto, Y; Hoshino, H; Nakase, H; Kataoka, H; Ohta, T; Fukuda, H; Tamiya, N; Kurogi, A; Ren, N; Nishimura, A; Arimura, K; Shimogawa, T; Yoshimoto, K; Onozuka, D; Ogata, S; Hagihara, A; Saito, N; Arai, H; Miyamoto, S; Tominaga, T; Iihara, K

    BMJ OPEN   13 ( 4 )   e068642   2023.4   ISSN:2044-6055

     More details

    Language:English   Publisher:BMJ Open  

    Objectives To examine the national, 6-year trends in in-hospital clinical outcomes of patients with subarachnoid haemorrhage (SAH) who underwent clipping or coiling and the prognostic influence of temporal trends in the Comprehensive Stroke Center (CSC) capabilities on patient outcomes in Japan. Design Retrospective study. Setting Six hundred and thirty-one primary care institutions in Japan. Participants Forty-five thousand and eleven patients with SAH who were urgently hospitalised, identified using the J-ASPECT Diagnosis Procedure Combination database. Primary and secondary outcome measures Annual number of patients with SAH who remained untreated, or who received clipping or coiling, in-hospital mortality and poor functional outcomes (modified Rankin Scale: 3-6) at discharge. Each CSC was assessed using a validated scoring system (CSC score: 1-25 points). Results In the overall cohort, in-hospital mortality decreased (year for trend, OR (95% CI): 0.97 (0.96 to 0.99)), while the proportion of poor functional outcomes remained unchanged (1.00 (0.98 to 1.02)). The proportion of patients who underwent clipping gradually decreased from 46.6% to 38.5%, while that of those who received coiling and those left untreated gradually increased from 16.9% to 22.6% and 35.4% to 38%, respectively. In-hospital mortality of coiled (0.94 (0.89 to 0.98)) and untreated (0.93 (0.90 to 0.96)) patients decreased, whereas that of clipped patients remained stable. CSC score improvement was associated with increased use of coiling (per 1-point increase, 1.14 (1.08 to 1.20)) but not with short-term patient outcomes regardless of treatment modality. Conclusions The 6-year trends indicated lower in-hospital mortality for patients with SAH (attributable to better outcomes), increased use of coiling and multidisciplinary care for untreated patients. Further increasing CSC capabilities may improve overall outcomes, mainly by increasing the use of coiling. Additional studies are necessary to determine the effect of confounders such as aneurysm complexity on outcomes of clipped patients in the modern endovascular era.

    DOI: 10.1136/bmjopen-2022-068642

    Web of Science

    Scopus

    PubMed

  • Disease burden and progression in patients with new-onset mild cognitive impairment and Alzheimer’s disease identified from Japanese claims data: Evidence from the LIFE Study. Reviewed

    Fukuda H*, Kanzaki H, Murata F, Maeda M, Ikeda M.

    Journal of Alzheimer's Disease   95 ( 4 )   1559 - 1572   2023.4

     More details

    Authorship:Lead author, Corresponding author  

  • Effects of a financial incentive scheme for dementia care on medical and long-term care expenditures: A propensity score-matched analysis using LIFE study data

    Kawabata, J; Fukuda, H

    PLOS ONE   18 ( 3 )   e0282965   2023.3   ISSN:1932-6203

     More details

    Language:English   Publisher:PLoS ONE  

    Objective Japan introduced a financial incentive scheme in April 2016 to improve hospital-based dementia care, but its effectiveness remains unclear. This study aimed to investigate the scheme's impact on medical and long-term care (LTC) expenditures, as well as on changes in care needs levels and daily living independence levels among older persons one year after hospital discharge. Methods We linked medical and LTC claims databases, and retrospectively identified patients who received LTC needs certification and daily living independence assessments in Fukuoka, Japan. Case patients (received care under the new scheme) were those admitted from April 2016 to March 2018, and control patients were those admitted from April 2014 to March 2016 (before the scheme was implemented). Through propensity score matching, we identified 260 case patients and 260 control patients, and compared using t-tests, and chi-square tests. Results The analyses found no significant differences between the case and control groups in medical expenditure (US$26,685 vs US$24,823, P = 0.37), LTC expenditure (US$16,870 vs US $14,374, P = 0.08), daily living independence level changes (26.5% vs 20.4%, P = 0.12), or care needs level changes (36.9% vs 30%, P = 0.11). Conclusions The financial incentive scheme for dementia care did not demonstrate any beneficial effects on patients' healthcare expenditures or health conditions. Further studies are needed to examine the scheme's long-term effects.

    DOI: 10.1371/journal.pone.0282965

    Web of Science

    Scopus

    PubMed

  • Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study. Reviewed International journal

    Nobuhiro Narii, Tetsuhisa Kitamura, Sho Komukai, Ling Zha, Masayo Komatsu, Fumiko Murata, Megumi Maeda, Kosuke Kiyohara, Tomotaka Sobue, Haruhisa Fukuda

    Vaccine   41 ( 13 )   2307 - 2313   2023.3   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The protective effect of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against cardiovascular disease has been investigated in the United States and Europe; however, its effect has not been fully established. This study aimed to investigate the protective effect of PPSV23 on cardiovascular events in adults aged ≥ 65 years. This population-based nested case-control study was conducted using the claims data and vaccine records between April 2015 and March 2020 from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. PPSV23 vaccination was identified using vaccination records in each municipality. The primary outcome was acute myocardial infarction (AMI) or stroke. The adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for PPSV23 vaccination were calculated using conditional logistic regression. Among 383,781 individuals aged ≥ 65 years, 5,356 and 25,730 individuals with AMI or stroke were matched with 26,753 and 128,397 event-free controls, respectively. Individuals who were PPSV23 vaccinated, compared with the unvaccinated individuals, had significantly lower odds of AMI or stroke events (aOR, 0.70 [95% CI, 0.62-0.80] and aOR, 0.81 [95% CI, 0.77-0.86], respectively). More recent PPSV23 vaccination was associated with lower odds ratios (AMI, aOR 0.55 [95% CI, 0.42-0.72] for 1-180 days and aOR 1.11 [95% CI, 0.84-1.47] for 720 days or longer; stroke, aOR 0.83 [95% CI, 0.74-0.93] for 1-180 days and aOR 0.90 [95% CI, 0.78-1.03] for 720 days or longer). Among Japanese older adults, individuals who were PPSV23 vaccinated, compared with unvaccinated individuals, had significantly lower odds of AMI or stroke events.

    DOI: 10.1016/j.vaccine.2023.02.077

    Web of Science

    Scopus

    PubMed

    researchmap

  • Survey of psychiatric symptoms among inpatients with COVID-19 using the Diagnosis Procedure Combination data and medical records in Japan. Reviewed

    Nakao T, Murayama K, Fukuda H, Eto N, Fujita K, Igata R, Ishikawa K, Isomura S, Kawaguchi T, Maeda M, Mitsuyasu H, Murata F, Nakamura T, Nishihara T, Ohashi A, Sato M, Yoshida Y, Kawasaki H, Ozone M, Yoshimura R, Tatebatashi H

    Brain, Behavior, & Immunity - Health   in press   2023.3

     More details

    Language:Others  

  • Effects of a financial incentive scheme for dementia care on medical and long-term care expenditures: A propensity score-matched analysis using LIFE Study data. Reviewed

    Kawabata J, Fukuda H

    Plos One   18 ( 3 )   e0282965   2023.3

     More details

    Language:Others  

  • Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS Study. Reviewed

    Fukuda H, Maeda M, Murata F

    Vaccine   in press   2023.3

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • Survey of psychiatric symptoms among inpatients with COVID-19 using the Diagnosis Procedure Combination data and medical records in Japan. Reviewed

    Nakao T, Murayama K, Fukuda H, Eto N, Fujita K, Igata R, Ishikawa K, Isomura S, Kawaguchi T, Maeda M, Mitsuyasu H, Murata F, Nakamura T, Nishihara T, Ohashi A, Sato M, Yoshida Y, Kawasaki H, Ozone M, Yoshimura R, Tatebatashi H

    Brain, Behavior, & Immunity - Health   in press   2023.3

     More details

  • Effects of a financial incentive scheme for dementia care on medical and long-term care expenditures: A propensity score-matched analysis using LIFE Study data. Reviewed

    Kawabata J, Fukuda H

    Plos One   18 ( 3 )   e0282965   2023.3

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • Development of a data platform for monitoring personal health records in Japan: The Sustaining Health by Integrating Next-generation Ecosystems (SHINE) Study Reviewed

    Haruhisa Fukuda, Fumiko Murata, Sachie Azuma, Masahiro Fujimoto, Shoma Kudo, Yoshiyuki Kobayashi, Kenshi Saho, Kazumi Nakahara, Rei Ono

    PLOS ONE   18 ( 2 )   e0281512 - e0281512   2023.2   ISSN:1932-6203 eISSN:1932-6203

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Public Library of Science (PLoS)  

    Background

    The Sustaining Health by Integrating Next-generation Ecosystems (SHINE) Study was developed as a data platform that incorporates personal health records (PHRs) into health-related data at the municipal level in Japan. This platform allows analyses of the associations between PHRs and future health statuses, and supports the production of evidence for developing preventive care interventions. Herein, we introduce the SHINE Study’s profile and describe its use in preliminary analyses.

    Methods

    The SHINE Study involves the collection of participants’ health measurements and their addition to various health-related data from the Longevity Improvement &amp; Fair Evidence (LIFE) Study. With cooperation from municipal governments, measurements can be acquired from persons enrolled in government-led long-term care prevention classes and health checkups who consent to participate in the SHINE Study. For preliminary analyses, we collected salivary test measurements, lifelog measurements, and gait measurements; these were linked with the LIFE Study’s database. We analyzed the correlations between these measurements and the previous year’s health care expenditures.

    Results

    We successfully linked PHR data of 33 participants for salivary test measurements, 44 participants for lifelog measurements, and 32 participants for gait measurements. Only mean torso speed in the gait measurements was significantly correlated with health care expenditures (r = -0.387, P = 0.029).

    Conclusion

    The SHINE Study was developed as a data platform to collect and link PHRs with the LIFE Study’s database. The analyses undertaken with this platform are expected to contribute to the development of preventive care tools and promote health in Japan.

    DOI: 10.1371/journal.pone.0281512

    Web of Science

    Scopus

    PubMed

    researchmap

  • Development of a Data Platform for Monitoring Personal Health Records in Japan: The Sustaining Health by Integrating Next-generation Ecosystems (SHINE) Study Reviewed

    Fukuda H, Murata F, Azuma S, Fujimoto M, Kudo S, Kobayashi Y, Saho K, Nakahara K, Ono R

    Plos One   18 ( 2 )   e0281512   2023.2

     More details

    Authorship:Lead author, Last author  

    researchmap

  • Claimed-based frailty index in Japanese older adults: a cohort study using LIFE Study. Reviewed

    Nakatsuka K, Ono R, Murata S, Akisue T, Fukuda H

    Journal of Epidemiology   34 ( 3 )   112 - 118   2023.1

     More details

    Authorship:Last author   Language:Others  

  • Comparative risk of fracture in community‐dwelling older adults initiating suvorexant versus Z‐drugs: results from LIFE study Reviewed

    71 ( 1 )   109 - 120   2023.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jgs.18068

  • Association between periodontal pocket depth determined during dental check-ups and new onset of diabetes in community residents: the LIFE study Reviewed

    TANI Naomichi, TAKEUCHI Kenji, FUKUDA Haruhisa

    Nihon Koshu Eisei Zasshi(JAPANESE JOURNAL OF PUBLIC HEALTH)   70 ( 1 )   39 - 47   2023.1   ISSN:05461766 eISSN:21878986

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society of Public Health  

    Association between periodontal pocket depth determined during dental check-ups and new onset of diabetes in community residents: the LIFE study

    DOI: 10.11236/jph.22-038

    PubMed

    CiNii Research

    researchmap

  • Association between metabolic syndrome and participation in colorectal cancer screening in Japan: A retrospective cohort analysis using LIFE Study data. Reviewed

    Murata F, Maeda M, Fukuda H

    Cancer Epidemiology   83   102335   2023.1

     More details

    Language:Others  

  • Claimed-based frailty index in Japanese older adults: a cohort study using LIFE Study. Reviewed

    Nakatsuka K, Ono R, Murata S, Akisue T, Fukuda H

    Journal of Epidemiology   in press   2023.1

     More details

    Authorship:Last author  

    researchmap

  • Association between metabolic syndrome and participation in colorectal cancer screening in Japan: A retrospective cohort analysis using LIFE Study data. Reviewed

    Murata F, Maeda M, Fukuda H

    Cancer Epidemiology   83   102335   2023.1

     More details

    Authorship:Last author, Corresponding author  

    researchmap

  • 地域住民の成人歯科健診における歯周ポケット検査と糖尿病発症の関連性 LIFE Study

    谷 直道, 竹内 研時, 福田 治久

    日本公衆衛生雑誌   70 ( 1 )   39 - 47   2023.1   ISSN:0546-1766

     More details

    Language:Japanese   Publisher:日本公衆衛生学会  

    目的 近年,糖尿病と歯周病には双方向の関連性があることが多数報告されている。しかしながら,歯周ポケットの深さと糖尿病の新規発症に関する縦断的な関連性についてはさらなる議論の余地がある。従って,本研究は地域住民における成人歯科健診データを用いて,歯周ポケットの深さと糖尿病の新規発症の関連性を検証することを目的とした。方法 本研究は,東京都某区で2016年4月から2019年3月までに成人歯科健診を受診した20歳以上の成人5,163人(57.4±13.9歳,女性66.3%)を対象として,歯科健診の歯周ポケットコードを用いて歯周ポケット健全群,4~5mm群,6mm以上群の3群に分類し2020年3月末日まで追跡を行った。さらに同区の国民健康保険および後期高齢者医療保険の医科レセプトデータ傷病名から,疑い病名を除く糖尿病のICD10コードを抽出し,歯科健診の受診日以降に発症した者を糖尿病ありと定義してアウトカムに用いた。糖尿病発症率の比較にはログランク検定及びCox比例ハザード回帰分析を用いた生存時間分析と感度分析を行った。結果 ログランク検定の結果,3群間の糖尿病累積発症率は有意に異なっていた(P<0.01)。また,性別,年齢,喫煙習慣,現在歯数,口腔清掃状態を調整したCox比例ハザード回帰分析の結果,歯周ポケット健全群に対する6mm以上群の調整ハザード比(95%信頼区間)は1.44(1.04-2.00)倍の有意な関連性が認められた。さらに40歳以上を対象とした感度分析の調整ハザード比(95%信頼区間)は歯周ポケット健全群に対して6mm以上群が1.55(1.11-2.16)倍,40歳以上の男性では1.72(1.04-2.85)倍の有意な関連性を認めた。しかし,40歳以上の女性には有意な関連性は認められなかった(1.39[0.89-2.18])。結論 本研究の結果,地域住民において歯周ポケットの深さと糖尿病の発症に関する縦断的な関連性が示唆された。特に,40歳以上の男性においてその関連性が顕著であったことから,40歳未満の若年層とりわけ若い男性に対して適切な歯科保健指導を実践し口腔状態を良好に保つことは口腔衛生の観点のみならず,将来的な糖尿病予防の観点からも重要であると考えられる。(著者抄録)

  • Distinct effects of community-based activities on long-term care needs: A study using zero-inflated Poisson regression. Reviewed

    Kumagai N, Fukuda H.

    Global Health Economics and Sustainability   1 ( 1 )   0891   2023.1

  • Disease Burden and Progression in Patients with New-Onset Mild Cognitive Impairment and Alzheimer's Disease Identified from Japanese Claims Data: Evidence from the LIFE Study

    Fukuda, H; Kanzaki, H; Murata, F; Maeda, M; Ikeda, M

    JOURNAL OF ALZHEIMERS DISEASE   95 ( 4 )   1559 - 1572   2023   ISSN:1387-2877 eISSN:1875-8908

     More details

    Language:English   Publisher:Journal of Alzheimer's Disease  

    Background: Accurate epidemiological data on mild cognitive impairment (MCI) and Alzheimer's disease (AD) can inform the development of prevention and control measures, but there is a lack of such data in Japan. Objective: To investigate the disease burden and progression in patients with new-onset MCI or AD in Japan. Methods: Using claims data, this multi-region cohort study was conducted on new-onset MCI and AD patients in 17 municipalities from 2014 to 2021. To characterize the patients, we investigated their age, comorbidities, and long-term care (LTC) needs levels at disease onset according to region type (urban, suburban, or rural). Disease burden was examined using health care expenditures and LTC expenditures, which were estimated for 1, 2, and 3 years after disease onset. Kaplan-Meier curves were plotted for AD progression in new-onset MCI patients and death in new-onset AD patients. Results: We analyzed 3,391 MCI patients and 58,922 AD patients. In MCI and AD patients, health care expenditures were high in the first year ($13,035 and $15,858, respectively), but had declined by the third year ($8,278 and $10,414, respectively). In contrast, LTC expenditures (daily living support) steadily increased over the 3-year period (MCI patients: $1,767 to $3,712, AD patients: $6,932 to $9,484). In the third year after disease onset, 30.9% of MCI patients developed AD and 23.3% of AD patients had died. Conclusions: This provides an important first look at the disease burden and progression of MCI and AD in Japan, which are high-priority diseases for a rapidly aging population.

    DOI: 10.3233/JAD-230471

    Web of Science

    Scopus

    PubMed

  • Risk of cardiovascular events leading to hospitalization after Streptococcus pneumoniae infection: A retrospective cohort LIFE study. Reviewed

    Nishimura N, Fukuda H

    BMJ Open   12 ( 11 )   e059713   2022.12

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Risk of cardiovascular events leading to hospitalization after Streptococcus pneumoniae infection: A retrospective cohort LIFE study.

  • Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study. Reviewed International journal

    Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    Open forum infectious diseases   9 ( 12 )   ofac636   2022.12   ISSN:2328-8957

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 Omicron BA.2 sublineage in Japan is unknown. We assessed the effectiveness of a third dose of COVID-19 mRNA vaccine compared with that of 2 doses. METHODS: We performed a population-based cohort study using a municipality database located in the Chubu region of Japan during the Omicron BA.1- and BA.2-predominant periods (January 1-March 31, 2022 and April 1-27, 2022, respectively). We included residents aged ≥16 years who received a second vaccine dose at ≥14 days before the start of each period, regardless of the third dose. We compared the data at 14 days after the second and third dose and at 2-week intervals from 14 days to 10 weeks after the third dose using a Cox regression model. Vaccine effectiveness was defined as (1 - hazard ratio) × 100 (%). RESULTS: In total, 295 705 and 288 184 individuals were included in the BA.1- and BA.2-predominant periods, respectively. The effectiveness of a third dose against infection was 62.4% and 48.1% in the BA.1- and BA.2-predominant periods, respectively. Vaccine effectiveness at 2-3 weeks and ≥10 weeks after the third dose decreased from 63.6% (95% confidence interval [CI], 56.4-69.5%) to 52.9% (95% CI, 41.1-62.3%) and from 54.5% (95% CI, 3.0-78.7%) to 40.1% (95% CI, 15.1-57.7%) in the BA.1- and BA.2-predominant periods, respectively. CONCLUSIONS: A third dose was moderately effective against BA.1 and BA.2 sublineages, but its effectiveness decreased by approximately 10% age points from 2-3 weeks to ≥10 weeks after the third vaccination.

    DOI: 10.1093/ofid/ofac636

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study Reviewed International journal

    Wataru Mimura, Chieko Ishiguro, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda

    International Journal of Infectious Diseases   125   58 - 60   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
    OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16-64 years during two periods: the Delta-predominant period (July 1-December 31, 2021) and the Omicron-predominant period (January 1-March 29, 2022). RESULTS: When comparing individuals who were vaccinated with those who were unvaccinated, the effectiveness of a second dose against symptomatic infection was 89.8&#37; (95&#37; confidence interval [CI]: 80.5-94.7&#37;) during the Delta-predominant period and 21.2&#37; (95&#37; CI: 11.0-30.3&#37;) during the Omicron-predominant period. The effectiveness of a third dose against symptomatic infection was 71.8&#37; (95&#37; CI: 60.1-80.1&#37;) during the Omicron-predominant period. CONCLUSION: Vaccine effectiveness against symptomatic infection decreased during the Omicron-predominant period but was maintained by a third dose.

    DOI: 10.1016/j.ijid.2022.10.001

  • The Effect of renin-angiotensin system inhibitors in cancer patients treated with anti-VEGF therapy. Reviewed

    Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K, Fukuda H

    Open Heart   9 ( 2 )   e002135.   2022.12

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    The Effect of renin-angiotensin system inhibitors in cancer patients treated with anti-VEGF therapy.

  • Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy

    Moriyama, S; Hieda, M; Kisanuki, M; Kawano, S; Yokoyama, T; Fukata, M; Kusaba, H; Maruyama, T; Baba, E; Akashi, K; Fukuda, H

    OPEN HEART   9 ( 2 )   2022.12   ISSN:2053-3624

     More details

    Language:English   Publisher:Open Heart  

    Background Cancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin-angiotensin system inhibitor (RASI) may have a positive synergistic effect with VSP inhibitors, the actual impact on clinical outcomes is unknown. Objectives The study aims to clarify whether RASIs exhibit clinical benefits for patients with cancer with hypertension. Method From the Longevity Improvement and Fair Evidence Study database, comprising Japanese claims data between 2016 and 2020, we reviewed 2380 patients treated with VSP inhibitors who received antihypertensive treatment during cancer therapy. The patients were classified into two groups: with-RASI (n=883) and without-RASI (n=1497). In addition, 1803 of these patients treated for hypertension with RASI-only (n=707) or calcium channel blocker-only (n=1096) were also reviewed. The time-to-treatment failure (TTF), the interval from initiation of chemotherapy to its discontinuation, was applied as the primary endpoint. Results The median TTFs were 167 (60-382) days in the with-RASI group and 161 (63-377) days in the without-RASI group (p=0.587). All models, including Cox proportional hazard models and multiple propensity score models, did not reveal the superiority of with-RASI treatment. In the propensity score matching model, the HR for treatment with-RASI compared with that for without-RASI was 0.96 (95% CI 0.86 to 1.06, p=0.386). In addition, the TTFs of RASI-only were not superior to calcium channel blocker-only (p=0.584). Conclusions RASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.

    DOI: 10.1136/openhrt-2022-002135

    Web of Science

    Scopus

    PubMed

  • The Effect of renin-angiotensin system inhibitors in cancer patients treated with anti-VEGF therapy. Reviewed

    Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K, Fukuda H

    Open Heart   9 ( 2 )   e002135.   2022.12

     More details

    Authorship:Last author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Risk of cardiovascular events leading to hospitalization after Streptococcus pneumoniae infection: A retrospective cohort LIFE study. Reviewed

    Nishimura N, Fukuda H

    BMJ Open   12 ( 11 )   e059713   2022.12

     More details

    Authorship:Last author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer’s Disease Patients in Japan: LIFE Study Reviewed

    90 ( 3 )   1177 - 1186   2022.11

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Background: Donepezil is frequently used to treat Alzheimer’s disease (AD) symptoms but is associated with early discontinuation. Determining the persistence rates of anti-dementia drug use after donepezil initiation may inform the development and improvement of treatment strategies, but there is little evidence from Japan. Objective: To determine anti-dementia drug persistence following donepezil initiation among AD patients in Japan using insurance claims data. Methods: Insurance claims data for AD patients with newly prescribed donepezil were obtained from 17 municipalities between April 2014 and October 2021. Anti-dementia drug persistence was defined as a gap of ≤60 days between the last donepezil prescription and a subsequent prescription of donepezil, another cholinesterase inhibitor, or memantine. Cox proportional hazards models were used to analyze the association between care needs levels and discontinuation. Results: We analyzed 20,474 AD patients (mean age±standard deviation: 82.2±6.3 years, women: 65.7%). The persistence rates were 89.1% at 30 days, 79.4% at 90 days, 72.6% at 180 days, 64.5% at 360 days, and 58.3% at 540 days after initiation. Among the care needs levels, the hazard ratio (95% confidence interval) for discontinuation was 1.01 (0.94–1.07) for patients with support needs, 1.12 (1.06–1.18) for patients with low long-term care needs, and 1.31 (1.21–1.40) for patients with moderate-to-high long-term care needs relative to independent patients. Conclusion: Japanese AD patients demonstrated low anti-dementia drug persistence rates that were similar to those of other countries. Higher long-term care needs were associated with discontinuation. Further measures are needed to improve drug persistence in AD patients.

    DOI: 10.3233/jad-220200

  • Risk of cardiovascular events leading to hospitalisation after <i>Streptococcus pneumoniae</i> infection: a retrospective cohort LIFE Study

    Nishimura, N; Fukuda, H

    BMJ OPEN   12 ( 11 )   e059713   2022.11   ISSN:2044-6055

     More details

    Language:English   Publisher:BMJ Open  

    Objectives To elucidate the risk of cardiovascular event occurrence following Streptococcus pneumoniae infection. Design Retrospective cohort study using a LIFE Study database. Setting Three municipalities in Japan. Participants Municipality residents who were enrolled in either National Health Insurance or the Latter-Stage Elderly Healthcare System from April 2014 to March 2020. Exposure Occurrence of S. pneumoniae infection. Primary outcome measures Occurrence of one of the following cardiovascular events that led to hospitalisation after S. pneumoniae infection: (1) coronary heart disease (CHD), (2) heart failure (HF), (3) stroke or (4) atrial fibrillation (AF). Results S. pneumoniae-infected patients were matched with non-infected patients for each cardiovascular event. We matched 209 infected patients and 43 499 non-infected patients for CHD, 179 infected patients and 44 148 non-infected patients for HF, 221 infected patients and 44 768 non-infected patients for stroke, and 241 infected patients and 39 568 non-infected patients for AF. During follow-up, the incidence rates for the matched infected and non-infected patients were, respectively, 38.6 (95% CI 19.9 to 67.3) and 30.4 (29.1 to 31.8) per 1000 person-years for CHD; 69.6 (41.9 to 108.8) and 50.5 (48.9 to 52.2) per 1000 person-years for HF; 75.4 (48.3 to 112.2) and 35.5 (34.1 to 36.9) per 1000 person-years for stroke; and 34.7 (17.9 to 60.6) and 11.2 (10.4 to 12.0) per 1000 person-years for AF. Infected patients were significantly more likely to develop stroke (adjusted HR: 2.05, 95% CI 1.22 to 3.47; adjusted subdistribution HR: 1.94, 95% CI 1.15 to 3.26) and AF (3.29, 1.49 to 7.26; 2.74, 1.24 to 6.05) than their non-infected counterparts. Conclusions S. pneumoniae infections elevate the risk of subsequent stroke and AF occurrence. These findings indicate that pneumococcal infections have short-term effects on patients' health and increase their midterm to long-term susceptibility to serious cardiovascular events.

    DOI: 10.1136/bmjopen-2021-059713

    Web of Science

    Scopus

    PubMed

  • The impact of mitral regurgitation on the incidence of stroke in patients with atrial fibrillation

    Hieda, M; Ono, Y; Moriyama, S; Kisanuki, M; Ishiguro, C; Sato, S; Fukuda, H; Akashi, K

    EUROPEAN HEART JOURNAL   43   546 - 546   2022.10   ISSN:0195-668X eISSN:1522-9645

     More details

  • 高齢者肺炎球菌ワクチンの接種率および接種関連要因の検討 LIFE Study

    山田 直輝, 中塚 清将, 手塚 真斗, 村田 典子, 前田 恵, 福田 治久, 秋末 敏宏, 小野 玲

    日本公衆衛生学会総会抄録集   81回   234 - 234   2022.9

     More details

    Language:Japanese  

  • Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. Reviewed International journal

    Chieko Ishiguro, Wataru Mimura, Fumiko Murata, Haruhisa Fukuda

    Vaccine   40 ( 42 )   6179 - 6186   2022.9   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    BACKGROUND: Japan currently lacks a data platform that can support quantitative assessments of the causal relationships between vaccines and adverse events. This study describes the development and application of the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study to facilitate such assessments. METHODS: A database was created by linking public insurance enrollees' claims data with vaccination records acquired from participating municipalities. To provide an overview of the study data, we produced descriptive statistics of sex, age, and vaccinations. We also conducted a pilot study using the database to assess influenza vaccine safety during the 2018/2019 season among older persons (≥65 years) residing in a single municipality. RESULTS: Our database was created using data from approximately 1.12 million individuals in 7 municipalities between 2013 and 2020. The data during fiscal year 2018 included 853,016 individuals (male: 363,079, female: 489,937) with a median age of 70 years (interquartile range: 52-79). We obtained information on 17 vaccine types, including the pneumococcal vaccine and influenza vaccine. In the pilot study, we analyzed 48,723 vaccinated persons matched with 48,723 unvaccinated persons. The only adverse event that occurred in both groups was Bell's palsy, which had an adjusted incidence rate ratio of 1.21 (95 &#37; confidence interval: 0.48-3.07). CONCLUSIONS: The VENUS Study is Japan's first healthcare data platform that enables comparative assessments of vaccinated and unvaccinated persons in large samples covering all age groups. Efforts are underway to increase the number of participating municipalities and to generate evidence on vaccine effectiveness and safety.

    DOI: 10.1016/j.vaccine.2022.08.069

    Web of Science

    Scopus

    PubMed

    researchmap

  • 高齢者肺炎球菌ワクチン接種が要介護認定に及ぼす影響 LIFE study

    手塚 真斗, 小野 玲, 中塚 清将, 山田 直輝, 秋末 敏宏, 村田 典子, 前田 恵, 福田 治久

    日本公衆衛生学会総会抄録集   81回   230 - 230   2022.9

     More details

    Language:Japanese  

  • 高齢者肺炎球菌ワクチンの接種率および接種関連要因の検討 LIFE Study

    山田 直輝, 中塚 清将, 手塚 真斗, 村田 典子, 前田 恵, 福田 治久, 秋末 敏宏, 小野 玲

    日本公衆衛生学会総会抄録集   81回   234 - 234   2022.9   ISSN:1347-8060

     More details

    Language:Japanese   Publisher:日本公衆衛生学会  

    researchmap

  • 高齢者肺炎球菌ワクチン接種が要介護認定に及ぼす影響 LIFE study

    手塚 真斗, 小野 玲, 中塚 清将, 山田 直輝, 秋末 敏宏, 村田 典子, 前田 恵, 福田 治久

    日本公衆衛生学会総会抄録集   81回   230 - 230   2022.9   ISSN:1347-8060

     More details

    Language:Japanese   Publisher:日本公衆衛生学会  

    researchmap

  • Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged ≥ 75 years in Japan: The LIFE-VENUS Study. Reviewed International journal

    Wataru Mimura, Chieko Ishiguro, Haruhisa Fukuda

    Vaccine   40 ( 34 )   5023 - 5029   2022.8   ISSN:0264-410X eISSN:1873-2518

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged ≥ 75 years in Japan: The LIFE-VENUS Study.
    BACKGROUND: Older persons are recommended to receive annual influenza vaccinations due to their increased susceptibility to influenza infections and related complications. Routine assessments of influenza vaccine effectiveness (IVE) in older persons may help to improve vaccine development and vaccination strategies, but there is a lack of consistent epidemiological data from Japan. This study aimed to evaluate IVE against hospitalization during the 2018/2019 season among older persons aged ≥ 75 years in Japan. METHODS: This cohort study was conducted using insurance claims data and vaccination records provided by the Longevity Improvement & Fair Evidence - Vaccine Effectiveness, Networking, and Universal Safety (LIFE-VENUS) Study. The study cohort comprised older persons aged ≥ 75 years residing in an urban municipality in Japan. Vaccinated participants were identified through vaccination records from October 2018 to January 2019, and were matched with unvaccinated participants using a 1:1 ratio. The IVE against hospitalization was calculated as (1-hazard ratio) × 100&#37; while adjusting for covariates such as age, sex, comorbidities, previous vaccinations, and care needs levels. RESULTS: We analyzed 30,881 vaccinated participants matched with 30,881 unvaccinated participants. Among these, 587 (1.9&#37;) vaccinated participants and 644 (2.1&#37;) unvaccinated participants were hospitalized during the 2018/2019 season. The adjusted IVE against hospitalization was estimated to be 28.9&#37; (16.6-39.4&#37;). CONCLUSIONS: The influenza vaccine for the 2018/2019 season showed moderate effectiveness among older persons in Japan. The LIFE-VENUS Study represents a potential platform for the continued monitoring of IVE among the older Japanese population.

    DOI: 10.1016/j.vaccine.2022.07.002

    Web of Science

    Scopus

    PubMed

    researchmap

  • Medical visits and health-care expenditures of patients attending orthopedic clinics during the COVID-19 pandemic in Japan: LIFE Study Reviewed

    Naomichi Tani, Haruhisa Fukuda

    International Journal for Quality in Health Care   34 ( 3 )   2022.7   ISSN:1353-4505 eISSN:1464-3677

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    Medical visits and health-care expenditures of patients attending orthopedic clinics during the COVID-19 pandemic in Japan: LIFE Study
    Abstract

    Background

    The first state of emergency for coronavirus disease 2019 (COVID-19) in Japan was imposed from April to May 2020. During that period, people were urged to avoid non-essential outings, which may have reduced their access to health care.

    Methods

    Using health-care claims data from a city in Fukuoka prefecture, Japan, we conducted a retrospective cohort study of the state of emergency’s impact on patients’ medical visits to orthopedic clinics and their associated health-care expenditures. These measures were compared between 2019 and 2020 using a year-over-year analysis and unpaired t-tests.

    Results

    The analysis showed that medical visits in 2020 significantly decreased by 23.7&#37; in April (P &amp;lt; 0.01) and 17.6&#37; in May (P &amp;lt; 0.01) when compared with the previous year. Similarly, monthly outpatient health-care expenditure significantly decreased by 2.4&#37; (P &amp;lt; 0.01) in April 2020 when compared with April 2019. In contrast, the health-care expenditure per capita per visit significantly increased by 1.5&#37; (P &amp;lt; 0.01) in June 2020 (after the state of emergency was lifted) when compared with June 2019.

    Conclusion

    As orthopedic clinics in Japan are reimbursed using a fee-for-service system, the increases in per capita expenditures after the state of emergency may be indicative of physician-induced demand. However, we posit that it is more likely that a post-emergency increase in anti-inflammatory and analgesic treatments for spondylopathies, low back pain and sciatica induced a temporary rise in these expenditures.

    DOI: 10.1093/intqhc/mzac056

    Web of Science

    Scopus

    PubMed

    researchmap

  • ASSOCIATIONS OF COMPREHENSIVE STROKE CENTER SCORES WITH MEDICAL AND LONG-TERM CARE EXPENDITURES IN ISCHEMIC STROKE PATIENTS AFTER HOSPITAL DISCHARGE: J-ASPECT & LIFE STUDY

    Ono, Y; Fukuda, H; Shimogawa, T; Takegami, M; Yoshimoto, K; Iihara, K

    VALUE IN HEALTH   25 ( 7 )   S414 - S414   2022.7   ISSN:1098-3015 eISSN:1524-4733

     More details

  • ASSOCIATIONS BETWEEN PSYCHIATRIC DISORDERS AND COVID-19 IN JAPAN: RESULTS FROM THE LIFE STUDY

    Murata, F; Maeda, M; Fukuda, H

    VALUE IN HEALTH   25 ( 7 )   S444 - S444   2022.7   ISSN:1098-3015 eISSN:1524-4733

     More details

  • Acute and delayed psychiatric sequelae among patients hospitalised with COVID-19: a cohort study using LIFE study data. Reviewed International journal

    Fumiko Murata, Megumi Maeda, Chieko Ishiguro, Haruhisa Fukuda

    General psychiatry   35 ( 3 )   e100802   2022.6   ISSN:2096-5923 eISSN:2517-729X

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Characterising the psychiatric sequelae of coronavirus disease 2019 (COVID-19) can inform the development of long-term treatment strategies. However, few studies have examined these sequelae at different time points after COVID-19 infection. Aims: The study aimed to investigate the incidences and risks of acute and delayed psychiatric sequelae in patients hospitalised with COVID-19 in Japan. Methods: This retrospective cohort study was conducted using a database comprising healthcare claims data from public health insurance enrollees residing in a Japanese city. We analysed a primary cohort comprising patients hospitalised with COVID-19 between March 2020 and July 2021 and two control cohorts comprising patients hospitalised with influenza or other respiratory tract infections (RTI) during the same period. We calculated the incidences of acute (1-3 months after infection) and delayed (4-6 months after infection) psychiatric sequelae. These sequelae were identified using diagnosis codes and categorised as mood/anxiety/psychotic disorder, mood disorder, anxiety disorder, psychotic disorder or insomnia. Multivariable logistic regression models were used to estimate the odds ratios (ORs) of psychiatric sequelae occurrence after COVID-19 infection compared with influenza and other RTI. Results: The study population with acute psychiatric sequela consisted of 662 patients with COVID-19, 644 patients with influenza, and 7369 patients with RTI who could be followed for 3 months; the study population with delayed psychiatric sequelae consisted of 371 patients with COVID-19, 546 patients with influenza, and 5397 patients with RTI who could be followed for 6 months. In the analysis of acute psychiatric sequelae, COVID-19 had significantly higher odds of mood/anxiety/psychotic disorder (OR: 1.39, p=0.026), psychotic disorder (OR: 2.13, p<0.001), and insomnia (OR: 2.59, p<0.001) than influenza, and significantly higher odds of insomnia (OR: 1.44, p=0.002) and significantly lower odds of anxiety disorder (OR: 0.56, p<0.001) than other RTI. In the analysis of delayed psychiatric sequelae, COVID-19 had significantly higher odds of psychotic disorder (OR: 2.25, p=0.007) than influenza, but significantly lower odds of anxiety disorder (OR: 0.55, p=0.011) than other RTI. Conclusions: COVID-19 was generally associated with an increased risk of psychiatric sequelae occurring within 3 months after infection, but had a lower risk of new psychiatric sequelae developing 4-6 months after infection.

    DOI: 10.1136/gpsych-2022-100802

    Web of Science

    Scopus

    PubMed

    researchmap

  • Clinical implication of the relationship between antimicrobial resistance and infection control activities in Japanese hospitals: a principal component analysis-based cluster analysis. Reviewed

    Shoji T, Sato N, Fukuda H, Muraki Y, Kawata K, Akazawa M

    Antibiotics   2022.4

     More details

    Language:Others  

  • Clinical implication of the relationship between antimicrobial resistance and infection control activities in Japanese hospitals: a principal component analysis-based cluster analysis. Reviewed

    Shoji T, Sato N, Fukuda H, Muraki Y, Kawata K, Akazawa M

    Antibiotics   2022.4

     More details

  • Medical expenditures for community-acquired pneumococcal disease in Japan. Reviewed

    Fukuda H, Onizuka H, Murata F

    Journal of National Institute of Public Health   72 ( 1 )   2022.3

     More details

    Language:Others  

  • Medical expenditures for community-acquired pneumococcal disease in Japan. Reviewed

    Fukuda H, Onizuka H, Murata F

    Journal of National Institute of Public Health   72 ( 1 )   2022.3

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • The Longevity Improvement & Fair Evidence (LIFE) Study: Overview of the Study Design and Baseline Participant Profile. Reviewed

    Fukuda H, Ishiguro C, Ono R, Kiyohara K

    Journal of Epidemiology   2022.3

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study

    Fukuda, H; Onizuka, H; Nishimura, N; Kiyohara, K

    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES   116   216 - 222   2022.3   ISSN:1201-9712 eISSN:1878-3511

     More details

    Language:English   Publisher:International Journal of Infectious Diseases  

    Objectives: This study aimed to identify the risk factors for pneumococcal disease. Methods: The study was performed using insurance claims data from the residents of 12 Japanese municipalities. Based on recorded diagnoses, we identified chronic medical conditions in each patient between April 2015 and March 2016 and examined the subsequent occurrence of a pneumococcal disease from April 2016 onward. Cox proportional hazards models were used to estimate the hazard ratio of each chronic medical condition for a pneumococcal disease occurrence. Results: The study was conducted on 732,235 patients, of whom, 61,306 (8.4%) were aged 0-18 years, 184,367 (25.2%) were aged 19-49 years, 126,078 (17.2%) were aged 50-64 years, and 360,484 (49.2%) were aged ≥65 years. A higher number of conditions was associated with a higher incidence of pneumococcal disease. Significant risk factors for pneumococcal disease in all patients included chronic heart disease, chronic lung disease, diabetes mellitus, cancer, and chronic renal disease. Furthermore, chronic lung disease, diabetes mellitus, aspiration pneumonia, and immunosuppressant use were risk factors among patients aged 50-64 years. Conclusions: Persons aged 50-64 years with multiple chronic medical conditions or with specific conditions are at a higher risk of developing pneumococcal disease, indicating a need to consider their inclusion in routine vaccination programs.

    DOI: 10.1016/j.ijid.2021.12.365

    Web of Science

    Scopus

    PubMed

  • Medical expenditures for community-acquired pneumococcal disease in Japan

    FUKUDA Haruhisa, ONIZUKA Hiroaki, MURATA Fumiko

    Journal of the National Institute of Public Health   71 ( 1 )   87 - 91   2022.2   ISSN:13476459 eISSN:24320722

     More details

    Language:English   Publisher:National Institute of Public Health  

    <p><b>Objectives</b>: The decision-making process for vaccination programs must be informed by cost-effectiveness analyses. This study was performed to quantify the medical expenditures for pneumococcal disease (PD) in Japan.</p><p><b>Methods</b>: Surveillance data from the Japan Nosocomial Infections Surveillance program and insurance claims data were collected from community-acquired PD patients admitted to 29 hospitals in Japan. Patients with positive blood specimens were designated as having invasive PD (IPD). We estimated the medical expenditures incurred during the PD hospitalization episodes.</p><p><b>Results</b>: The study sample comprised 1,358 PD patients from 28 hospitals between April 2015 and September 2017. Of these, 69 were IPD patients and 1,289 were non-IPD patients. The mean medical expenditures (standard deviation) for all PD patients, IPD patients, and non-IPD patients were estimated to be $6,610 ($13,133), $13,975 ($16,415), and $6,216 ($12,823), respectively.</p><p><b>Conclusion</b>: This study is the first to quantify the medical expenditures for community-acquired PD in Japan.</p>

    DOI: 10.20683/jniph.71.1_87

    CiNii Research

  • Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study. Reviewed

    Fukuda H, Onizuka H, Nishimura N, Kiyohara K

    International Journal of Infectious Diseases   2022.2

     More details

    Language:Others  

    Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study.

  • Clinical Implication of the Relationship between Antimicrobial Resistance and Infection Control Activities in Japanese Hospitals: A Principal Component Analysis-Based Cluster Analysis. International journal

    Tomokazu Shoji, Natsu Sato, Haruhisa Fukuda, Yuichi Muraki, Keishi Kawata, Manabu Akazawa

    Antibiotics (Basel, Switzerland)   11 ( 2 )   2022.2   ISSN:2079-6382

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    There are few multicenter investigations regarding the relationship between antimicrobial resistance (AMR) and infection-control activities in Japanese hospitals. Hence, we aimed to identify Japanese hospital subgroups based on facility characteristics and infection-control activities. Moreover, we evaluated the relationship between AMR and hospital subgroups. We conducted a cross-sectional study using administrative claims data and antimicrobial susceptibility data in 124 hospitals from April 2016 to March 2017. Hospitals were classified using cluster analysis based the principal component analysis-transformed data. We assessed the relationship between each cluster and AMR using analysis of variance. Ten variables were selected and transformed into four principal components, and five clusters were identified. Cluster 5 had high infection control activity. Cluster 2 had partially lower activity of infection control than the other clusters. Clusters 3 and 4 had a higher rate of surgeries than Cluster 1. The methicillin-resistant Staphylococcus aureus (MRSA)/S. aureus detection rate was lowest in Cluster 1, followed, respectively, by Clusters 5, 2, 4, and 3. The MRSA/S. aureus detection rate differed significantly between Clusters 4 and 5 (p = 0.0046). Our findings suggest that aggressive examination practices are associated with low AMR whereas surgeries, an infection risk factor, are associated with high AMR.

    DOI: 10.3390/antibiotics11020229

    Web of Science

    Scopus

    PubMed

    researchmap

  • Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study. Reviewed

    Fukuda H, Onizuka H, Nishimura N, Kiyohara K

    2022.2

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • 日本における市中肺炎球菌感染症による医療費(Medical expenditures for community-acquired pneumococcal disease in Japan)

    福田 治久, 鬼塚 浩明, 村田 典子

    保健医療科学   71 ( 1 )   87 - 91   2022.2   ISSN:1347-6459

     More details

    Language:English   Publisher:国立保健医療科学院  

    目的:ワクチン接種プログラムの意思決定プロセスには,費用対効果評価が必要である.本研究の目的は,市中肺炎球菌感染症(PD)による医療費を推定することである.方法:日本の29のDPC対象病院に入院した市中肺炎球菌感染症患者について,厚生労働省院内感染対策サーベイランス事業(JANIS)の検査部門データとDPCデータを突合した.JANISデータにおいて血液検体が陽性の患者を侵襲性肺炎球菌感染症(IPD)と定めた.市中肺炎球菌感染症症例の医療費を推定した.結果:解析対象症例は28病院における1,358症例である.IPD症例は69症例,非IPD症例は1,289症例であった.全PD症例,IPD症例,非IPD症例における平均医療費(標準偏差)は,それぞれ6,610ドル(13,133ドル),13,975ドル(16,415ドル),6,216ドル(12,823ドル)と推定された.結論:本研究は日本において市中肺炎球菌感染症による医療費を初めて定量化することができた.(著者抄録)

  • Economic Status and Mortality in Patients with Alzheimer's Disease in Japan: The Longevity Improvement and Fair Evidence Study Reviewed

    Rei Ono, Kazuaki Uchida, Kiyomasa Nakatsuka, Maeda Megumi, Haruhisa Fukuda

    Journal of the American Medical Directors Association   23 ( 1 )   161 - 164   2022.1   ISSN:1525-8610 eISSN:1538-9375

     More details

    Language:Others   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    Economic Status and Mortality in Patients with Alzheimer's Disease in Japan: The Longevity Improvement and Fair Evidence Study

    DOI: 10.1016/j.jamda.2021.08.025

    Web of Science

    Scopus

    PubMed

    researchmap

  • PROGRESSION OF MILD COGNITIVE IMPAIRMENT CASES TO ALZHEIMER'S DISEASE: LIFE STUDY

    Fukuda, H; Kanzaki, H; Ono, R

    VALUE IN HEALTH   25 ( 1 )   S122 - S122   2022.1   ISSN:1098-3015 eISSN:1524-4733

     More details

  • RISK OF CARDIOVASCULAR EVENTS AFTER STREPTOCOCCUS PNEUMONIAE INFECTIONS: LIFE STUDY

    Nishimura, N; Fukuda, H

    VALUE IN HEALTH   25 ( 1 )   S125 - S126   2022.1   ISSN:1098-3015 eISSN:1524-4733

     More details

  • Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan. Reviewed International journal

    Tomokazu Shoji, Ryusei Muto, Haruhisa Fukuda, Yuichi Muraki, Keishi Kawata, Manabu Akazawa

    Antimicrobial stewardship & healthcare epidemiology : ASHE   2 ( 1 )   e147   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: To compare the incremental costs and healthcare utilization of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with those of methicillin-susceptible S. aureus (MSSA) bacteremia. DESIGN: Retrospective cohort study using data from April 2014 to March 2015. SETTING: Antimicrobial resistance surveillance and hospital claims data from 16 Japanese hospitals. PATIENTS: The study included 73 patients with S. aureus bacteremia: 23 with MRSA and 50 with MSSA. METHODS: MRSA bacteremia was identified using blood cultures and drug-susceptibility tests. MRSA- and MSSA-related medical practices were evaluated. The costs were calculated and compared. All the medical costs were classified into empirical and definitive therapy periods and expressed in Japanese yen (JPY, 1 USD = 106 JPY). Additionally, costs at aggressive and passive bacterial test-performing facilities were compared. RESULTS: No significant differences existed in MRSA-related resource use per patient episode between MRSA and MSSA bacteremia during empirical therapy. However, during definitive therapy, in MRSA bacteremia compared with MSSA bacteremia, this difference was higher. The average MRSA-related costs of empirical therapy for MRSA and MSSA were 13,380 and 9,140 JPY (126 and 86 USD) per patient, and for definitive therapy, they were 69,810 and 29,510 JPY (659 and 278 USD) per patient, respectively. No significant differences were noted. Conversely, the average examination costs during definitive therapy differed significantly: 9,740 vs 3,850 JPY (92 vs 36 USD), respectively (P = .0294). Furthermore, the incremental costs in aggressive facilities were lower for the definitive therapy period than those in passive facilities. CONCLUSIONS: In the definitive therapy period, MRSA bacteremia had higher incremental costs and greater use of healthcare resources. In addition, the incremental costs in aggressive facilities were lower than those in passive facilities.

    DOI: 10.1017/ash.2022.280

    Scopus

    PubMed

    researchmap

  • 承認後ワクチンの有効性・安全性評価のためのデータベース構築と活用:VENUS Study

    石黒 智恵子, 福田 治久

    医薬品医療機器レギュラトリーサイエンス   53 ( 6 )   507 - 510   2022   ISSN:18846076 eISSN:24366226

     More details

    Language:Japanese   Publisher:一般財団法人 医薬品医療機器レギュラトリーサイエンス財団  

    DOI: 10.51018/pmdrs.53.6_507

    CiNii Research

  • Regional Disparity of Reperfusion Therapy for Acute Ischemic Stroke in Japan: A Retrospective Analysis of Nationwide Claims Data from 2010 to 2015. Reviewed

    Maeda M, Fukuda H, Matsuo R, Ago T, Kitazono T, Kamouchi M

    J Am Heart Assoc   2021.12

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Healthcare expenditure attributable to dementia with Lewy bodies in Japan: LIFE Study Reviewed

    Rei Ono, Kiyomasa Nakatsuka, Kazuaki Uchida, Haruhisa Fukuda

    Alzheimer's & Dementia   17 ( S10 )   2021.12

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/alz.053750

  • Medical care and long-term care expenditures attributable to Alzheimer's disease onset: Results from the LIFE Study. International journal

    Fukuda H, Ono R, Maeda M, Murata F

    Journal of Alzheimer's Disease   84 ( 2 )   807 - 817   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Medical Care and Long-Term Care Expenditures Attributable to Alzheimer's Disease Onset: Results from the LIFE Study.
    BACKGROUND: Alzheimer's disease (AD) can increase both medical care and long-term care (LTC) costs, but the latter are frequently neglected in estimates of AD's economic burden. OBJECTIVE: To elucidate the economic burden of new AD cases in Japan by estimating patient-level medical care and LTC expenditures over 3 years using a longitudinal database. METHODS: The study was performed using monthly claims data from residents of 6 municipalities in Japan. We identified patients with new AD diagnoses between April 2015 and March 2016 with 3 years of follow-up data. Medical care and LTC expenditures were estimated from 1 year before onset until 3 years after onset. To quantify the additional AD-attributable expenditures, AD patients were matched with non-AD controls using propensity scores, and their differences in expenditures were calculated. RESULTS: After propensity score matching, the AD group and non-AD group each comprised 1748 individuals for analysis (AD group: mean age±standard deviation, 81.9±7.6 years; women, 66.0&#37;). The total additional expenditures peaked at &#36;1398 in the first month, followed by &#36;1192 and &#36;1031 in the second and third months, respectively. The additional LTC expenditures increased substantially 3 months after AD onset (&#36;227), and gradually increased thereafter. These additional LTC expenditures eventually exceeded the additional medical care expenditures in the second year after AD onset. CONCLUSION: Although total AD-attributable expenditures peaked just after disease onset, the impact of LTC on these expenditures rose over time. Failure to include LTC expenditures would severely underestimate the economic burden of AD.

    DOI: 10.3233/JAD-201508

  • アルツハイマー型認知症とレビー小体型認知症の診断後月別医療費推移 LIFE Study

    小野 玲, 中塚 清将, 内田 一彰, 福田 治久

    35 ( 4 )   644 - 644   2021.10

     More details

    Language:Japanese  

  • Changes to hospital inpatient volume after newspaper reporting of medical errors. Reviewed

    Fukuda H

    Journal of Patient Safety   17 ( 5 )   e401 - e405   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Changes to hospital inpatient volume after newspaper reporting of medical errors.

  • The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan Reviewed

    Tomotaka Sobue, Haruhisa Fukuda, Tetsuya Matsumoto, Bennett Lee, Shuhei Ito, Satoshi Iwata

    16 ( 8 )   e0256379 - e0256379   2021.8

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan
    Introduction

    The COVID-19 pandemic caused by SARS-CoV-2 has now affected tens of millions of people globally. It is the hope that vaccines against SARS-CoV-2 will deliver a comprehensive solution to this global pandemic; however, this will require extensive national vaccination programs. Ultimately, clinical conditions and even sudden unexplained death will occur around the time of vaccination, thus a distinction needs to be made between events that are causally related to the vaccine or temporally related to vaccination. This study aimed to estimate the background occurrence of 43 clinical conditions in the Japanese population.

    Methods

    A retrospective cohort study was conducted from 2013 to 2019 using data from two large healthcare claims databases (MDV and JMDC) in Japan. The estimated number of new cases and incidence were calculated based on the actual number of new cases identified in the databases. The PubMed and Ichushi-web databases, as well as grey literature such as guidelines and government statistics, were also searched to identify any publications related to incidence of these conditions in Japan.

    Results and conclusion

    The estimates of the number of total cases and incidence were similar for the MDV and JMDC databases for some diseases. In addition, some estimates were similar to those in the scientific literature. For example, from the MDV and JMDC databases, estimates of incidence of confirmed Bell’s palsy in 2019 were 41.7 and 47.9 cases per 100,000 population per year, respectively. These estimates were of the same order from the scientific publication. Determining whether clinical conditions occurring around the time of vaccination are causally or only temporally related to vaccination will be critical for public health decision makers as well as for the general public. Comparison of background occurrence at the population level may provide some additional objective evidence for the evaluation of temporality or causality.

    DOI: 10.1371/journal.pone.0256379

  • National database study of trends in bacteraemia aetiology among children and adults in Japan: a longitudinal observational study. Reviewed

    Kusama Y, Ito K, Fukuda H, Matsunaga N, Ohmagari N

    BMJ Open   in press   2021.4

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    National database study of trends in bacteraemia aetiology among children and adults in Japan: a longitudinal observational study.

  • Changes in percutaneous coronary intervention practice in Japan during the COVID-19 outbreak: LIFE Study. Reviewed

    Maeda M, Fukuda H, Kiyohara K, Miki R, Kitamura T

    Acute Medicine & Surgery   2021.2

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • 病床機能報告制度を用いた日常生活動作とリハビリテーション提供時間の関係. Reviewed

    小田太史, 福田治久

    日本公衆衛生雑誌   68 ( 1 )   3 - 11   2021.1

     More details

    Language:Others  

  • 病院における感染対策製品の使用状況とMRSA検出率との関連. Reviewed

    山田絵理佳, 松浦江美, 福田治久.

    保健学研究   34   31 - 38   2021.1

     More details

    Language:Japanese  

  • Nationwide temporal trend analysis of reperfusion therapy utilization and mortality in acute ischemic stroke patients in Japan. Reviewed

    Maeda M, Fukuda H, Matsuo R, Kiyuna F, Ago T, Kitazono T, Kamouchi M

    Medicine   2021.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R Reviewed International journal

    Haruhisa Fukuda, Kosuke Kiyohara, Daisuke Sato, Tetsuhisa Kitamura, Satoshi Kodera

    Value in Health   24 ( 4 )   497 - 504   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jval.2020.10.022

  • Healthcare resources attributable to methicillin-resistant Staphylococcus aureus orthopedic surgical site infections. Reviewed

    Fukuda H, Sato D, Iwamoto T, Yamada K, Matsushita K

    Scientific Reports   2020.10

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Healthcare resources attributable to methicillin-resistant Staphylococcus aureus orthopedic surgical site infections.

  • A Real-World Comparison of 1-year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 versus CoreValve versus Evolut R. Reviewed

    Fukuda H, Kiyohara K, Sato D, Kitamura T, Kodera S

    Value in Health   2020.10

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Low-intensity pulsed ultrasound is frequently used to treat fractures after osteosynthesis in elderly patients: A study using open data from the National Database of Health Insurance Claims of Japan. Reviewed

    Jingushi S, Fukuda H

    2020.9

     More details

    Language:Others  

    Low-intensity pulsed ultrasound is frequently used to treat fractures after osteosynthesis in elderly patients: A study using open data from the National Database of Health Insurance Claims of Japan.

  • Pharmacist-supported antimicrobial stewardship in a retirement home Reviewed

    Shigemichi Takito, Yoshiki Kusama, Haruhisa Fukuda, Satoshi Kutsuna

    Journal of Infection and Chemotherapy   26 ( 8 )   858 - 861   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jiac.2020.04.008

  • Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma Reviewed

    Haruhisa Fukuda, Daisuke Sato, Kensuke Moriwaki, Haku Ishida

    PLOS ONE   15 ( 8 )   e0237316 - e0237316   2020.8

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0237316

  • The effects of raising the long‐term care insurance co‐payment rate on the utilization of long‐term care services Reviewed

    20 ( 7 )   685 - 690   2020.7

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ggi.13935

  • The effects of raising the long-term care insurance co-payment rate on the utilization of long-term care services Reviewed

    Yugo Soga, Fumiko Murata, Megumi Maeda, Haruhisa Fukuda

    Geriatrics and Gerontology International   20 ( 7 )   685 - 690   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ggi.13935

  • Comparing Retreatments and Expenditures in Flow Diversion Versus Coiling for Unruptured Intracranial Aneurysm Treatment: A Retrospective Cohort Study Using a Real-World National Database Reviewed

    Haruhisa Fukuda, Daisuke Sato, Yoriko Kato, Wataro Tsuruta, Masahiro Katsumata, Hisayuki Hosoo, Yuji Matsumaru, Tetsuya Yamamoto

    Neurosurgery   87 ( 1 )   63 - 70   2020.7

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Comparing Retreatments and Expenditures in Flow Diversion Versus Coiling for Unruptured Intracranial Aneurysm Treatment: A Retrospective Cohort Study Using a Real-World National Database

    DOI: 10.1093/neuros/nyz377

  • Pharmacist-supported antimicrobial stewardship in a retirement home. Reviewed International journal

    Shigemichi Takito, Yoshiki Kusama, Haruhisa Fukuda, Satoshi Kutsuna

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   26 ( 8 )   858 - 861   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jiac.2020.04.008

  • Effect of income on length of stay in a hospital or long-term care facility among older adults with dementia in Japan. Reviewed International journal

    Fumiko Murata, Akira Babazono, Haruhisa Fukuda

    International journal of geriatric psychiatry   35 ( 3 )   302 - 311   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/gps.5248

  • Obstacles to antimicrobial use surveillance using claims data in elderly care facilities in Japan

    Yoshiki Kusama, Kumiko Suzuk, Yoshiaki Gu, Haruhisa Fukuda, Masahiro Ishikane, Kayoko Hayakawa, Norio Ohmagari

    Japanese Journal of Chemotherapy   68 ( 2 )   210 - 215   2020.3

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

  • Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan. Reviewed International journal

    Haruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, Sachiko Ohde, Shinichi Noto, Ryo Watanabe, Osamu Takahashi

    PharmacoEconomics   38 ( 3 )   297 - 306   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s40273-019-00861-x

  • Antimicrobial Utilization and Antimicrobial Resistance in Patients With Haematological Malignancies in Japan: A Multi-Centre Cross-Sectional Study Reviewed International journal

    Wataru Mimura, Haruhisa Fukuda, Manabu Akazawa

    Ann Clin Microbiol Antimicrob   19 ( 1 )   7 - 7   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12941-020-00348-0

  • Longitudinal trends of and factors associated with inappropriate antibiotic prescribing for non-bacterial acute respiratory tract infection in Japan: A retrospective claims database study, 2012–2017 Reviewed

    14 ( 10 )   e0223835 - e0223835   2019.10

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0223835

  • 日本の高齢者施設におけるレセプト情報を利用した抗菌薬使用量調査の問題点 Reviewed

    日馬由貴, 鈴木久美子, 具芳明, 福田治久, 石金正裕, 早川佳代子, 大曲貴夫

    日本化学療法学会雑誌   68 ( 2 )   210 - 215   2019.10

     More details

    Language:Others  

  • Eight-Year Experience of Antimicrobial Stewardship Program and the Trend of Carbapenem Use at a Tertiary Acute-Care Hospital in Japan-The Impact of Postprescription Review and Feedback Reviewed

    Tsubasa Akazawa, Yoshiki Kusama, Haruhisa Fukuda, Kayoko Hayakawa, Satoshi Kutsuna, Yuki Moriyama, Hirotake Ohashi, Saeko Tamura, Kei Yamamoto, Ryohei Hara, Ayako Shigeno, Masayuki Ota, Masahiro Ishikane, Shunichiro Tokita, Hiroyuki Terakado, Norio Omagari

    Open Forum Infect Dis   6 ( 10 )   ofz389   2019.9

     More details

    Language:Others  

  • Impact of a national medical fee schedule revision on the cessation of physician home visits among older patients in Tokyo: A retrospective study. Reviewed International journal

    Chie Teramoto, Tatsuro Ishizaki, Seigo Mitsutake, Haruhisa Fukuda, Takashi Naruse, Sayuri Shimizu, Hideki Ito

    Health & social care in the community   27 ( 4 )   899 - 906   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hsc.12707

  • レセプトデータを用いた医療費分析における診療報酬改定の補正方法 Reviewed

    福田治久, 佐藤大介, 福田敬

    保健医療科学   68 ( 2 )   2019.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • A comparative analysis of treatment costs for home-based care and hospital-based care in enteral nutrition patients: A retrospective analysis of claims data

    M. Maeda, H. Fukuda, S. Shimizu, T. Ishizaki

    Health Policy   123 ( 4 )   367 - 372   2019.4

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    A comparative analysis of treatment costs for home-based care and hospital-based care in enteral nutrition patients: A retrospective analysis of claims data

    DOI: 10.1016/j.healthpol.2018.12.006

  • Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan Reviewed

    K. Moriwaki, H. Fukuda

    Osteoporosis International   30 ( 2 )   299 - 310   2019.2

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan

    DOI: 10.1007/s00198-018-4798-9

  • 公立病院再編による経営改善効果に関する研究 Reviewed

    大谷泰史, 福田治久

    日本医療・病院管理学会誌   56 ( 1 )   17 - 27   2019.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Inpatient expenditures attributable to hospital-onset Clostridium difficile infection: a nationwide case-control study in Japan. Reviewed

    Fukuda H, Yano T, Shimono N

    PharmacoEconomics   36 ( 11 )   1367 - 1376   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Inpatient expenditures attributable to hospital-onset Clostridium difficile infection: a nationwide case-control study in Japan.

  • Do pharmacists have the most potential for patient safety in Japan? Learning from a 2010 nationwide survey Reviewed

    Hirose Masahiro, Nishimura Nobuhiro, Kumakura Shiyunichi, Telloyan John Arthur, Igawa Mikio, Fukuda Haruhisa, Imanaka Yuichi

    Journal of Hospital Administration   7 ( 3 )   40 - 48   2018.4

     More details

    Language:English  

    Do pharmacists have the most potential for patient safety in Japan? Learning from a 2010 nationwide survey
    Background: Unlike in many other countries, patient safety (PS) in Japan has been promoted under the social insurance medical fee schedule, with the implementation of preferential medical fee paid to medical institutions as incentives. Meanwhile, many hospitals do not assign a full-time physician as PS manager at PS division due to the shortage of physicians.Objective: The Health Ministry in Japan has been promoting PS by utilizing the preferential patient safety countermeasure fee (PPSCF) since 2006. This study aims to address the potential of pharmacists for PS at hospitals implementing the PPSCF.Methods: A nationwide questionnaire survey targeting 2,674 hospitals with the PPSCF was performed from 2010 to 2011. Of the 669 hospitals that responded, 627 hospitals were eligible for analysis, including 178 hospitals implementing PPSCF 1 with 400 beds or more (group A), 286 hospitals implementing PPSCF 1 with 399 beds or fewer (group B), and 163 hospitals implementing PPSCF 2 (group C).Results: Although the mean values of PS activities for nurses were the highest among physicians, nurses, and pharmacists, the values per person recalculated for pharmacists were the highest, and the ranges of the values per person for pharmacists were narrowest across the three professional groups. For example, the number per person of incident reports filed in group A was 2.37 ± 0.30 for pharmacists, 1.14 ± 0.11 for physicians, and 2.09 ± 0.31 for nurses (p = .002). For pharmacists, those values were 2.37 ± 0.30 in group A, 2.43 ± 0.14 in group B and 2.35 ± 0.19 in group C (p = .802).Conclusions: Across health professionals, pharmacists may have the most potential for PS under the social insurance medical fee schedule in Japan.

  • Effects of changes in eating speed on obesity in patients with diabetes: a secondary analysis of longitudinal health check-up data Reviewed

    Yumi Hurst, Haruhisa Fukuda

    BMJ Open   8 ( 1 )   e019589 - e019589   2018.1

     More details

    Language:Others   Publishing type:Research paper (scientific journal)  

    Effects of changes in eating speed on obesity in patients with diabetes: a secondary analysis of longitudinal health check-up data
    Objective

    Few studies have examined the causal relationships between lifestyle habits and obesity. With a focus on eating speed in patients with type 2 diabetes, this study aimed to analyse the effects of changes in lifestyle habits on changes in obesity using panel data.

    Methods

    Patient-level panel data from 2008 to 2013 were generated using commercially available insurance claims data and health check-up data. The study subjects comprised Japanese men and women (n=59 717) enrolled in health insurance societies who had been diagnosed with type 2 diabetes during the study period. Body mass index (BMI) was measured, and obesity was defined as a BMI of 25 or more. Information on lifestyle habits were obtained from the subjects’ responses to questions asked during health check-ups. The main exposure of interest was eating speed (‘fast’, ‘normal’ and ‘slow’). Other lifestyle habits included eating dinner within 2 hours of sleeping, after-dinner snacking, skipping breakfast, alcohol consumption frequency, sleep adequacy and tobacco consumption. A generalised estimating equation model was used to examine the effects of these habits on obesity. In addition, fixed-effects models were used to assess these effects on BMI and waist circumference.

    Results

    The generalised estimating equation model showed that eating slower inhibited the development of obesity. The ORs for slow (0.58) and normal-speed eaters (0.71) indicated that these groups were less likely to be obese than fast eaters (P<0.001). Similarly, the fixed-effects models showed that eating slower reduced BMI and waist circumference. Relative to fast eaters, the coefficients of the BMI model for slow and normal-speed eaters were −0.11 and −0.07, respectively (P<0.001).

    Discussion

    Changes in eating speed can affect changes in obesity, BMI and waist circumference. Interventions aimed at reducing eating speed may be effective in preventing obesity and lowering the associated health risks.

    DOI: 10.1136/bmjopen-2017-019589

  • Comparative economic evaluation of home-based and hospital-based palliative care for terminal cancer patients Reviewed

    Koki Kato, Haruhisa Fukuda

    GERIATRICS & GERONTOLOGY INTERNATIONAL   17 ( 11 )   2247 - 2254   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ggi.12977

  • Cumulative number of hospital bed days among older adults in the last year of life: A retrospective cohort study Reviewed

    Tatsuro Ishizaki, Masaya Shimmei, Haruhisa Fukuda, Eun-Hwan Oh, Chiho Shimada, Tomoko Wakui, Hiroko Mori, Ryutaro Takahashi

    GERIATRICS & GERONTOLOGY INTERNATIONAL   17 ( 5 )   737 - 743   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ggi.12777

  • Impact of nonadherence on complication risks and healthcare costs in patients newly-diagnosed with Reviewed

    Haruhisa Fukuda, Miki Mizobe

    DIABETES RESEARCH AND CLINICAL PRACTICE   123   55 - 62   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.diabres.2016.11.007

  • 抗菌薬適正使用評価のための分析フレームワークの構築. Invited Reviewed

    #山中直子, @今村陽子, @福田治久

    日本環境感染学会誌   in press   2016.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan Reviewed

    Haruhisa Fukuda, Shunya Ikeda, Takeru Shiroiwa, Takashi Fukuda

    PHARMACOECONOMICS   34 ( 10 )   1005 - 1014   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s40273-016-0402-3

  • Cost-Effectiveness Analysis of Safety-Engineered Devices Reviewed

    Haruhisa Fukuda, Kensuke Moriwaki

    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY   37 ( 9 )   1012 - 1021   2016.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1017/ice.2016.110

  • Patient-related risk factors for surgical site infection following eight types of gastrointestinal surgery Reviewed

    H. Fukuda

    JOURNAL OF HOSPITAL INFECTION   93 ( 4 )   347 - 354   2016.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jhin.2016.04.005

  • Identification of Covert Atrial Fibrillation in Cryptogenic Ischemic Stroke: Current Clinical Practice in Japan Reviewed

    Kazunori Toyoda, Ken Okumura, Yoichiro Hashimoto, Takanori Ikeda, Takashi Komatsu, Teruyuki Hirano, Haruhisa Fukuda, Kazuo Matsumoto, Masahiro Yasaka

    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES   25 ( 8 )   1829 - 1837   2016.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.012

  • MRSA感染症における追加的医療資源の推計. Reviewed

    高木康文, 福田治久

    日本環境感染学会誌   31 ( 3 )   173 - 180   2016.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    &emsp;本研究の目的は,MRSA感染症における追加的医療資源(入院日数・出来高換算医療費)の推計である. &emsp;対象は調査病院を2012年12月~2014年12月に退院した患者で,解析手法はMRSA感染有無を目的変数にしたロジスティック回帰によって推定される傾向スコアによるマッチング法を用いた.傾向スコア推定後,DPC10桁が同一でスコアが近似するMRSA感染者と非感染者を1対1でマッチングした.また,時間依存バイアスに対処したマッチング法も併せて行った.両者の医療資源の差異の平均から追加医療資源を算出し有意差の検定は対応のあるt検定を用いた. &emsp;解析対象症例数は24,538例で,感染者数は47名であった.MRSA感染症による入院日数の延長は時間依存バイアスに対処した場合:13.1日(95&#37;信頼区間3.7日&ndash;22.4日,p=0.008)および医療費の増加は107.0万円(31.7万円&ndash;182.2万円,p=0.007)であり,時間依存バイアスに対処しない場合:21.2日(95&#37;信頼区間11.7日&ndash;30.8日,p<0.001)および医療費の増加は160.7万円(64.3万円&ndash;257.0万円,p=0.001)と算出された. &emsp;本研究は,傾向スコアを用い時間依存バイアスに対処したマッチング法でMRSA感染症による追加的医療費を推計した.結果,時間依存バイアスに対処しなければ結果を過大評価することが明らかとなった.本推計値は感染制御における費用対効果を計る資料として活用できる.

    DOI: 10.4058/jsei.31.173

  • 潜因性脳梗塞と塞栓源不明脳塞栓症:わが国における臨床的意義と潜在性心房細動検出の重要性. Reviewed

    豊田一則, 奥村謙, 橋本洋一郎, 池田隆徳, 小松隆, 平野照之, 福田治久, 松本万夫, 矢坂正弘

    脳卒中   38 ( 2 )   77 - 85   2016.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    発症原因を特定できない潜因性脳梗塞は,病型分類法によって診断基準が異なり,脳梗塞全体に占める頻度も16~39%と研究間で差が大きい.この中に塞栓症が多く含まれると考えられ,塞栓源不明脳塞栓症という概念も提唱された.とくに潜在性心房細動が注目され,植込み型心電図記録計を用いた長期間の観察では3 割の患者に心房細動が同定された.次世代型植込み型心電図記録計は小型で遠隔監視が可能であり,海外では潜在性心房細動の検出目的に用いられている.心房細動を同定できれば,確立した再発予防法として抗凝固薬を使用でき,脳梗塞再発予防に利するであろう.次世代型植込み型記録計を国内で潜在性心房細動検出目的に用いることを日本脳卒中学会から厚生労働省に要望している.使用が承認された場合は,わが国の診療事情に合わせて頭部MRIを含めたより詳細な診断に基づいて,検査に相応しい患者を抽出すべきと考え,その基準を提案する.

    DOI: 10.3995/jstroke.10416

  • Cost-effectiveness analysis for diabetes care Reviewed

    Haruhisa Fukuda

    Nippon rinsho. Japanese journal of clinical medicine   74   707 - 712   2016.4

     More details

    Language:English  

  • The Development of Statistical Models for Predicting Surgical Site Infections in Japan: Toward a Statistical Model-Based Standardized Infection Ratio Reviewed

    Haruhisa Fukuda, Manabu Kuroki

    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY   37 ( 3 )   260 - 271   2016.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1017/ice.2015.302

  • Reducing needlestick injuries through safety-engineered devices: results of a Japanese multi-centre study Reviewed

    H. Fukuda, N. Yamanaka

    JOURNAL OF HOSPITAL INFECTION   92 ( 2 )   147 - 153   2016.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jhin.2015.09.019

  • Has the Reform of the Japanese Healthcare Provision System Improved the Value in Healthcare? A Cost-Consequence Analysis of Organized Care for Hip Fracture Patients Reviewed

    Haruhisa Fukuda, Sayuri Shimizu, Tatsuro Ishizaki

    PLOS ONE   10 ( 7 )   e0133694   2015.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0133694

  • ペニシリン耐性肺炎球菌感染による追加的医療資源:JANIS全入院患者部門データを用いた推定. Reviewed

    小原 仁, 齋藤 潤栄, 福田 治久

    日本環境感染学会誌   30 ( 3 )   165 - 173   2015.6

     More details

    Language:Japanese  

    耐性菌感染による重症化と治療期間の延伸は,追加的な医療資源量の増加をもたらす.これは逼迫する医療費の適正化に向けた施策の障害にもなっている.本研究では,Japan Nosocomial Infection Surveillance全入院患者部門データ(以下,JANISデータ)において判定されているペニシリン耐性肺炎球菌(penicillin-resistant Streptococcus pneumoniae: PRSP)感染症例をもとに耐性菌感染による追加的医療資源量の推計を行った.解析対象となるデータは,調査協力を得られた1病院から直接収集したJANISデータと診断群分類別包括評価(Diagnosis Procedure Combination/Per-Diem Payment System)データを用いた.PRSP感染者と非感染者の判定はJANISデータに基づいた.すべての対象症例を病名と術式行為が一致する層別に分類し,各層からプロペンシティスコアをもとにPRSP感染有無に関するマッチングを行った.このマッチングされたペア差の平均値から追加的医療資源となる在院日数と入院医療費を推定した.   すべてのペアを対象にしたPRSP感染による在院日数の増加は2.79日であった.また年齢区分5歳未満では在院日数2.08日,入院医療費110,634円の増加が認められた.本研究では,PRSP感染によって生じる追加的医療資源量を推計した.この耐性菌感染によって在院日数の増大と5歳未満においては在院日数と入院医療費の増大が明らかとなった.本研究成果は,感染制御に関する費用対効果を踏まえた技術評価の側面を支える基礎資料として,広く貢献できるものと考える.耐性菌感染の抑制に向けた包括的な感染制御の発展が期待される.

    DOI: 10.4058/jsei.30.165

  • 医療材料を対象とした臨床試験データの費用効果分析への利活用可能性の検討 Reviewed

    福田 治久

    レギュラトリーサイエンス学会誌   5 ( 1 )   1 - 12   2015.2

     More details

    Language:Others  

    DOI: 10.14982/rsmp.5.1

  • 外来患者の逆紹介がその後の入院率に与える効果. Reviewed

    小原 仁, 福田 治久

    日本医療・病院管理学会誌   52 ( 1 )   19 - 26   2015.2

     More details

    Language:Japanese  

    医療連携を主体とした機能分化の推進が期待されている。しかしながら,機能分化を可能とする病院の外来縮小は進んでいない。本研究は,機能分化に向けた逆紹介の課題要因を明らかにするとともに,外来縮小の方針決定に影響を与えると考えられた逆紹介とその後の入院率との関連を明らかにすることを目的とした。南風病院呼吸器内科に外来受診をした慢性閉塞性肺疾患(COPD)と喘息疾患の再診患者を対象にロジスティック回帰分析を行った。入院率の比較については傾向スコアマッチングを用いた生存時間分析を実施した。解析の結果,長期処方実績や複数科外来受診などの要因が逆紹介と関連していた。また生存時間分析による入院率の比較では,外来患者の逆紹介とその後の入院率の減少に関連は認められなかった。一般外来の縮小に向けた外来患者の逆紹介が推進されることで,外来診療における地域医療の機能分化が期待された。

    DOI: 10.11303/jsha.52.19

  • 医療関連感染領域の医療経済評価における費用の評価手法

    福田 治久

    日本環境感染学会誌   29 ( 6 )   387 - 395   2014.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 医療関連感染領域の医療経済評価における有効性の評価手法

    福田 治久

    日本環境感染学会誌   29 ( 6 )   396 - 404   2014.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 特定保険医療材料を対象にしたレセプトデータ分析の実施可能性 Reviewed

    福田 治久

    レギュラトリーサイエンス学会誌   4 ( 3 )   257 - 264   2014.10

     More details

    Language:Others  

    DOI: 10.14982/rsmp.4.257

  • Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry Reviewed

    Ryu Matsuo, Masahiro Kamouchi, Haruhisa Fukuda, Jun Hata, Yoshinobu Wakisaka, Junya Kuroda, Tetsuro Ago, Takanari Kitazono

    PLOS ONE   9 ( 10 )   e110444.   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0110444

  • 医療関連感染領域における医療経済評価の実施手法の概要 Invited

    福田 治久

    日本環境感染学会誌   29 ( 5 )   324 - 332   2014.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    近年,我が国の医療財政は著しく逼迫しており,診療報酬の総体的な抑制は,医療機関経営の財務をも圧迫している.そのため,限られた医療資源の効率的配分の実現が強く求められており,診療報酬制度は効率性を勘案した評価へとパラダイムシフトが起こりつつある.同時に,医療機関内部においても,どの領域のどの活動にどの程度の資源を投じるか?を科学的に意思決定する動きが加速度的に増しているものと思われる.医療経済評価とは,こうした政策レベル・病院経営レベルにおける意思決定を科学的に判断するためのツールである.   本稿では,医療経済評価の基本的な考え方と,医療経済評価の実施手法について解説する.実施手法は広範囲に及ぶため,医療経済評価の核となる,(1)分析の立場,(2)比較対照,(3)分析手法,(4)分析期間,(5)アウトカム指標,(6)費用の測定,(7)割引,(8)不確実性の取り扱い,の中心事項について紹介する.

    DOI: 10.4058/jsei.29.324

  • Can Experience Improve Hospital Management? Reviewed

    Haruhisa Fukuda, Kazuhide Okuma, Yuichi Imanaka

    PLOS ONE   9 ( 9 )   e106884   2014.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0106884

  • 手術部位感染サーベイランスデータの評価と分析 Invited

    福田 治久

    日本環境感染学会誌   29 ( 4 )   231 - 239   2014.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.4058/jsei.29.231

  • 多変量回帰分析:科学論文を読み解くための基礎知識 Invited

    福田 治久

    日本環境感染学会誌   29 ( 4 )   240 - 255   2014.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 保健医療における費用対効果の評価方法と活用 医療経済評価研究における分析手法に関するガイドライン

    福田敬, 白岩健, 池田俊也, 五十嵐中, 赤沢学, 石田博, 能登真一, 齋藤信也, 坂巻弘之, 下妻晃二郎, 田倉智之, 福田治久, 森脇健介, 冨田奈穂子, 小林慎

    保健医療科学   62 ( 6 )   325 - 640   2013.12

     More details

    Language:Japanese  

    日本においては、現在のところ実践的に広く使用されている医療経済評価ガイドラインは存在しない。このことは、各研究者によって行われる分析間の比較可能性を困難にし、さらには使用する分析手法がブラックボックスにおちいりやすく、経済評価の透明性が損なわれる結果にもつながっている。そこで、各国で作成されている医療経済評価ガイドラインや公表されている文献を参照しながら、研究班に参加した専門家のコンセンサスによってガイドラインを作成していった。研究班は経済評価の専門家から構成され、まずはガイドラインに必要な13セクションを同定した。各セクション内において、経済評価を行う上で方法論上の論点になる部分を抽出し、それに対する回答を作成するための検討を重ねていった。このプロセスは、2011年度と2012年度の2年度にわたって継続して行われ、参加したメンバーのコンセンサスにより、最終版は2012年度末に完成した。各項目は、簡潔な文章によって記述され、その意味するところを明確にするため3つの星によるレーティングシステムを用いた。ガイドラインでは、原則としては公的医療費支払者の立場を標準とする。ただし、分析の目的によってはそれ以外の立場を用いてもよい。アウトカム指標は、分析者が最も適すると考えるアウトカム指標を用いてよいが、質調整生存年(QALY)を用いた分析を含めることを推奨している。割引率は、費用・効果ともに年率2&#37;で割り引くことを推奨している。本ガイドラインが、日本における経済評価研究の質と比較可能性を高めることが期待される。(著者抄録)

  • Toward the rational use of standardized infection ratios to benchmark surgical site infections Reviewed

    Haruhisa Fukuda, Keita Morikane, Manabu Kuroki, Shinichiro Taniguchi, Takashi Shinzato, Fumie Sakamoto, Kunihiko Okada, Hiroshi Matsukawa, Yuko Ieiri, Kouji Hayashi, Shin Kawai

    AMERICAN JOURNAL OF INFECTION CONTROL   41 ( 9 )   810 - 814   2013.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ajic.2012.10.004

  • Assessment of Methodology to Compare Surgical-Site Infection Rates Across Institutions A Nationwide Multi-Center Study Using JANIS Data Reviewed

    Haruhisa Fukuda

    Japanese Journal of Environmental Infections   28 ( 2 )   63 - 73   2013.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.4058/jsei.28.63

  • Impact of surgical site infections after open and laparoscopic colon and rectal surgeries on postoperative resource consumption Reviewed

    H. Fukuda, K. Morikane, M. Kuroki, S. Kawai, K. Hayashi, Y. Ieiri, H. Matsukawa, K. Okada, F. Sakamoto, T. Shinzato, S. Taniguchi

    INFECTION   40 ( 6 )   649 - 659   2012.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s15010-012-0317-7

  • インシデントレポートからみた臨床研修病院における転倒・転落事例の臨床疫学的側面 Reviewed

    江上廣一, 廣瀬昌博, 津田佳彦, 大濱京子, 本田順一, 島弘志, 中林愛恵, 福田治久, 今中雄一, 小林祥泰

    日本医療・病院管理学会誌   49 ( 4 )   205 - 215   2012.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    2007∼09年度に収集された転倒・転落のインシデントレポート1,764件を対象に,転倒率(件/1,000患者・日)を用いて転倒・転落に関する疫学的側面を検討した。患者の平均年齢は男66.6±18.8歳(950件),女69.9±19.2歳(814件)であった。全体の転倒率は1.84件/1,000患者・日,性別では男2.06および女1.87であった。年齢別では,70歳代が2.82件/1,000患者・日(555件)でもっとも高く,高齢者ほど高い傾向にあった。診療科別において,外科系では整形外科が最低で1.14件/1,000患者・日,内科系では循環器内科および呼吸器内科が最低で1.97を示し,外科系より内科系診療科が高い傾向にあった。また,入院から転倒発生までの日数における転倒率(転倒件数)について,入院翌日が0.16件/1,000患者・日(118件)でもっとも高く,ついで入院3日目が0.12(84件),入院当日が0.11(78件)で以降漸減していた。転倒発生の平均値は12.4日であった。 転倒率からみた転倒の疫学的側面から,入院診療科や入院からの日数に応じた防止策を講じることが必要である。

    DOI: 10.11303/jsha.49.205

  • インシデントレポートからみた臨床研修病院における転倒・転落事例の臨床疫学的側面 Reviewed

    江上 廣一, 廣瀬 昌博, 津田 佳彦, 大濱 京子, 本田 順一, 島 弘志, 中林 愛恵, 福田 治久, 今中 雄一, 小林 祥泰

    日本医療・病院管理学会誌   49 ( 4 )   15 - 25   2012.10

     More details

    Language:Japanese  

  • 一般事例における追加的医療費算出の試み

    江上 廣一, 廣瀬 昌博, 津田 佳彦, 大濱 京子, 本田 順一, 島 弘志, 福田 治久, 今中 雄一

    日本医療・病院管理学会誌   49 ( Suppl. )   109 - 109   2012.9

     More details

    Language:Japanese  

  • 本院における患者安全文化醸成度に関する検討

    津田 佳彦, 廣瀬 昌博, 江上 廣一, 大濱 京子, 本田 順一, 島 弘志, 福田 治久, 今中 雄一

    日本医療・病院管理学会誌   49 ( Suppl. )   134 - 134   2012.9

     More details

    Language:Japanese  

  • GISによる急性期医療機関から回復期医療機関への転院によるアクセシビリティの解析:大腿骨頸部骨折地域連携クリティカルパスを例にとって Reviewed

    清水沙友里, 福田治久

    日本医療・病院管理学会誌   49 ( 3 )   173 - 181   2012.8

     More details

    Language:Japanese  

    地域連携クリティカルパスをはじめとする地域医療連携の促進によって,患者は技術の高度化・専門化の恩恵を受けながら効率的かつ安全に医療を受けることが可能になる。一方で,医療連携の促進による患者の移動傾向等のアクセシビリティはほとんど明らかになっていない。 そこで本研究は,地域連携の先進的地域の急性期病院において,(1)患者の来院圏の可視化 (2)回復期病院への転院によるアクセシビリティの変化をGISを用いて明らかにすることを目的とした。 本研究における急性期医療機関の実質的な医療圏は,二次医療圏を超えた広範な地域にわたり,32.5%は二次医療圏外の回復期医療機関に転院していた。医療法で定められる二次医療圏と実質的な診療圏の乖離が地理的に明らかとなった。GISを用いてアクセシビリティを把握することによって,医療の実態を反映した医療資源の整備や,医療計画の立案等に活用可能であることが示唆された。

    DOI: 10.11303/jsha.49.173

  • GISによる急性期医療機関から回復期医療機関への転院によるアクセシビリティの解析:大腿骨頸部骨折地域連携クリティカルパスを例にとって Reviewed

    清水 沙友里, 福田 治久

    日本医療・病院管理学会誌   49 ( 3 )   45 - 53   2012.7

     More details

    Language:Japanese  

  • 医療安全対策の有効性評価に係わる課題:インシデント報告システム活性化対策を例にして Reviewed

    福田 治久

    医療の質・安全学会誌   7 ( 1 )   37 - 47   2012.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 計画管理料算定病院における大腿骨頸部骨折および脳卒中を対象にした地域連携クリティカルパスの運用状況に関する全国実態調査 Reviewed

    福田 治久

    日本医療・病院管理学会誌   49 ( 1 )   31 - 39   2012.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    厚生労働省は21世紀の医療提供体制の方向性として地域連携を掲げており,これを達成するツールとして地域連携パスがある。本研究は,(1)地域連携を積極的に実施している病院の特徴,および,(2)連携パス運用による機能分化の促進効果,を明らかにすることを目的に実施した。 地域連携診療計画管理料(計画管理料)を算定している全計画管理病院(625病院)を対象に,質問票調査を行った。データ解析には線形回帰モデルを用いた。 232病院(37.1&#37;)から回答を得た。大腿骨頸部骨折症例に対する計画管理料算定割合の高い病院の特徴として,患者数の多さ(p=0.002),短い平均在院日数(p=0.005)などが検出された。診療計画に転院基準を定めた病院は,定めのない病院に比べて,大腿骨頸部骨折の急性期平均在院日数が12.8&#37;短かった(p=0.036)。 本研究は,地域連携を実施する上で,診療計画に転院基準を定めることの重要性を示唆するものである。

    DOI: 10.11303/jsha.49.31

  • Estimates of Postoperative Resource Utilization Attributable to Surgical Site Infection in Gastrectomy Patients Evidence from the JANIS/DPC Integrated Database Reviewed

    Haruhisa Fukuda

    Japanese Journal of Environmental Infections   27 ( 6 )   389 - 396   2012.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.4058/jsei.27.389

  • インシデントレポートにおける転倒転落事例の疫学

    江上 廣一, 廣瀬 昌博, 津田 佳彦, 大濱 京子, 本田 順一, 島 弘志, 今中 雄一, 福田 治久

    日本医療・病院管理学会誌   48 ( Suppl. )   140 - 140   2011.7

     More details

    Language:Japanese  

  • 患者安全の醸成とキャリア、Lag timeの関連に関する検討

    津田 佳彦, 廣瀬 昌博, 江上 廣一, 大濱 京子, 本田 順一, 島 弘志, 今中 雄一, 福田 治久

    日本医療・病院管理学会誌   48 ( Suppl. )   147 - 147   2011.7

     More details

    Language:Japanese  

  • 医療安全対策加算算定病院における医療安全管理体制の整備に関する実態調査

    廣瀬 昌博, 福田 治久, 三原 美津江, 伊藤 孝史, 兼児 敏浩, 今中 雄一, 江上 廣一, 津田 佳彦, 本田 順一

    日本医療・病院管理学会誌   48 ( Suppl. )   144 - 144   2011.7

     More details

    Language:Japanese  

  • Costs of hospital-acquired infection and transferability of the estimates: a systematic review Reviewed

    H. Fukuda, J. Lee, Y. Imanaka

    INFECTION   39 ( 3 )   185 - 199   2011.6

     More details

    Language:English  

    DOI: 10.1007/s15010-011-0095-7

  • 病院管理データによる転倒・転落に起因する追加的医療費算出の試み

    中林 愛恵, 廣瀬 昌博, 伊藤 孝史, 三原 美津江, 福田 治久, 竹村 匡正, 岡本 和也, 今中 雄一

    日本医療マネジメント学会雑誌   12 ( Suppl. )   248 - 248   2011.6

     More details

    Language:Japanese  

  • 3臨床研修病院における転倒転落および一般事例のLag timeに関する研究

    津田 佳彦, 廣瀬 昌博, 福田 治久, 江上 廣一, 大濱 京子, 本田 順一, 島 弘志, 今中 雄一

    日本医療マネジメント学会雑誌   12 ( Suppl. )   177 - 177   2011.6

     More details

    Language:Japanese  

  • Cost effectiveness analysis of liver transplantation

    Haruhisa Fukuda, Hirohisa Imai

    Liver Cancer: Causes, Diagnosis and Treatment   195 - 222   2011.4

     More details

    Language:English  

  • Variations in analytical methodology for estimating costs of hospital-acquired infections: a systematic review Reviewed

    H. Fukuda, J. Lee, Y. Imanaka

    JOURNAL OF HOSPITAL INFECTION   77 ( 2 )   93 - 105   2011.2

     More details

    Language:English  

    DOI: 10.1016/j.jhin.2010.10.006

  • A comparative analysis of incident reporting lag times in academic medical centres in Japan and the USA Reviewed

    S. E. Regenbogen, M. Hirose, Y. Imanaka, E-H Oh, H. Fukuda, A. A. Gawande, T. Takemura, H. Yoshihara

    QUALITY & SAFETY IN HEALTH CARE   19 ( 6 )   e10   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/qshc.2008.029215

  • 補助療法の診療プロセスに関する施設間比較 乳房温存術症例を対象にしたDPCデータを用いた検討

    福田 治久, 大隈 和英, 猪飼 宏, 今中 雄一

    医療情報学連合大会論文集   30回   927 - 928   2010.11

     More details

    Language:Japanese  

  • Impact of system-level activities and reporting design on the number of incident reports for patient safety Reviewed

    H. Fukuda, Y. Imanaka, M. Hirose, K. Hayashida

    QUALITY & SAFETY IN HEALTH CARE   19 ( 2 )   122 - 127   2010.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/qshc.2008.027532

  • Change in clinical practice after publication of guidelines on breast cancer treatment Reviewed

    Haruhisa Fukuda, Yuichi Imanaka, Tatsuro Ishizaki, Kazuhide Okuma, Takako Shirai

    INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE   21 ( 5 )   372 - 378   2009.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/intqhc/mzp037

  • Assessment of transparency of cost estimates in economic evaluations of patient safety programmes Reviewed

    Haruhisa Fukuda, Yuichi Imanaka

    JOURNAL OF EVALUATION IN CLINICAL PRACTICE   15 ( 3 )   451 - 459   2009.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-2753.2008.01033.x

  • The subjective incremental cost of informed consent and documentation in hospital care: a multicentre questionnaire survey in Japan Reviewed

    Haruhisa Fukuda, Yuichi Imanaka, Hiroe Kobuse, Kenshi Hayashida, Genki Murakami

    JOURNAL OF EVALUATION IN CLINICAL PRACTICE   15 ( 2 )   234 - 241   2009.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-2753.2008.00987.x

  • DPCに基づく包括支払い制度導入後の乳癌治療への影響と変化

    大隈 和英, 福田 治久, 関本 美穂, 猪飼 宏, 濱田 啓義, 今中 雄一

    日本外科学会雑誌   110 ( 臨増2 )   327 - 327   2009.2

     More details

    Language:Japanese  

  • Factors associated with system-level activities for patient safety and infection control Reviewed

    Haruhisa Fukuda, Yuichi Imanaka, Masahiro Hirose, Kenshi Hayashida

    HEALTH POLICY   89 ( 1 )   26 - 36   2009.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.healthpol.2008.04.009

  • Economic evaluations of maintaining patient safety systems in teaching hospitals Reviewed

    Haruhisa Fukuda, Yuichi Imanaka, Masahiro Hirose, Kenshi Hayashida

    HEALTH POLICY   88 ( 2-3 )   381 - 391   2008.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.healthpol.2008.04.004

  • Cost of hospital-wide activities to improve patient safety and infection control: A multi-centre study in Japan Reviewed

    Haruhisa Fukuda, Yuichi Imanaka, Kenshi Hayashida

    HEALTH POLICY   87 ( 1 )   100 - 111   2008.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.healthpol.2008.02.006

  • Comparisons of risk-adjusted clinical outcomes for patients with aneurysmal subarachnoid haemorrhage across eight teaching hospitals in Japan Reviewed

    Tatsuro Ishizaki, Yuichi Imanaka, Miho Sekimoto, Haruhisa Fukuda, Hanako Mihara

    JOURNAL OF EVALUATION IN CLINICAL PRACTICE   14 ( 3 )   416 - 421   2008.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-2753.2007.00882.x

  • 臨床研修病院における医療安全システムの構築状況に関する研究 Reviewed

    福田治久, 今中雄一, 廣瀬昌博, 林田賢史

    日本医療・病院管理学会誌   45 ( 2 )   95 - 104   2008.4

     More details

    Language:Japanese  

  • インシデント報告運用システムが報告件数に及ぼす効果

    福田 治久, 廣瀬 昌博, 林田 賢史, 今中 雄一

    医療の質・安全学会誌   2 ( Suppl. )   125 - 125   2007.11

     More details

    Language:Japanese  

  • 臨床研修病院における医療安全活動の展開

    福田 治久, 廣瀬 昌博, 林田 賢史, 今中 雄一

    医療の質・安全学会誌   2 ( Suppl. )   145 - 145   2007.11

     More details

    Language:Japanese  

  • Measuring hospital-wide activity volume for patient safety and infection control: a multi-centre study in Japan Reviewed

    Kenshi Hayashida, Yuichi Imanaka, Haruhisa Fukuda

    BMC HEALTH SERVICES RESEARCH   7 ( 140 )   2007.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1472-6963-7-140

  • 感染制御に係るコストとコスト計算の質の評価 Reviewed

    福田治久, 今中雄一

    病院管理   44 ( 2 )   143 - 151   2007.4

     More details

    Language:Others  

  • Risk adjusted resource utilization for ami patients treated in Japanese hospitals Reviewed

    Edward Evans, Yuichi Imanaka, Miho Sekimoto, Tatsuro Ishizaki, Kenshi Hayashida, Haruhisa Fukuda, Eun-Hwan Oh

    HEALTH ECONOMICS   16 ( 4 )   347 - 359   2007.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hec.1177

  • Evaluation of acute myocardial infarction in-hospital mortality using a risk-adjustment model based on Japanese administrative data Reviewed

    K. Hayashida, Y. Imanaka, M. Sekimoto, H. Kobuse, Haruhisa Fukuda

    Journal of International Medical Research   35 ( 5 )   590 - 596   2007.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1177/147323000703500502

▼display all

Books

  • 健康経済学講義(健康経済学のデータベース)

    福田治久( Role: Joint author)

    東京大学出版会  2023.10 

     More details

    Language:Japanese   Book type:Scholarly book

  • 新時代の臨床糖尿病学(下)ーより良い血糖管理をめざして一

    福田治久( Role: Joint author)

    日本臨休社  2016.4 

     More details

    Language:Japanese   Book type:Scholarly book

  • 感染管理・感染症看護テキスト

    福田 治久( Role: Joint author)

    照林社  2015.6 

     More details

    Language:Japanese   Book type:Scholarly book

  • 医療経済評価の具体的な活用法

    福田 治久( Role: Joint author)

    技術情報協会  2014.12 

     More details

    Language:Japanese   Book type:Scholarly book

  • 医療の質の指標化と改善

    福田 治久, 大隈 和英, 関本 美穂, 今中 雄一( Role: Joint author)

    南山堂  2011.6 

     More details

    Language:Japanese   Book type:General book, introductory book for general audience

  • 「病院」の教科書

    福田 治久( Role: Joint author)

    医学書院  2010.7 

     More details

    Language:Japanese   Book type:General book, introductory book for general audience

  • 「病院」の教科書

    福田 治久( Role: Joint author)

    医学書院  2010.7 

     More details

    Language:Japanese   Book type:General book, introductory book for general audience

  • 医療制度・医療政策・医療経済

    福田 治久( Role: Joint author)

    丸善出版  2013.3 

     More details

    Language:Others   Book type:Scholarly book

  • 薬剤師のための感染制御マニュアル(第3版)

    福田治久, 今中雄一( Role: Joint author)

    薬事日報社  2011.12 

     More details

    Language:Others   Book type:Scholarly book

  • Liver Cancer: Causes, Diagnosis and Treatment

    Fukuda H, Imai H( Role: Joint author)

    Nova Biomedical Press  2011.11 

     More details

    Language:Others   Book type:Scholarly book

  • 「病院」の教科書 (医療安全管理)

    福田 治久( Role: Joint author)

    医学書院  2010.7 

     More details

    Language:Others  

▼display all

Presentations

  • NDBを用いた循環器データベース研究の実施方法. Invited

    福田治久.

    第83回日本循環器学会学術集会  2019.3 

     More details

    Event date: 2019.3

    Language:Japanese  

    Venue:横浜   Country:Japan  

  • 医療経済評価の制度への応用に向けて-制度化に向けた諸課題への対応:レセプトデータ活用の観点から- Invited

    福田 治久

    国際医薬経済・アウトカム研究学会(ISPOR)日本部会  2015.3 

     More details

    Event date: 2015.3

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  • JANIS手術部位感染部門データを用いた日本版標準化感染比算出モデルの開発

    福田 治久

    第30回日本環境感染学会総会  2015.2 

     More details

    Event date: 2015.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:神戸   Country:Japan  

  • 米国NHSNのリスク評価法とその日本への導入の課題 Invited

    福田 治久

    第26回日本外科感染症学会総会学術集会  2013.11 

     More details

    Event date: 2013.11

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:神戸   Country:Japan  

  • SSI サーベランス調査項目関連構造の統計解析

    林 崇弘, 黒木学, 福田 治久

    第43回品質管理学会年次大会  2013.11 

     More details

    Event date: 2013.11

    Language:Japanese  

    Venue:大阪   Country:Japan  

  • 消化器外科における手術部位感染制御による医療費節約効果

    福田 治久

    第24回日本外科感染症学会総会  2011.12 

     More details

    Event date: 2011.12

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:三重   Country:Japan  

  • インシデント報告に対するフィードバック活動の有効性評価に関する現状及び課題

    福田 治久

    第5回医療の質・安全学会学術集会  2010.11 

     More details

    Event date: 2010.11

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  • Proposal of economic evaluation guideline in Japan International conference

    Fukuda T, Akazawa M, Haruhisa Fukuda, Igarashi A, Ikeda S, Ishida H, Kobayashi M, Moriwaki K, Noto S, Sakamaki H, Saito S, Shimozuma K, Shiroiwa T, Takura T, Tomita N

    18th Annual European Meeting on International Society for Pharmacoeconomics and Outcomes Research  2013.10 

     More details

    Language:English  

    Country:Ireland  

  • シンポジウム54. データリンケージで切り拓く!住むだけで健康になれるスマートシティを目指して:VPD(vaccine preventable diseases)対策に向けた予防接種台帳の利活用.

    福田治久

    第83回日本公衆衛生学会総会  2024.10 

     More details

    Event date: 2024.10

    Presentation type:Symposium, workshop panel (public)  

    researchmap

  • Effectiveness of Maternal mRNA COVID-19 Vaccination Against COVID-19 Symptomatic Infection and Hospitalization in Infants Aged < 6 Months During the SARS-CoV-2 Omicron-Predominant Period: VENUS Study.

    Ishiguro C, Mimura W, Maeda M, Murata F, Fukuda H

    2024 ISPE Annual Meeting  2024.8 

     More details

    Event date: 2024.8

    Presentation type:Poster presentation  

    researchmap

  • Pilot study on the application of rapid cycle analysis method for post-marketing active vaccine safety surveillance using COVID-19 vaccines in Japan: the VENUS Study.

    Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H

    2024 ISPE Annual Meeting  2024.8 

     More details

    Event date: 2024.8

    Presentation type:Oral presentation (general)  

    researchmap

  • Missing data analysis methods to correct outcome mismeasurement in pharmacoepidemiological studies using electronic medical information: Methodologies and recommendations for future validation studies.

    Takeuchi Y, Kumamaru H, Ishiguro C, Fukuda H, Shinozaki T

    2024 ISPE Annual Meeting  2024.8 

     More details

    Event date: 2024.8

    Presentation type:Poster presentation  

    researchmap

  • 肺炎球菌ワクチン接種有無別の死因分析:VENUS Study.

    村田典子, 前田恵, 福田治久

    第98回日本感染症学会学術講演会・第72回日本化学療法学会総会合同学会  2024.6 

     More details

    Event date: 2024.6

    Presentation type:Oral presentation (general)  

    researchmap

  • シンポジウム30:自治体基盤による医療・介護・保健・行政データを統合したデータベース研究:LIFE Study. Invited

    福田治久

    第66回日本老年医学会学術集会  2024.6 

     More details

    Event date: 2024.6

    Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • 生活保護受給開始前後での医科・歯科医療費の変化:LIFE Study.

    塩田千尋, 竹内研時, 玉田雄大, 草間太郎, 福田治久, 小坂健

    第73回日本口腔衛生学会学術大会  2024.5 

     More details

    Event date: 2024.5

    Presentation type:Oral presentation (general)  

    researchmap

  • COVID-19 pandemic encourages childhood vaccination in Japan: findings from the VENUS study.

    Asai Y, Tsuzuki Y, Koizumi R, Murata F, Maeda M, Ohmagari N, Ishiguro C, Fukuda H

    34th ECCMID European Congress of Clinical Microbiology and Infectious Diseases  2024.4 

     More details

    Event date: 2024.4

    Presentation type:Poster presentation  

    researchmap

  • Incidence and Risk Factors of Cardiovascular Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy Using Big Data.

    Hieda M, Nakahara S, Moriyama S, Kisanuki M, Ishiguro C, Akashi K, Fukuda H

    第88回日本循環器学会学術集会  2024.3 

     More details

    Event date: 2024.3

    Presentation type:Oral presentation (general)  

    researchmap

  • 新型コロナウイルス2価ワクチン有効性の経時的変化:VENUS Study.

    玉田雄大, 塩田千尋, 竹内研時, 小坂健, 前田恵, 村田典子, 福田治久

    第94回日本衛生学会学術総会  2024.3 

     More details

    Event date: 2024.3

    Presentation type:Oral presentation (general)  

    researchmap

  • 高血圧患者の受診状況と脳卒中発症との関連性: LIFE Study.

    本田和也, 前田恵, 村田典子, 福田治久

    STROKE2024  2024.3 

     More details

    Event date: 2024.3

    Presentation type:Oral presentation (general)  

    researchmap

  • 75歳居宅高齢者における口腔乾燥を起こす薬剤服薬と口腔状態の関連:LIFE study.

    石丸美穂, 大野幸子, 佐藤美寿々, 竹内研時, 玉田雄大, 村田典子, 前田恵, 相田潤, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Poster presentation  

    researchmap

  • 救急搬送患者の重症度別5年生存率:LIFE Study.

    平國響, 清原康介, 前田恵, 村田典子, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Poster presentation  

    researchmap

  • 基礎疾患別にみた要支援・要介護度の推移:LIFE Study.

    小田太史, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    researchmap

  • レセプトデータにおける死亡定義の妥当性評価:LIFE Study.

    前田恵, 村田典子, 小田太史, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Oral presentation (general)  

    researchmap

  • コロナウイルス変異株流行期別におけるCOVID-19罹患後精神症状の発生率:VENUS Study.

    村田典子, 前田恵, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Oral presentation (general)  

    researchmap

  • 歯周疾患に対するレセプトデータ病名・処置の妥当性の検証:LIFE Study.

    大野幸子, 石丸美穂, 佐藤美寿々, 井田有亮, 竹内研時, 玉田雄大, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Poster presentation  

    researchmap

  • 重症COVID-19サバイバーの退院180日以内死亡率と総医療費の比較検証:LIFE Study.

    川端潤, 前田恵, 村田典子, 後藤健一, 福田治久

    第34回日本疫学会学術総会  2024.1 

     More details

    Event date: 2024.1 - 2024.2

    Presentation type:Poster presentation  

    researchmap

  • The change in utilization of dental care for outpatient and hone-visit among older adults during the COVID-19 pandemic in Japan.

    Kusama T, Tamada Y, Kiuchi S, Osaka K, Maeda M, Murata F, Fukuda H, Takeuchi K

    2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • The change in utilization of dental care for outpatient and hone-visit among older adults during the COVID-19 pandemic in Japan.

    Kusama T, Tamada Y, Kiuchi S, Osaka K, Maeda M, Murata F, Fukuda H, Takeuchi K

    第71回国際歯科研究学会日本部会[JADR]総会・学術大会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 骨粗鬆症患者の経口ビスフォスフォネート製剤治療開始前の歯科受診率:LIFE Study.

    山口征啓, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • ACE阻害薬による肺炎予防効果の検証:LIFE Study.

    上村亮介, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • MRワクチン接種の有無と背景因子についての研究:LIFE Study.

    吉野麻衣, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • レセプトデータベースを用いた高齢者心不全患者の心不全治療薬の有効性検討:LIFE Study.

    前原将太, 稗田道成, 中島直樹, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • レセプトデータに基づく外来を含むCOVID-19患者特定アルゴリズムの バリデーション研究:VENUS Study.

    近持卓, 三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会. 2023年11月16日~18日. 京都.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • 帯状疱疹ワクチン接種者の特徴に関する記述疫学研究:LIFE Study.

    村田典子, 前田恵, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • 新型コロナウイルス罹患後疾患に対するコロナワクチン接種の効果:VENUS study.

    金晟娥, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • 新型コロナワクチン小児接種における家庭別接種状況および接種要因:VENUS Study.

    前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Language:Others  

    Country:Other  

  • ACE阻害薬による肺炎予防効果の検証:LIFE Study.

    上村亮介, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • 帯状疱疹ワクチン接種者の特徴に関する記述疫学研究:LIFE Study.

    村田典子, 前田恵, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • レセプトデータベースを用いた高齢者心不全患者の心不全治療薬の有効性検討:LIFE Study.

    前原将太, 稗田道成, 中島直樹, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • レセプトデータに基づく外来を含むCOVID-19患者特定アルゴリズムの バリデーション研究:VENUS Study.

    近持卓, 三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会. 2023年11月16日~18日. 京都.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • MRワクチン接種の有無と背景因子についての研究:LIFE Study.

    吉野麻衣, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 新型コロナウイルス罹患後疾患に対するコロナワクチン接種の効果:VENUS study.

    金晟娥, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    researchmap

  • 骨粗鬆症患者の経口ビスフォスフォネート製剤治療開始前の歯科受診率:LIFE Study.

    山口征啓, 前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • 新型コロナワクチン小児接種における家庭別接種状況および接種要因:VENUS Study.

    前田恵, 村田典子, 福田治久

    第28回日本薬剤疫学会学術総会.  2023.11 

     More details

    Event date: 2023.11

    Presentation type:Poster presentation  

    researchmap

  • 運動習慣と肺炎球菌ワクチン接種が肺炎関連入院に与える影響:LIFE-VENUS Study.

    村田典子, 前田恵, 小野玲, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • COVID-19流行の乳幼児定期予防接種完了への影響:VENUS Study.

    芝野航大, 中塚清将, 前田恵, 村田典子, 秋末敏宏, 福田治久, 小野玲

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • MAFLDによる冠動脈疾患および脳血管疾患へのリスクの評価:LIFE Study.

    明野由里奈, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • Test-negative designによる新型コロナウイルス2価ワクチンの有効性評価:VENUS Study.

    玉田雄大, 竹内研時, 草間太郎, 小坂健, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • レセプトデータにおける新型コロナウイルス感染症後遺症患者の特徴:LIFE Study.

    山口征啓, 村田典子, 前田恵, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • ロタウイルスワクチン接種および家族構成との関連:VENUS Study.

    前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • 介護認定調査による高齢高血圧患者の服薬アドヒアランスとその関連要因の検討:LIFE Study.

    相良空美, 後藤健一, 福田治久, 村田典子, 前田恵

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • 後期高齢者のACSCによる3次救急病院への緊急入院実態:LIFE Study.

    松岡佳孝, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会. 2023年10月31日~11月2日. つくば.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • 特定保健指導による腹囲体重減少達成群と未達成群による効果検証:LIFE Study.

    佐藤有希子, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • 生後25ヶ月未満の乳幼児のRSV感染症に関する記述疫学:LIFE Study.

    井上雅子, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Language:Others  

    Country:Other  

  • COVID-19流行の乳幼児定期予防接種完了への影響:VENUS Study.

    芝野航大, 中塚清将, 前田恵, 村田典子, 秋末敏宏, 福田治久, 小野玲

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 後期高齢者のACSCによる3次救急病院への緊急入院実態:LIFE Study.

    松岡佳孝, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会. 2023年10月31日~11月2日. つくば.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 介護認定調査による高齢高血圧患者の服薬アドヒアランスとその関連要因の検討:LIFE Study.

    相良空美, 後藤健一, 福田治久, 村田典子, 前田恵

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • ロタウイルスワクチン接種および家族構成との関連:VENUS Study.

    前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • レセプトデータにおける新型コロナウイルス感染症後遺症患者の特徴:LIFE Study.

    山口征啓, 村田典子, 前田恵, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • Test-negative designによる新型コロナウイルス2価ワクチンの有効性評価:VENUS Study.

    玉田雄大, 竹内研時, 草間太郎, 小坂健, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • MAFLDによる冠動脈疾患および脳血管疾患へのリスクの評価:LIFE Study.

    明野由里奈, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 特定保健指導による腹囲体重減少達成群と未達成群による効果検証:LIFE Study.

    佐藤有希子, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Poster presentation  

    researchmap

  • 運動習慣と肺炎球菌ワクチン接種が肺炎関連入院に与える影響:LIFE-VENUS Study.

    村田典子, 前田恵, 小野玲, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • 生後25ヶ月未満の乳幼児のRSV感染症に関する記述疫学:LIFE Study.

    井上雅子, 前田恵, 村田典子, 福田治久

    第82回日本公衆衛生学会総会.  2023.10 

     More details

    Event date: 2023.10 - 2023.11

    Presentation type:Oral presentation (general)  

    researchmap

  • Rebamipideは整形外科を受診する胃潰瘍低リスク患者においてNSAIDs潰瘍発生を予防する:LIFE Studyデータベースを利用したネステッドケースコントロール研究.

    山手智志, 濵井敏, 石黒智恵子, 福田治久, 中島康晴

    第50回日本股関節学会学術集会.  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • Rebamipideは整形外科を受診する胃潰瘍低リスク患者においてNSAIDs潰瘍発生を予防する:LIFE Studyデータベースを利用したネステッドケースコントロール研究.

    山手智志, 濵井敏, 石黒智恵子, 福田治久, 中島康晴

    第50回日本股関節学会学術集会.  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Oral presentation (general)  

    researchmap

  • ロタウイルスワクチンにおける有効性評価:VENUS Study.

    前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • ロタウイルスワクチンにおける有効性評価:VENUS Study.

    前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Oral presentation (general)  

    researchmap

  • 新型コロナウイルスワクチン接種とコロナウイルス罹患後精神症状発現との関連性:VENUS Study.

    村田典子, 前田恵, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • HPVワクチンの積極的勧奨再開による接種率の影響の評価:VENUS Study.

    佐澤真比呂, 石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • オミクロンBA.5流行期における高齢者に対するオミクロン対応2価ワクチンの有効性評価:VENUS Study.

    三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • 小児における新型コロナウイルスワクチンの初回免疫の有効性評価:VENUS Study.

    石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会. 2023年10月21日~22日. 静岡.  2023.10 

     More details

    Event date: 2023.10

    Language:Others  

    Country:Other  

  • HPVワクチンの積極的勧奨再開による接種率の影響の評価:VENUS Study.

    佐澤真比呂, 石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Poster presentation  

    researchmap

  • 新型コロナウイルスワクチン接種とコロナウイルス罹患後精神症状発現との関連性:VENUS Study.

    村田典子, 前田恵, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会.  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Oral presentation (invited, special)  

    researchmap

  • 小児における新型コロナウイルスワクチンの初回免疫の有効性評価:VENUS Study.

    石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会. 2023年10月21日~22日. 静岡.  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Oral presentation (general)  

    researchmap

  • オミクロンBA.5流行期における高齢者に対するオミクロン対応2価ワクチンの有効性評価:VENUS Study.

    三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久

    第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会  2023.10 

     More details

    Event date: 2023.10

    Presentation type:Poster presentation  

    researchmap

  • 国保加入者における新規高血圧患者の服薬アドヒアランスの実態とその要因の分析:LIFE Study.

    相良空美, 後藤健一, 福田治久

    第45回日本高血圧学会総会  2023.9 

     More details

    Event date: 2023.9

    Language:Others  

    Country:Other  

  • 国保加入者における新規高血圧患者の服薬アドヒアランスの実態とその要因の分析:LIFE Study.

    相良空美, 後藤健一, 福田治久

    第45回日本高血圧学会総会  2023.9 

     More details

    Event date: 2023.9

    Presentation type:Oral presentation (general)  

    researchmap

  • 日本のリアルワールドデータの実際:LIFE studyで日本の公衆衛生を支える Invited

    福田治久

    統計関連学会連合  2023.9 

     More details

    Event date: 2023.9

    Language:Others  

    Country:Other  

  • 日本のリアルワールドデータの実際:LIFE studyで日本の公衆衛生を支える Invited

    福田治久

    統計関連学会連合  2023.9 

     More details

    Event date: 2023.9

    Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS Study.

    Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H

    ICPE 2023  2023.8 

     More details

    Event date: 2023.8

    Language:Others  

    Country:Other  

  • Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS Study.

    Ishiguro C, Mimura W, Maeda M, Murata F, Fukuda H

    ICPE 2023  2023.8 

     More details

    Event date: 2023.8

    Language:Others  

    Country:Other  

  • Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS Study.

    Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H

    ICPE 2023  2023.8 

     More details

    Event date: 2023.8

    Presentation type:Poster presentation  

    researchmap

  • Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS Study.

    Ishiguro C, Mimura W, Maeda M, Murata F, Fukuda H

    ICPE 2023  2023.8 

     More details

    Event date: 2023.8

    Presentation type:Poster presentation  

    researchmap

  • Association between Auditory Impairment and the Onset of Alzheimer's Disease: The LIFE Study. Invited

    Fukuda H, Fujii T, Maeda M, Murata F, Ono R

    Alzheimer's Association International Conference 2023.  2023.7 

     More details

    Event date: 2023.7

    Language:Others  

    Country:Other  

  • Association between Auditory Impairment and the Onset of Alzheimer's Disease: The LIFE Study.

    Fukuda H, Fujii T, Maeda M, Murata F, Ono R

    Alzheimer's Association International Conference 2023.  2023.7 

     More details

    Event date: 2023.7

    Presentation type:Poster presentation  

    researchmap

  • 新型コロナウイルス感染症罹患後における精神症状の発生状況. Invited

    福田治久

    第119回日本精神神経学会学術総会.  2023.6 

     More details

    Event date: 2023.6

    Language:Others  

    Country:Other  

  • 新型コロナウイルス感染症罹患後における精神症状の発生状況. Invited

    福田治久

    第119回日本精神神経学会学術総会.  2023.6 

     More details

    Event date: 2023.6

    Presentation type:Symposium, workshop panel (public)  

    researchmap

  • Influence of COVID-19 lockdown on day care and home care affects the care level: LIFE study.

    Nakatsuka K, Ono R, Akisue T, Fukuda H

    IAGG Asia Oceania Regional Congress 2023  2023.6 

     More details

    Event date: 2023.6

    Language:Others  

    Country:Other  

  • Association between knee arthroplasty and incidence of dementia in older adults with knee osteoarthritis: LIFE Study.

    Shibano K, Uchida K, Nakamura J, Encho H, Mizuta S, Nakatsuka K, Akisue T, Fukuda H, Ono R

    IAGG Asia Oceania Regional Congress 2023  2023.6 

     More details

    Event date: 2023.6

    Language:Others  

    Country:Other  

  • Association between knee arthroplasty and incidence of dementia in older adults with knee osteoarthritis: LIFE Study.

    Shibano K, Uchida K, Nakamura J, Encho H, Mizuta S, Nakatsuka K, Akisue T, Fukuda H, Ono R

    IAGG Asia Oceania Regional Congress 2023  2023.6 

     More details

    Event date: 2023.6

    Presentation type:Oral presentation (general)  

    researchmap

  • Influence of COVID-19 lockdown on day care and home care affects the care level: LIFE study.

    Nakatsuka K, Ono R, Akisue T, Fukuda H

    IAGG Asia Oceania Regional Congress 2023  2023.6 

     More details

    Event date: 2023.6

    Presentation type:Oral presentation (general)  

    researchmap

  • Rebamipideは変形性関節症/腰痛症患者のNSAIDs潰瘍を予防する-LIFE Study データベースによるネステッドケースコントロール研究-.

    山手智志, 濵井敏, 石黒智恵子, 福田治久, 中島康晴.

    第96回日本整形外科学会学術総会  2023.5 

     More details

    Event date: 2023.5

    Language:Others  

    Country:Japan  

  • Rebamipideは変形性関節症/腰痛症患者のNSAIDs潰瘍を予防する-LIFE Study データベースによるネステッドケースコントロール研究-.

    山手智志, 濵井敏, 石黒智恵子, 福田治久, 中島康晴.

    第96回日本整形外科学会学術総会  2023.5 

     More details

    Event date: 2023.5

    Country:Japan  

    researchmap

  • The association between seasonal influenza vaccination and antimicrobial consumption in Japan from 2014/15 to 2019/20 season.

    Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H.

    33rd ECCMID 2023  2023.4 

     More details

    Event date: 2023.4

    Language:Others  

    Country:Other  

  • The association between seasonal influenza vaccination and antimicrobial consumption in Japan from 2014/15 to 2019/20 season.

    Tsuzuki S, Murata F, Maeda M, Asai Y, Koizumi R, Ohmagari N, Fukuda H.

    33rd ECCMID 2023  2023.4 

     More details

    Event date: 2023.4

    researchmap

  • 急性期脳梗塞新規発症後の医療費・介護費:LIFE Study.

    福田治久, 前田恵, 村田典子, 下川能史, 有村公一, 飯原弘二.

    2023.3 

     More details

    Event date: 2023.3

    Language:Others  

    Country:Japan  

  • 急性期脳梗塞新規発症後の医療費・介護費:LIFE Study.

    福田治久, 前田恵, 村田典子, 下川能史, 有村公一, 飯原弘二.

    Stroke2023.  2023.3 

     More details

    Event date: 2023.3

    Country:Japan  

    researchmap

  • コロナウイルスワクチン接種によるCOVID-19の入院医療費・在院日数比較:VENUS Study.

    前田恵, 村田典子, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • 高齢者のインフルエンザワクチン接種がフレイルに与える効果:LIFE Study.

    村田典子, 前田恵, 中塚清将, 小野玲, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • 疥癬患者の特徴と有病率:LIFE Study.

    山口征啓, 村田典子, 前田恵, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • 日本人高齢者における咬合状態とアルツハイマー病発症との関連:大規模コホート研究の結果(LIFE Study).

    宮野貴士, 金子諒右, 穴田貴久, 鮎川保則, 加藤幸一郎, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • 地域住民のpersonal health recordのモニタリング・プラットフォームの開発:SHINE Study.

    福田治久, 村田典子, 東幸恵, 藤本雅大, 工藤将馬, 小林吉之, 佐保賢志, 中原和美, 小野玲.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • ワクチン接種後有害事象評価方法の比較(コホートデザイン、自己対照ケースシリーズデザイン):VENUS Study.

    佐藤俊太朗, 勝田友博, 川添百合香, 高橋政樹, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Language:Others  

    Country:Japan  

  • コロナウイルスワクチン接種によるCOVID-19の入院医療費・在院日数比較:VENUS Study.

    前田恵, 村田典子, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • 地域住民のpersonal health recordのモニタリング・プラットフォームの開発:SHINE Study.

    福田治久, 村田典子, 東幸恵, 藤本雅大, 工藤将馬, 小林吉之, 佐保賢志, 中原和美, 小野玲.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • ワクチン接種後有害事象評価方法の比較(コホートデザイン、自己対照ケースシリーズデザイン):VENUS Study.

    佐藤俊太朗, 勝田友博, 川添百合香, 高橋政樹, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • 日本人高齢者における咬合状態とアルツハイマー病発症との関連:大規模コホート研究の結果(LIFE Study).

    宮野貴士, 金子諒右, 穴田貴久, 鮎川保則, 加藤幸一郎, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • 高齢者のインフルエンザワクチン接種がフレイルに与える効果:LIFE Study.

    村田典子, 前田恵, 中塚清将, 小野玲, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • 疥癬患者の特徴と有病率:LIFE Study.

    山口征啓, 村田典子, 前田恵, 福田治久.

    第33回日本疫学会学術総会.  2023.2 

     More details

    Event date: 2023.2

    Country:Japan  

    researchmap

  • 23価肺炎球菌莢膜ポリサッカライドワクチン接種後有害事象に対する能動的解析:VENUS Study.

    勝田友博, 佐藤俊太朗, 川添百合香, 高橋政樹, 石黒智恵子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • 自治体基盤データベースを活用した新型コロナウイルスワクチンの安全性評価:VENUS Study. Invited

    石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • 新型コロナウイルスワクチンの有効性および安全性の評価システムの開発:VENUS Study. Invited

    福田治久, 石黒智恵子, 前田恵, 村田典子.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • 新型コロナウイルス感染者等情報把握・管理支援システム(HER-SYS)とワクチン接種記録システム(VRS)のリンケージによるバリデーション研究:VENUS Study.

    堀江悠生, 石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • デルタ株,オミクロン株流行期における新型コロナウイルスワクチンの有効性評価:VENUS Study.

    三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • COVID-19による家庭内感染における新型コロナウイルスワクチンの効果検証:VENUS Study.

    前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • 23価肺炎球菌莢膜ポリサッカライドワクチン接種後有害事象に対する能動的解析:VENUS Study.

    勝田友博, 佐藤俊太朗, 川添百合香, 高橋政樹, 石黒智恵子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Country:Japan  

    researchmap

  • 新型コロナウイルスワクチンの有効性および安全性の評価システムの開発:VENUS Study. Invited

    福田治久, 石黒智恵子, 前田恵, 村田典子.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

    researchmap

  • デルタ株,オミクロン株流行期における新型コロナウイルスワクチンの有効性評価:VENUS Study.

    三村亘, 石黒智恵子, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Country:Japan  

    researchmap

  • COVID-19による家庭内感染における新型コロナウイルスワクチンの効果検証:VENUS Study.

    前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Country:Japan  

    researchmap

  • 新型コロナウイルス感染者等情報把握・管理支援システム(HER-SYS)とワクチン接種記録システム(VRS)のリンケージによるバリデーション研究:VENUS Study.

    堀江悠生, 石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Country:Japan  

    researchmap

  • 自治体基盤データベースを活用した新型コロナウイルスワクチンの安全性評価:VENUS Study. Invited

    石黒智恵子, 三村亘, 前田恵, 村田典子, 福田治久.

    第26回日本ワクチン学会学術集会.  2022.11 

     More details

    Event date: 2022.11

    Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

    researchmap

  • 保健・医療・行政データを用いたtest-negativeデザインによるCOVID-19ワクチンの有効性評価:VENUS Study.

    玉田雄大, 竹内研時, 草間太郎, 小坂健, 前田恵, 村田典子, 福田治久.

    第5回日本臨床疫学会学術大会.  2022.11 

     More details

    Event date: 2022.11

    Language:Others  

    Country:Japan  

  • 保健・医療・行政データを用いたtest-negativeデザインによるCOVID-19ワクチンの有効性評価:VENUS Study.

    玉田雄大, 竹内研時, 草間太郎, 小坂健, 前田恵, 村田典子, 福田治久.

    第5回日本臨床疫学会学術大会.  2022.11 

     More details

    Event date: 2022.11

    Country:Japan  

    researchmap

  • Comparative risk of femur fracture in patients receiving suvorexant versus those receiving z-drugs: an observational cohort study in Japan.

    Adomi M, Fukuda H.

    ISPE's 14th Asian Conference on Pharmacoepidemiology.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Other  

  • Comparative risk of femur fracture in patients receiving suvorexant versus those receiving z-drugs: an observational cohort study in Japan.

    Adomi M, Fukuda H.

    ISPE's 14th Asian Conference on Pharmacoepidemiology.  2022.10 

     More details

    Event date: 2022.10

    researchmap

  • COVID-19流行前後における特定健診結果の変化:LIFE Study.

    筑紫智哉, 村田典子, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Japan  

  • 高齢者肺炎球菌ワクチン接種が要介護認定に及ぼす影響:LIFE study.

    手塚真斗, 小野玲, 中塚清将, 山田直輝, 秋末敏宏, 村田典子, 前田恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Japan  

  • 生活保護世帯と国保加入世帯の子供の歯科受診の比較:LIFE Study.

    東幸恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Japan  

  • 日本における高齢者肺炎球菌ワクチンの接種率および接種関連要因: LIFE study.

    山田直輝, 中塚清将, 小野玲, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Japan  

  • メタボリッククシンドロームと大腸がん検診受診の関連性:LIFE Study.

    村田典子, 前田恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Language:Others  

    Country:Japan  

  • COVID-19流行前後における特定健診結果の変化:LIFE Study.

    筑紫智哉, 村田典子, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Country:Japan  

    researchmap

  • メタボリッククシンドロームと大腸がん検診受診の関連性:LIFE Study.

    村田典子, 前田恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Country:Japan  

    researchmap

  • 日本における高齢者肺炎球菌ワクチンの接種率および接種関連要因: LIFE study.

    山田直輝, 中塚清将, 小野玲, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Country:Japan  

    researchmap

  • 高齢者肺炎球菌ワクチン接種が要介護認定に及ぼす影響:LIFE study.

    手塚真斗, 小野玲, 中塚清将, 山田直輝, 秋末敏宏, 村田典子, 前田恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Country:Japan  

    researchmap

  • 生活保護世帯と国保加入世帯の子供の歯科受診の比較:LIFE Study.

    東幸恵, 福田治久.

    第81回日本公衆衛生学会総会.  2022.10 

     More details

    Event date: 2022.10

    Country:Japan  

    researchmap

  • 自治体基盤データベースを用いたワクチンの有効性・安全性の評価システム Invited

    福田治久

    第60回日本医療・病院管理学会学術総会  2022.9 

     More details

    Event date: 2022.9

    Language:Others  

    Country:Other  

  • 自治体基盤データベースを用いたワクチンの有効性・安全性の評価システム Invited

    福田治久

    第60回日本医療・病院管理学会学術総会  2022.9 

     More details

    Event date: 2022.9

    Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • 保健・医療・介護・行政データの大規模統合データベース研究基盤の開発とライフコース健康学に向けた展望:LIFE Study. Invited

    福田治久.

    第12回レギュラトリーサイエンス学会学術大会.  2022.9 

     More details

    Event date: 2022.9

    Language:Others  

    Country:Japan  

  • 承認後ワクチンのリアルワールドエビデンス創出に向けた自治体基盤データベース構築における品質管理の予備的検討:VENUS Study.

    宮岡大純, 堀江悠生, 三村亘, 福田治久, 石黒智恵子.

    第12回レギュラトリーサイエンス学会学術大会.  2022.9 

     More details

    Event date: 2022.9

    Language:Others  

    Country:Japan  

  • 保健・医療・介護・行政データの大規模統合データベース研究基盤の開発とライフコース健康学に向けた展望:LIFE Study. Invited

    福田治久.

    第12回レギュラトリーサイエンス学会学術大会.  2022.9 

     More details

    Event date: 2022.9

    Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

    researchmap

  • 承認後ワクチンのリアルワールドエビデンス創出に向けた自治体基盤データベース構築における品質管理の予備的検討:VENUS Study.

    宮岡大純, 堀江悠生, 三村亘, 福田治久, 石黒智恵子.

    第12回レギュラトリーサイエンス学会学術大会.  2022.9 

     More details

    Event date: 2022.9

    Country:Japan  

    researchmap

  • The Impact of Mitral Regurgitation on the Incidence of Stroke in Patients with Atrial fibrillation.

    Hieda M, Ono Y, Moriyama S, Kisanuki M, Ishiguro C, Sato S, Fukuda H, Akashi K.

    ESC Congress 2022.  2022.8 

     More details

    Event date: 2022.8

    Language:Others  

    Country:Other  

  • The Impact of Mitral Regurgitation on the Incidence of Stroke in Patients with Atrial fibrillation.

    Hieda M, Ono Y, Moriyama S, Kisanuki M, Ishiguro C, Sato S, Fukuda H, Akashi K.

    ESC Congress 2022.  2022.8 

     More details

    Event date: 2022.8

    researchmap

  • Continuation rates of newly prescribed donepezil among patients with Alzheimer's disease in Japan: LIFE Study.

    Fukuda H, Maeda M, Murata F.

    Alzheimer's Association International Conference 2022.  2022.7 

     More details

    Event date: 2022.7 - 2022.8

    Language:Others  

    Country:Other  

  • Continuation rates of newly prescribed donepezil among patients with Alzheimer's disease in Japan: LIFE Study.

    Fukuda H, Maeda M, Murata F.

    Alzheimer's Association International Conference 2022.  2022.7 

     More details

    Event date: 2022.7 - 2022.8

    researchmap

  • レセプトデータを用いた抜歯後出血の分析 -LIFE Study-.

    中村純也, 中塚清将, 小野玲, 芝辻豪士, 髙橋潤平, 西尾英莉, 足立了平, 福田治久.

    第32回日本老年歯科医学会  2022.6 

     More details

    Event date: 2022.6

    Language:Others  

    Country:Japan  

  • レセプトデータを用いた抜歯後出血の分析 -LIFE Study-.

    中村純也, 中塚清将, 小野玲, 芝辻豪士, 髙橋潤平, 西尾英莉, 足立了平, 福田治久.

    第32回日本老年歯科医学会  2022.6 

     More details

    Event date: 2022.6

    Country:Japan  

    researchmap

  • 新型コロナウイルス感染拡大による要介護認定の変動:LIFE Study.

    中塚清将, 小野玲, 福田治久.

    第64回日本老年医学会学術集会.  2022.6 

     More details

    Event date: 2022.6

    Language:Others  

    Country:Japan  

  • 新型コロナウイルス感染拡大による要介護認定の変動:LIFE Study.

    中塚清将, 小野玲, 福田治久.

    第64回日本老年医学会学術集会.  2022.6 

     More details

    Event date: 2022.6

    Country:Japan  

    researchmap

  • Associations between Psychiatric Disorders and COVID-19 in JAPAN: Results from the LIFE Study.

    Murata F, Maeda M, Fukuda H.

    ISPOR 2022.  2022.5 

     More details

    Event date: 2022.5

    Language:Others  

    Country:Other  

  • Associations of Comprehensive Stroke Center Scores with Medical and Long-Term Care Expenditures in Ischemic Stroke Patients after Hospital Discharge: J-ASPECT & LIFE Study.

    Ono Y, Fukuda H, Shimogawa T, Takegami M, Yoshimoto K, Iihara K.

    ISPOR 2022.  2022.5 

     More details

    Event date: 2022.5

    Language:Others  

    Country:Other  

  • Associations between Psychiatric Disorders and COVID-19 in JAPAN: Results from the LIFE Study.

    Murata F, Maeda M, Fukuda H.

    ISPOR 2022.  2022.5 

     More details

    Event date: 2022.5

    researchmap

  • Associations of Comprehensive Stroke Center Scores with Medical and Long-Term Care Expenditures in Ischemic Stroke Patients after Hospital Discharge: J-ASPECT & LIFE Study.

    Ono Y, Fukuda H, Shimogawa T, Takegami M, Yoshimoto K, Iihara K.

    ISPOR 2022.  2022.5 

     More details

    Event date: 2022.5

    researchmap

  • レセプトデータベースを用いた関節リウマチ患者における生物学的製剤の継続に関連する因子の解析:LIFE Study.

    藤本翔, 有信洋二郎, 綾野雅宏, 三苫弘喜, 小野伸之, 木本泰孝, 赤司浩一, 堀内孝彦, 新納宏昭, 福田治久, 佐藤俊太朗, 石黒智恵子

    第63回九州リウマチ学会.  2022.3 

     More details

    Event date: 2022.3

    Language:Others  

    Country:Other  

  • レセプトデータベースを用いた関節リウマチ患者における生物学的製剤の継続に関連する因子の解析:LIFE Study.

    藤本翔, 有信洋二郎, 綾野雅宏, 三苫弘喜, 小野伸之, 木本泰孝, 赤司浩一, 堀内孝彦, 新納宏昭, 福田治久, 佐藤俊太朗, 石黒智恵子

    第63回九州リウマチ学会.  2022.3 

     More details

    Event date: 2022.3

    Presentation type:Oral presentation (general)  

    researchmap

  • 高齢者肺炎球菌ワクチン接種と疾病罹患・総医療費の関連性:LIFE Study.

    小田太史, 勝田友博, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 所得変化と帯状疱疹発症の関連性:LIFE Study.

    鬼塚浩明, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 全人工膝関節置換術後患者の急性期リハビリ単位数の違いと健康寿命の関連性:LIFE Study.

    臼井裕太, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 問診による服薬状態の回答状況と医療費および血管疾患発生率:LIFE Study.

    秋本万里奈, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 特定保健指導の判定基準となる腹囲と心血管リスク評価の有用性:LIFE Study

    相良空美, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 入院時支援加算取得による在院日数短縮への効果:LIFE Study.

    神崎寛志, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 歯科健診における歯周病判定と糖尿病発生の関連性:LIFE Study.

    谷直道, 竹内研時, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 一般介護予防事業における有効性評価に関する多自治体研究:LIFE Study.

    前田恵, 村田典子, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 新型コロナウイルス感染症退院後の新規発症疾患に関する検討:LIFE Study.

    村田典子, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 認知症ケア加算の効果検証:LIFE Study.

    川端潤, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • みなし健診受診者を含めた市町村国保の特定健診受診率の検証:LIFE Study.

    東幸恵, 福田治久

    第80回日本公衆衛生学会総会  2021.12 

     More details

    Event date: 2021.12

    Language:Others  

    Country:Other  

  • 軽度認知障害症例の医療・介護費:LIFE Study.

    神崎寛志, 小野玲, 福田治久

    第40回日本認知症学会学術集会.  2021.11 

     More details

    Event date: 2021.11

    Language:Others  

    Country:Other  

  • アルツハイマー型認知症とレビー小体型認知症の診断後月別医療費推移:LIFE Study.

    小野玲, 中塚清将, 内田一彰, 福田治久

    第40回日本認知症学会学術集会.  2021.11 

     More details

    Event date: 2021.11

    Language:Others  

    Country:Other  

  • レセプトデータを用いた抗血栓療法患者における抜歯後出血の分析: LIFE Study.

    中村純也, 中塚清将, 芝辻豪士, 福田治久

    第66回日本口腔外科学会総会.  2021.11 

     More details

    Event date: 2021.11

    Language:Others  

    Country:Other  

  • 高齢者におけるがんの発症がフレイルおよび骨折に及ぼす影響:LIFE Study.

    中塚清将, 小野玲, 村田峻輔, 福田治久

    第4回日本臨床疫学会  2021.10 

     More details

    Event date: 2021.10

    Language:Others  

    Country:Other  

  • Healthcare expenditure attributable to dementia with Lewy bodies in Japan: LIFE Study.

    Ono R, Nakatsuka K, Uchida K, Fukuda H

    Alzheimer's Association International Conference 2021  2021.7 

     More details

    Event date: 2021.7

    Language:Others  

    Country:Other  

  • レセプトデータを使用した要介護発生における高齢期がんのインパクト:Longevity Improvement & Fair Evidence (LIFE) Study.

    小野玲, 中塚清将, 福田治久

    第63回日本老年医学会学術集会  2021.6 

     More details

    Event date: 2021.6 - 2021.7

    Language:Others  

    Country:Other  

  • レセプトデータを使用した高齢期のがん腫別要介護発生:LIFE Study.

    小野玲, 中塚清将, 福田治久

    第6回日本がんサポーティブケア学会学術集会  2021.5 

     More details

    Event date: 2021.5 - 2021.6

    Language:Others  

    Country:Other  

  • Association between low-income status and death in Japanese patients with heart failure: LIFE Study. International conference

    Maeda M, Fukuda H.

    ISPOR Asia Pacific 2020  2021.7 

     More details

    Event date: 2020.9

    Language:English  

    Country:Korea, Republic of  

  • Economic status and mortality in Alzheimer's disease patients in Japan: LIFE Study. International conference

    Ono R, Maeda M, Fukuda H.

    Alzheimer's Association International Conference 2020  2020.7 

     More details

    Event date: 2020.7

    Language:English  

    Country:Netherlands  

  • Healthcare expenditures attributable to Alzheimer's disease in Japan: LIFE Study. International conference

    Fukuda H, Maeda M, Ono R.

    Alzheimer's Association International Conference 2020.  2020.7 

     More details

    Event date: 2020.7

    Language:English  

    Country:Netherlands  

  • 介護レセプトデータを用いた供給者誘発需要の検証.

    岩本哲哉, 福田治久.

    第3回日本臨床疫学会年次学術大会  2019.9 

     More details

    Event date: 2019.9

    Language:Japanese  

    Venue:福岡   Country:Japan  

  • Low-intensity pulsed ultrasound was frequently used for fresh fractures in elderly female patients according to the open data from the National Database of Health Insurance Claims of Japan. International conference

    Jingushi S, Fukuda H.

    The 16 th Biennial Conference of the International Society for Fracture Repair ORS ISFR 2018  2018.10 

     More details

    Event date: 2018.10

    Language:English  

    Country:Japan  

  • カルバペネム系抗菌薬の使用量と緑膿菌のカルバペネム系抗菌薬への感受性の関係:多施設比較研究

    金子拓也, 福田治久, 三村美智, 此村恵子, 赤沢学.

    第138回日本薬学会年会  2018.3 

     More details

    Event date: 2018.3

    Language:Japanese  

    Venue:金沢   Country:Japan  

  • 手術部位感染発生率の病院間比較結果フィードバックの有効性評価.

    福田治久.

    第32回日本環境感染学会総会  2017.2 

     More details

    Event date: 2017.2

    Language:Japanese  

    Venue:神戸   Country:Japan  

  • 一般外来の縮小に向けた逆紹介とその後の入院率との関連.

    小原 仁, 福田 治久

    第52回日本医療病院管理学会学術総会  2014.9 

     More details

    Event date: 2014.9

    Language:Japanese  

    Venue:東京   Country:Japan  

  • 厚生労働省DPC影響評価調査データを用いて算出した推測病床利用率の利用可能性に関する検討.

    溝部 彌希, 福田 治久

    第52回日本医療病院管理学会学術総会  2014.9 

     More details

    Event date: 2014.9

    Language:Japanese  

    Venue:東京   Country:Japan  

  • Nationwide survey for pharmacists on patient safety cultures in Japan. International conference

    Hirose M, Tsuda Y, Haruhisa Fukuda, Imanaka Y

    18th Annual International Meeting on International Society for Pharmacoeconomics and Outcomes Research  2013.5 

     More details

    Event date: 2013.5

    Language:English  

    Country:United States  

  • 経管栄養実施患者における在宅医療および入院医療の医療費比較.

    前田恵, 福田治久, 石崎達郎

    第76回日本公衆衛生学会総会  2017.11 

     More details

    Language:Japanese  

    Country:Other  

  • カルバペネム系抗菌薬の使用量と緑膿菌のカルバペネム系抗菌薬への感受性の関係:多施設比較研究.

    金子拓也, 福田治久, 三村美智, 此村恵子, 赤沢学

    第138回日本薬学会年会  2018.3 

     More details

    Language:Japanese  

    Country:Other  

  • 急性期病院における抗緑膿菌薬の処方実態と薬剤耐性菌発生率の関係.

    三村美智, 福田治久, 金子拓也, 此村恵子, 赤沢学

    第138回日本薬学会年会  2018.3 

     More details

    Language:Japanese  

    Country:Other  

  • 病院経営の改善に向けた入院診療収益と関連指標との関係性の検証.

    荒川正太, 福田治久

    第56回日本医療・病院管理学会学術総会  2018.10 

     More details

    Language:Japanese  

    Country:Other  

  • 病院情報の公表における医療機関群別がんのStage分類の不明率の検証.

    一番ヶ瀬智和, 福田治久

    第56回日本医療・病院管理学会学術総会  2018.10 

     More details

    Language:Japanese  

    Country:Other  

  • 病床機能報告公表データを用いたリハビリテーション単位数と日常生活機能評価の関連.

    小田太史, 福田治久

    第56回日本医療・病院管理学会学術総会  2018.10 

     More details

    Language:Japanese  

    Country:Other  

  • Attributable inpatient costs of hospital-onset Clostridium difficile infection: a nationwide case-control study in Japan. International conference

    Fukuda H, Yano T, Shimono N

    IDWeek2018  2018.10 

     More details

    Language:English  

    Country:Other  

    Attributable inpatient costs of hospital-onset Clostridium difficile infection: a nationwide case-control study in Japan.

  • Low-intensity pulsed ultrasound was frequently used for fresh fractures in elderly female patients according to the open data from the National Database of Health Insurance Claims of Japan.

    Jingushi S, Fukuda H

    The 16 th Biennial Conference of the International Society for Fracture Repair ORS ISFR  2018.11 

     More details

    Language:Others  

    Country:Other  

  • 未破裂脳動脈瘤症例に対するフローダイバーターとコイル塞栓術の医療費分析:ナショナルデータベース研究.

    福田治久, 佐藤大介, 加藤依子, 山田恵祐, 勝又雅裕, 細尾久幸, 鶴田和太郎

    第34回日本脳神経血管内治療学会学術総会  2018.11 

     More details

    Language:Japanese  

    Country:Other  

  • Healthcare expenditures for the treatment of patients with hepatocellular carcinoma in Japan. International conference

    Fukuda H, Ishida H, Sato D, Moriwaki K

    ISPOR Europe 2018  2018.11 

     More details

    Language:English  

    Country:Other  

    Healthcare expenditures for the treatment of patients with hepatocellular carcinoma in Japan.

  • 抗菌薬使用が薬剤感受性に及ぼす効果:Antimicrobial Consumption Improvement Project.

    福田治久, 矢野貴久, 下野信行

    第34回日本環境感染学会総会  2019.2 

     More details

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Country:Other  

  • 成人市中肺炎における抗菌薬使用状況の検証:Antimicrobial Consumption Improvement Project.

    一番ヶ瀬智和, 福田治久

    第34回日本環境感染学会総会  2019.2 

     More details

    Language:Others  

    Country:Other  

  • JANIS検査部門の還元情報が薬剤感受性に及ぼす効果.

    福田治久, 藤田烈

    第34回日本環境感染学会総会  2019.2 

     More details

    Language:Others  

    Country:Other  

  • NDBを用いた循環器データベース研究の実施方法 Invited

    福田治久

    第83回日本循環器学会学術集会  2019.3 

     More details

    Language:Others  

    Country:Other  

  • レセプトデータを用いた急性期脳梗塞症例の識別モデルの開発:ナショナルデータベース研究.

    福田治久, 佐藤大介, 前田恵, 松尾龍, 鴨打正浩

    第44回日本脳卒中学会学術集会  2019.3 

     More details

    Language:Others  

    Country:Other  

  • Decreasing of National Antibiotic Consumption and Economic Impact during 2013-2017 in Japan.

    Kusama Y, Ishikane M, Fukuda H, Yumura E, Tanaka C, Kimura Y, Hayakawa K, Muraki Y, Yamasaki D, Tanabe M, Ohmagari N

    The 29th European Congress of Clinical Microbiology & Infectious Diseases.  2019.4 

     More details

    Language:Others  

    Country:Other  

  • Analysis of the association between activities of daily living and rehabilitation time using data from a hospital bed function report.

    Oda F, Fukuda H

    The 13th International Society of Physical and Rehabilitation Medicine World Congress (ISPRM 2019)  2019.6 

     More details

    Language:Others  

    Country:Other  

  • 介護レセプトデータを用いた供給者誘発需要の検証.

    岩本哲哉, 福田治久

    第3回日本臨床疫学会年次学術大会  2019.7 

     More details

    Language:Others  

    Country:Other  

  • 整形外科領域のSSIと医療経済 Invited

    福田治久

    第42回日本骨・関節感染症学会総会  2019.7 

     More details

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Country:Other  

  • Assessment of record linkage using administrative claims data and antimicrobial susceptibility testing data.

    Mimura W, Fukuda H, Konomura K, Akazawa M

    ISPE's 12th Asian Conference on Pharmacoepidemiology  2019.10 

     More details

    Language:Others  

    Country:Other  

  • Antimicrobial utilization and infection caused by Gram-negative bacteria in patients with haematological malignancies in Japan: A multi-centre cross-sectional study.

    Mimura W, Fukuda H, Akazawa M

    ISPOR Europe  2019.11 

     More details

    Language:Others  

    Country:Other  

  • 自治体病院における医業収益の関連要因:大規模経営管理データのパネルデータ解析.

    福田治久

    第57回日本医療・病院管理学会学術総会.  2019.11 

     More details

    Language:Others  

    Country:Other  

  • 夜間・休日の時間外受診における 抗菌薬処方および翌日の未受診状況.

    前田恵, 福田治久, 日馬由貴, 松永展明, 大曲貴夫

    第57回日本医療・病院管理学会学術総会  2019.11 

     More details

    Language:Others  

    Country:Other  

  • JHAIS手術部位感染サーベイランス部門参加が感染率に及ぼす効果.

    福田治久, 森兼啓太

    第35回日本環境感染学会総会.  2020.2 

     More details

    Language:Others  

    Country:Other  

  • Healthcare expenditures attributable to Alzheimer's disease in Japan: LIFE Study.

    Fukuda H, Maeda M, Ono R

    Alzheimer's Association International Conference  2020.6 

     More details

    Language:Others  

    Country:Other  

  • Economic status and mortality in Alzheimer's disease patients in Japan: LIFE Study.

    Ono R, Maeda M, Fukuda H

    Alzheimer's Association International Conference  2020.6 

     More details

    Language:Others  

    Country:Other  

  • Association between low-income status and death in Japanese patients with heart failure: LIFE Study.

    Maeda M, Fukuda H

    ISPOR Asia Pacific  2020.9 

     More details

    Language:Others  

    Country:Other  

  • アルツハイマー病発症が医療・介護費用に及ぼす効果 LIFE Study

    福田 治久, 小野 玲

    2020.10 

     More details

    Language:Japanese  

    Country:Japan  

  • 心不全患者における低所得と発症時重症度との関連:LIFE Study.

    前田恵, 福田治久

    第79回日本公衆衛生学会総会.  2020.10 

     More details

    Language:Others  

    Country:Other  

  • COPD新規診断患者における所得状態と急性憎悪および死亡との関連性:LIFE study.

    川内はるな, 福田治久

    第79回日本公衆衛生学会総会.  2020.10 

     More details

    Language:Others  

    Country:Other  

  • レセプトデータを用いた糖尿病患者の歯科受診状況と抜歯の分析.

    藤久保美紀, 福田治久

    第79回日本公衆衛生学会総会.  2020.10 

     More details

    Language:Others  

    Country:Other  

  • A病院の外来採血室における業務効率に影響を与える要因分析.

    東幸恵, 小林より子, 福田治久

    第58回日本医療・病院管理学会総会  2020.10 

     More details

    Language:Others  

    Country:Other  

  • Additional medical expenditures attributable to pneumococcal disease in Japan.

    Fukuda H

    IDWeek  2020.10 

     More details

    Language:Others  

    Country:Other  

  • アルツハイマー病発症が医療・介護費用に及ぼす効果:LIFE Study.

    福田治久, 小野玲

    第39回日本認知症学会学術集会.  2020.11 

     More details

    Language:Others  

    Country:Other  

  • Difference-in-Differences推定による認知症患者医療費における二次予防効果の検証.

    田中伸治, 福田治久

    第68回福岡県公衆衛生学会.  2021.5 

     More details

    Language:Others  

    Country:Other  

  • 血管内皮増殖因子シグナル阻害薬使用中の高血圧症(既往 /新規発症)は良好な臨床指標である.

    森山祥平, 稗田道成, 福田治久, 河野正太郎, 横山拓, 深田光敬, 草場仁志, 馬場英司, 赤司浩一

    第130回日本循環器学会九州地方会.  2021.6 

     More details

    Language:Others  

    Country:Other  

  • Renin-Angiotensin System Inhibitors Can Be A First Choice Drug for Hypertension in Patients Treated with Vascular Endothelial Growth Factor Inhibitors.

    Moriyama S, Hieda M, Fukuda H, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K

    European Society of Cardiology  2021.8 

     More details

    Language:Others  

    Country:Other  

  • Impact of Hypertension on Clinical Outcome in Patients treated with Vascular Endothelial Growth Factor Inhibitors.

    Moriyama S, Hieda M, Fukuda H, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K

    European Society of Cardiology  2021.8 

     More details

    Language:Others  

    Country:Other  

  • DPC/JANISデータを用いた医療施設の特徴付けと薬剤耐性との関連性評価

    佐藤 夏津, 莊司 智和, 福田 治久, 村木 優一, 河田 圭司, 赤沢 学

    日本環境感染学会総会プログラム・抄録集  2021.9 

     More details

    Language:Japanese  

    Country:Japan  

  • 臨床疫学会COVID-19流行下における受診行動と医療費の変化に関する記述的分析:LIFE study.

    谷直道, 福田治久

    第4回日本臨床疫学会  2021.10 

     More details

    Language:Others  

    Country:Other  

  • 歯科健診における歯周病判定と糖尿病発生の関連性 LIFE Study

    谷 直道, 竹内 研時, 福田 治久

    日本公衆衛生学会総会抄録集  2021.11 

     More details

    Language:Japanese  

    Country:Japan  

  • Risk of Cardiovascular Events After Streptococcus pneumoniae Infections: LIFE Study.

    Nishimura N, Fukuda H

    ISPOR Europe  2021.11 

     More details

    Language:Others  

    Country:Other  

  • Risk factors for pneumococcal disease in persons with chronic medical conditions: LIFE Study.

    Onizuka H, Nishimura N, Kiyohara K, Fukuda H

    ISPOR Europe  2021.11 

     More details

    Language:Others  

    Country:Other  

  • Progression of Mild Cognitive Impairment Cases to Alzheimer's Disease: LIFE Study.

    Fukuda H, Kanzaki H, Ono R

    ISPOR Europe  2021.11 

     More details

    Language:Others  

    Country:Other  

  • 承認後ワクチンの定量的な安全性モニタリング評価体制の構築に向けた検討:LIFE-VENUS Study.

    石黒智恵子, 三村亘, 福田治久

    第25回日本ワクチン学会学術集会.  2021.12 

     More details

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Country:Other  

  • 後期高齢者における2018/2019シーズンのインフルエンザワクチン有効性評価:LIFE-VENUS Study.

    三村亘, 石黒智恵子, 福田治久

    第25回日本ワクチン学会学術集会.  2021.12 

     More details

    Language:Others  

    Country:Other  

  • 予防接種台帳と医療レセプトデータの統合データベースの開発:LIFE-VENUS Study.

    福田治久, 石黒智恵子, 村田典子

    第25回日本ワクチン学会学術集会.  2021.12 

     More details

    Language:Others   Presentation type:Symposium, workshop panel (public)  

    Country:Other  

  • レセプトデータ分析における併存疾患の評価に関する検証.

    前田恵, 福田治久

    第55回日本医療・病院管理学会学術総会  2017.10 

     More details

    Language:Japanese  

    Country:Other  

  • 手術部位感染発生による病院持ち出し費用の推定

    福田 治久

    第27回日本環境感染学会総会  2012.2 

     More details

    Language:Others  

    Country:Other  

  • 手術部位感染による追加的医療費の推定方法の比較:マッチング比較法 vs. 多変量解析法

    福田 治久

    第27回日本環境感染学会総会  2012.2 

     More details

    Language:Japanese  

    Country:Other  

  • 心臓血管外科における手術部位感染発生の経済的インパクト

    福田 治久

    第27回日本環境感染学会総会  2012.2 

     More details

    Language:Japanese  

    Country:Other  

  • 大腿骨頸部骨折症例を対象にした地域連携型医療と一病院完結型医療の医療費比較

    福田 治久

    第7回日本医療経済学会  2012.7 

     More details

    Language:Japanese  

    Country:Other  

  • 手術部位感染発生による経済的インパクトの推定:全国多施設研究

    福田 治久

    第50回日本医療・病院管理学会学術総会  2012.10 

     More details

    Language:Japanese  

    Country:Other  

  • 消化器手術における手術部位感染を対象にしたStandardized Infection Ratioの算出モデルの検証

    福田 治久

    第25回日本外科感染症学会総会学術集会  2012.11 

     More details

    Language:Japanese  

    Country:Other  

  • 大腸手術実施症例における手術部位感染発生による追加的医療資源の推定:全国多施設研究

    福田 治久

    第25回日本外科感染症学会総会学術集会  2012.11 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Country:Other  

  • 手術部位感染の危険因子:JANIS/DPC統合データベースを用いた多施設共同研究

    福田 治久

    第28回日本環境感染学会総会  2013.3 

     More details

    Language:Others  

    Country:Other  

  • 厚生労働省DPC影響評価調査データを用いて算出した推測病床利用率の利用可能性に関する検討

    溝部彌希, 福田 治久

    第52回日本医療病院管理学会学術総会  2014.9 

     More details

    Language:Others  

    Country:Other  

  • 一般外来の縮小に向けた逆紹介とその後の入院率との関連

    小原 仁, 福田 治久

    第52回日本医療病院管理学会学術総会  2014.9 

     More details

    Language:Others  

    Country:Other  

  • Medical expenditures associated with type 2 diabetes mellitus in Japan: A large claims database study. International conference

    17th Annual European Meeting on International Society for Pharmacoeconomics and Outcomes Research  2014.11 

     More details

    Language:English  

    Country:Other  

    Medical expenditures associated with type 2 diabetes mellitus in Japan: A large claims database study.

  • 2型糖尿病患者に対するフットケアの有効性評価:医療費へ及ぼす影響.

    永吉円, 福田治久

    第53回日本糖尿病学会九州地方会  2015.11 

     More details

    Language:Others  

    Country:Other  

  • 診療報酬明細書データを用いた糖原病疾病費用分析.

    謝瑛子, 福田治久

    第53回日本医療病院管理学会学術総会  2015.11 

     More details

    Language:Others  

    Country:Other  

  • 日本版標準化感染比算出モデルの開発:JANIS手術部位感染部門全病院データ利用研究.

    福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • 消化器外科領域における手術部位感染の患者関連リスク因子の検証:国内多施設共同研究.

    福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • 安全機構付き鋭利器材の針刺し防止効果の推定:国内多施設共同研究.

    福田治久, 山中直子

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • 安全機構付き鋭利器材の費用効果分析.

    福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • MRSA感染症による追加的医療資源の算出:プロペンシティ・スコア解析.

    高木康文, 福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • MRSA感染症におけるリスク因子の推定.

    高木康文, 福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • JANISおよびDPCデータを用いた抗菌薬適正使用による薬剤費削減効果.

    山中直子, 今村陽子, 福田治久

    第31回日本環境感染学会総会  2016.2 

     More details

    Language:Others  

    Country:Other  

  • Impact of patient nonadherence to diabetes treatment on complication risks and healthcare costs. International conference

    Mizobe M, Fukuda H

    21st Annual International Meeting on International Society for Pharmacoeconomics and Outcomes Research  2016.5 

     More details

    Language:Others   Presentation type:Oral presentation (general)  

    Country:Other  

  • Should the government intervene in the implementation on safety-engineered devices? Evidence from a cost-effectiveness analysis of needlestick injuries. International conference

    Fukuda H, Moriwaki K

    21st Annual International Meeting on International Society for Pharmacoeconomics and Outcomes Research  2016.5 

     More details

    Language:Others   Presentation type:Oral presentation (general)  

    Country:Other  

  • 潜因性脳梗塞発症患者に対する植込型心電図記録計の費用効果分析.

    福田治久, 細谷昌礼, Quiroz Maria, 松本万夫, 松尾龍, 鴨打正浩

    第42回日本脳卒中学会学術集会  2017.3 

     More details

    Language:Japanese  

    Country:Other  

  • Cost-Effectiveness of Implementing Guidelines for the Treatment of Glucocorticoid-Induced Osteoporosis in Japan. International conference

    Moriwaki K, Fukuda H

    Society for Medical Decision Making 39th Annual North American Meeting  2017.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    Country:Other  

    Cost-Effectiveness of Implementing Guidelines for the Treatment of Glucocorticoid-Induced Osteoporosis in Japan.

  • 介護保険自己負担割合の引き上げが介護保険サービス利用に与える影響.

    曽我雄吾, 村田典子, 福田治久

    第76回日本公衆衛生学会総会  2017.10 

     More details

    Language:Japanese  

    Country:Other  

  • 公立病院再編による経営改善効果に関する研究.

    大谷泰史, 福田治久

    第55回日本医療・病院管理学会学術総会  2017.10 

     More details

    Language:Japanese  

    Country:Other  

  • 新型コロナウイルス感染症(COVID-19)罹患後精神症状と精神保健施設における対応 新型コロナウイルス感染症罹患後における精神症状の発生状況

    福田 治久

    精神神経学雑誌  2023.6  (公社)日本精神神経学会

     More details

    Language:Japanese  

  • 新型コロナウイルス感染拡大による要介護認定の変動 LIFE Study

    中塚 清将, 小野 玲, 福田 治久

    日本老年医学会雑誌  2022.5  (一社)日本老年医学会

     More details

    Language:Japanese  

  • 新型コロナウイルスワクチン接種と新型コロナウイルス罹患後精神症状発現との関連性 VENUS Study

    村田 典子, 前田 恵, 小野 玲, 福田 治久

    臨床とウイルス  2023.9  日本臨床ウイルス学会

     More details

    Language:Japanese  

  • 後期高齢者のACSCによる3次救急病院への緊急入院実態 LIFE Study

    松岡 佳孝, 前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • 帯状疱疹ワクチン接種者の特徴に関する記述疫学研究 LIFE Study

    村田 典子, 前田 恵, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • 小児における新型コロナウイルスワクチンの初回免疫の有効性評価 VENUS Study

    石黒 智恵子, 三村 亘, 前田 恵, 村田 典子, 福田 治久

    臨床とウイルス  2023.9  日本臨床ウイルス学会

     More details

    Language:Japanese  

  • 地域住民のpersonal health recordのモニタリング・プラットフォームの開発 SHINE Study

    福田 治久, 村田 典子, 東 幸恵, 藤本 雅大, 工藤 将馬, 小林 吉之, 佐保 賢志, 中原 和美, 小野 玲

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • 国保加入者における新規高血圧患者の服薬アドヒアランスの実態とその要因の分析 LIFE Study

    相良 空美, 後藤 健一, 福田 治久

    日本高血圧学会総会プログラム・抄録集  2023.9  (NPO)日本高血圧学会

     More details

    Language:Japanese  

  • 介護認定調査による高齢高血圧患者の服薬アドヒアランスと関連要因の検討 LIFE Study

    相良 空美, 後藤 健一, 福田 治久, 村田 典子, 前田 恵

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • ワクチン接種後有害事象評価方法の比較(コホートデザイン、自己対照ケースシリーズデザイン) VENUS Study

    佐藤 俊太朗, 勝田 友博, 川添 百合香, 高橋 政樹, 福田 治久

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • ロタウイルスワクチン接種および家族構成との関連 VENUS Study

    前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • ロタウイルスワクチンにおける有効性評価 VENUS Study

    前田 恵, 福田 治久, 村田 典子

    臨床とウイルス  2023.9  日本臨床ウイルス学会

     More details

    Language:Japanese  

  • レセプトデータを用いた抜歯後出血の分析 LIFE Study

    中村 純也, 芝辻 豪士, 高橋 潤平, 西尾 英莉, 足立 了平, 福田 治久

    日本老年歯科医学会総会・学術大会プログラム・抄録集  2022.6  (一社)日本老年歯科医学会

     More details

    Language:Japanese  

  • レセプトデータを用いた抜歯後出血の分析 LIFE Study

    中村 純也, 芝辻 豪士, 高橋 潤平, 西尾 英莉, 足立 了平, 福田 治久

    老年歯科医学  2022.9  (一社)日本老年歯科医学会

     More details

    Language:Japanese  

  • レセプトデータに基づく外来を含むCOVID-19患者特定アルゴリズムのバリデーション研究 VENUS Study

    近持 卓, 三村 亘, 石黒 智恵子, 前田 恵, 村田 典子, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • レセプトデータにおける新型コロナウイルス感染症後遺症患者の特徴 LIFE Study

    山口 征啓, 前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • メタボリッククシンドロームと大腸がん検診受診の関連性 LIFE Study

    村田 典子, 前田 恵, 福田 治久

    日本公衆衛生学会総会抄録集  2022.9  日本公衆衛生学会

     More details

    Language:Japanese  

  • コロナウイルスワクチン接種によるCOVID-19の入院医療費・在院日数比較 VENUS Study

    前田 恵, 村田 典子, 福田 治久

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • オミクロンBA.5流行期における高齢者に対するオミクロン対応2価ワクチンの有効性評価 VENUS Study

    三村 亘, 石黒 智恵子, 前田 恵, 村田 典子, 福田 治久

    臨床とウイルス  2023.9  日本臨床ウイルス学会

     More details

    Language:Japanese  

  • Test-negative designによる新型コロナウイルス2価ワクチンの有効性評価 VENUS Study

    玉田 雄大, 竹内 研時, 草間 太郎, 小坂 健, 前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • Rebamipideは変形性関節症/腰痛症患者のNSAIDs潰瘍を予防する LIFE Studyデータベースによるネステッドケースコントロール研究

    山手 智志, 濱井 敏, 石黒 智恵子, 福田 治久, 中島 康晴

    日本整形外科学会雑誌  2023.3  (公社)日本整形外科学会

     More details

    Language:Japanese  

  • Rebamipideは変形性関節症/腰痛症患者のNSAIDs潰瘍を予防する LIFE Studyデータベースによるネステッドケースコントロール研究

    山手 智志, 濱井 敏, 石黒 智恵子, 福田 治久, 中島 康晴

    日本関節病学会誌  2023.6  (一社)日本関節病学会

     More details

    Language:Japanese  

  • MRワクチン接種の有無と背景因子についての研究 LIFE Study

    吉野 麻衣, 前田 恵, 村田 典子, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • MAFLDによる冠動脈疾患および脳血管疾患へのリスクの評価 LIFE Study

    明野 由里奈, 前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • HPVワクチンの積極的勧奨再開による接種率の影響の評価 VENUS Study

    佐澤 真比呂, 石黒 智恵子, 三村 亘, 前田 恵, 村田 典子, 福田 治久

    臨床とウイルス  2023.9  日本臨床ウイルス学会

     More details

    Language:Japanese  

  • COVID-19流行前後における特定健診結果の変化 LIFE Study

    筑紫 智哉, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2022.9  日本公衆衛生学会

     More details

    Language:Japanese  

  • COVID-19流行の乳幼児定期予防接種完了への影響 VENUS Study

    芝野 航大, 中塚 清将, 前田 恵, 村田 典子, 秋末 敏宏, 福田 治久, 小野 玲

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • ACE阻害薬による肺炎予防効果の検証 LIFE Study

    上村 亮介, 前田 恵, 村田 典子, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • 新型コロナウイルス罹患後疾患に対するコロナワクチン接種の効果 VENUS study

    金 晟娥, 前田 恵, 村田 典子, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • 高齢者肺炎球菌ワクチン接種が要介護認定に及ぼす影響 LIFE study

    手塚 真斗, 小野 玲, 中塚 清将, 山田 直輝, 秋末 敏宏, 村田 典子, 前田 恵, 福田 治久

    日本公衆衛生学会総会抄録集  2022.9  日本公衆衛生学会

     More details

    Language:Japanese  

  • 高齢者肺炎球菌ワクチンの接種率および接種関連要因の検討 LIFE Study

    山田 直輝, 中塚 清将, 手塚 真斗, 村田 典子, 前田 恵, 福田 治久, 秋末 敏宏, 小野 玲

    日本公衆衛生学会総会抄録集  2022.9  日本公衆衛生学会

     More details

    Language:Japanese  

  • 高齢者心不全患者の心不全治療薬の有効性検討 LIFE Study

    前原 将太, 稗田 道成, 中島 直樹, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • 高齢者のインフルエンザワクチン接種がフレイルに与える効果 LIFE Study

    村田 典子, 前田 恵, 中塚 清将, 小野 玲, 福田 治久

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • 骨粗鬆症患者の経口ビスフォスフォネート製剤治療開始前の歯科受診率 LIFE Study

    山口 征啓, 村田 典子, 前田 恵, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • 運動習慣と肺炎球菌ワクチン接種が肺炎関連入院に与える影響 The VENUS Study

    村田 典子, 前田 恵, 小野 玲, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • 認知症罹患後のがん,心筋梗塞,脳血管疾患の関係 LIFE Study

    小野 玲, 中塚 清将, 村田 典子, 前田 恵, 福田 治久

    老年精神医学雑誌  2022.11  (株)ワールドプランニング

     More details

    Language:Japanese  

  • 認知症罹患後のがん,心筋梗塞,脳血管疾患の関係 LIFE Study

    小野 玲, 中塚 清将, 村田 典子, 前田 恵, 福田 治久

    Dementia Japan  2022.10  (一社)日本認知症学会

     More details

    Language:Japanese  

  • 自治体基盤データベースを用いたワクチンの有効性・安全性の評価システム

    福田 治久

    日本医療・病院管理学会誌  2022.9  (一社)日本医療・病院管理学会

     More details

    Language:Japanese  

  • 疥癬患者の特徴および有病率 LIFE Study

    山口 征啓, 村田 典子, 前田 恵, 福田 治久

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • 生活保護受給開始前後での医科・歯科医療費の変化 LIFE Study

    塩田 千尋, 竹内 研時, 玉田 雄大, 草間 太郎, 福田 治久, 小坂 健

    口腔衛生学会雑誌  2024.4  (一社)日本口腔衛生学会

     More details

    Language:Japanese  

  • 生活保護世帯と国保加入世帯の子供の歯科受診の比較 LIFE Study

    東 幸恵, 福田 治久

    日本公衆衛生学会総会抄録集  2022.9  日本公衆衛生学会

     More details

    Language:Japanese  

  • 生後25ヵ月未満の乳幼児のRSV感染症に関する記述疫学 LIFE Study

    井上 雅子, 前田 恵, 村田 典子, 福田 治久

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • 特定保健指導による腹囲および体重の減少達成群と未達成群による効果検証 LIFE Study

    佐藤 有希子, 福田 治久, 村田 典子, 前田 恵

    日本公衆衛生学会総会抄録集  2023.10  日本公衆衛生学会

     More details

    Language:Japanese  

  • 歯周病と新規糖尿病発症の併存と年間医療費との関連 LIFE Study

    衣川 安奈, 竹内 研時, 玉田 雄大, 草間 太郎, 佐藤 美寿々, 福田 治久, 小坂 健

    口腔衛生学会雑誌  2024.4  (一社)日本口腔衛生学会

     More details

    Language:Japanese  

  • 日本人高齢者における咬合状態とアルツハイマー病発症との関連 大規模コホート研究の結果(LIFE Study)

    宮野 貴士, 金子 諒右, 穴田 貴久, 鮎川 保則, 加藤 幸一郎, 福田 治久

    Journal of Epidemiology  2023.2  (一社)日本疫学会

     More details

    Language:Japanese  

  • 新規うつ病罹患と医療費の関係性

    薬王 麻記子, 前田 恵, 村田 典子, 福田 治久

    健康支援  2024.2  日本健康支援学会

     More details

    Language:Japanese  

  • 新型コロナワクチン小児接種における家庭別接種状況および接種要因 VENUS Study

    前田 恵, 村田 典子, 福田 治久

    薬剤疫学  2023.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

▼display all

MISC

  • ワクチンデータベースを用いたワクチンの有効性・安全性の科学的検証 Reviewed

    福田治久

    医学のあゆみ   2023.9

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 感染予防活動の成果を示す!医療経済評価.

    福田 治久

    2015.5

     More details

    Language:Japanese  

  • 安全機構付き鋭利器材を対象にした医療経済評価の手法

    福田 治久

    2015.3

     More details

    Language:Japanese  

  • ワクチンデータベースを用いたワクチンの有効性・安全性の科学的検証 Invited

    福田治久

    医学のあゆみ(週刊医学のあゆみ)   286 ( 11 )   921 - 927   2023.9

     More details

  • 医療システムの質・効率・公正 医療経済学の新たな展開(Vol.9) ワクチンデータベースを用いたワクチンの有効性・安全性の科学的検証

    福田 治久

    医学のあゆみ   286 ( 11 )   921 - 927   2023.9   ISSN:0039-2359

     More details

    Language:Japanese   Publisher:医歯薬出版(株)  

    日本にはワクチンの有効性と安全性を検証できるワクチンデータベースが構築されていない.それによりワクチンに対する信頼性がゆらぎ,HPVワクチンやCOVID-19ワクチンの接種率の低迷といった社会問題を生じさせている.そのため,ワクチンデータベースの開発は喫緊の課題である.現在,アカデミア主導で,自治体基盤によるワクチンデータベースの開発研究が始まっている(VENUS Study).自治体が保有している,予防接種台帳と医療レセプトデータを個人単位でリンケージしたデータベースである.さらに,当該データベースを用いた有効性と安全性の科学的検証も始まっている.本稿では,ワクチンデータベースの開発と実践を行ってきたVENUS Studyにおける取り組みについて紹介する.また,ワクチンテータベースの今後の展望について述べる.(著者抄録)

  • 今月のTopic 市販後安全対策 承認後ワクチンの有効性・安全性評価のためのデータベース構築と活用 VENUS Study

    石黒 智恵子, 福田 治久

    医薬品医療機器レギュラトリーサイエンス   53 ( 6 )   507 - 510   2022.12   ISSN:1884-6076

     More details

    Language:Japanese   Publisher:(一財)医薬品医療機器レギュラトリーサイエンス財団  

  • 保健・医療・介護データの統合解析の現状と課題について

    福田治久

    2020.12

     More details

    Language:Japanese  

  • 感染対策に活用できる費用対効果

    福田治久

    2019.5

     More details

    Language:Japanese  

  • 血液・体液暴露に関する経済的視点

    細見由美子, 福田治久

    2019.3

     More details

    Language:Japanese  

  • 医療関連感染と医療経済

    福田治久.

    2018.10

     More details

    Language:Japanese  

  • SHOULD THE GOVERNMENT INTERVENE IN THE IMPLEMENTATION ON SAFETY-ENGINEERED DEVICES? EVIDENCE FROM A COST-EFFECTIVENESS ANALYSIS OF NEEDLESTICK INJURIES

    H. Fukuda, K. Moriwaki

    VALUE IN HEALTH   2016.5

     More details

    Language:English  

    DOI: 10.1016/j.jval.2016.03.722

  • 感染対策の弱点克服! レベルアップのための特別講義(第28回)感染予防活動の成果を示そう! 知っておきたい医療経済評価(2)医療経済評価をやってみよう!

    福田 治久

    2015.10

     More details

    Language:Japanese  

  • 感染対策の弱点克服! レベルアップのための特別講義(第27回)感染予防活動の成果を示そう! 知っておきたい医療経済評価(1)医療経済評価ってどういうもの?

    福田 治久

    2015.9

     More details

    Language:Japanese  

  • PROPOSAL OF ECONOMIC EVALUATION GUIDELINE IN JAPAN

    T. Fukuda, M. Akazawa, H. Fukuda, A. Igarashi, S. Ikeda, H. Ishida, M. Kobayashi, K. Moriwaki, S. Noto, H. Sakamaki, S. Saito, K. Shimozuma, T. Shiroiwa, T. Takura, N. Tomita

    VALUE IN HEALTH   2013.11

     More details

    Language:English  

    DOI: 10.1016/j.jval.2013.08.1772

  • 日本版医療技術評価(HTA)のための有効性・経済性データの利用可能性

    福田 治久

    医療経済研究機構レター   2013.4

     More details

    Language:Japanese  

  • 医療材料等に係る保険償還価格設定のための医療経済学的評価の在り方に関する研究

    福田 治久

    平成24年度医療経済研究機構自主研究事業報告書   2013.3

     More details

    Language:Others  

  • 日本版医療経済評価ガイドラインの開発:日本版医療技術評価(HTA)のための有効性・経済性データの整備

    福田 治久

    平成24年度医療経済研究機構自主研究事業報告書   2013.3

     More details

    Language:Others  

  • 病院・診療所の機能分化:医療経済学的アプローチからの問題認識と対応策

    福田 治久

    月刊保険診療   2012.12

     More details

    Language:Japanese  

  • THE ROLE OF PHARMACIST FOR PATIENT SAFETY: A NATIONWIDE SURVEY ON PATIENT SAFETY MANAGEMENT SYSTEM

    M. Hirose, H. Fukuda, Y. Imanaka, Y. Tsuda, K. Egami, J. Honda, H. Shima

    VALUE IN HEALTH   2012.6

     More details

    Language:English  

  • トータルの医療費に及ぼす地域連携パス作成の影響評価に関する実証的調査研究

    福田治久, 清水沙友里

    平成23年度医療経済研究機構自主研究事業報告書   2012.3

     More details

    Language:Japanese  

  • 医療関連感染に関する経済評価研究: 感染制御活動の経済的価値の呈示に向けて.

    福田 治久

    週刊社会保障   2011.6

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 医療関連感染による追加的医療費

    福田 治久

    医療経済研究機構レター   2011.6

     More details

    Language:Others  

  • アドバース・イベントによる追加的医療費の推計:医療関連感染による追加的医療費に関するSystematic Review.

    福田治久

    平成22年度医療経済研究機構自主研究事業報告書   2011.3

     More details

    Language:Others  

  • エビデンスに基づいた医療安全方策の検証に向けて

    福田 治久

    医療経済研究機構レター   2010.4

     More details

    Language:Japanese  

  • 医療安全を向上させるための組織・システムに関する調査研究.

    福田治久

    平成21年度医療経済研究機構自主研究事業報告書   2010.3

     More details

    Language:Others  

  • Economic evaluations of maintaining patient safety systems in teaching hospitals (vol 88, pg 381, 2008)

    Haruhisa Fukuda, Yuichi Imanaka, Masahiro Hirose, Kenshi Hayashida

    HEALTH POLICY   2009.9

     More details

    Language:English  

    DOI: 10.1016/j.healthpol.2009.03.001

  • Factors associated with system-level activities for patient safety and infection control (vol 89, pg 26, 2009)

    Haruhisa Fukuda, Yuichi Imanaka, Masahiro Hirose, Kenshi Hayashida

    HEALTH POLICY   2009.9

     More details

    Language:English  

    DOI: 10.1016/j.healthpol.2009.03.002

  • 乳房温存術後放射線治療の診療パターン : 外来および入院医療に関する多施設横断研究

    福田 治久, 大隈 和英, 今中 雄一

    日本医療・病院管理学会誌 = Journal of the Japan Society for Healthcare administration   2008.10

     More details

    Language:Japanese  

  • Change in the use of breast conserving surgery before and after guideline publication in Japan

    H. Fukuda, Y. Imanaka, T. Ishizaki

    VALUE IN HEALTH   2008.5

     More details

    Language:English  

  • Evaluation of the impact of patient safety activities on the number of voluntary incident reports at teaching hospitals in Japan

    H. Fukuda, Y. Imanaka, M. Hirose, K. Hayashida

    VALUE IN HEALTH   2008.5

     More details

    Language:English  

  • 病院感染対策専従者の配置が対策活動の普及に与えるインパクトの推定

    福田治久, 今中雄一, 廣瀬昌博, 林田賢史

    環境感染   2008.1

     More details

    Language:Japanese  

  • 安全管理および感染制御に要するコスト:全国大規模研究

    今中雄一, 福田治久, 廣瀬昌博, 林田賢史

    病院管理   2007.9

     More details

    Language:Japanese  

  • 安全管理活動の投入資源に関連する施設要因の検証

    福田 治久, 今中 雄一, 廣瀬 昌博, 林田 賢史

    病院管理   2007.9

     More details

    Language:Japanese  

  • 説明と同意および記録作成に要するコストの推計 患者本位の医療の基盤整備に向けて

    福田 治久, 小伏 寛枝, 村上 玄樹, 林田 賢史, 今中 雄一

    医療の質・安全学会誌   2006.11

     More details

    Language:Japanese  

  • 救急現場のコスト問題を考える: 感染制御とコスト.

    福田 治久, 今中 雄一

    2006.9

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 医療安全(安全管理・感染制御)対策に係るコスト把握のためのフレームワークの構築

    今中 雄一, 福田 治久, 林田 賢史

    病院管理   2006.8

     More details

    Language:Japanese  

  • 医療安全(安全管理・感染制御)対策に係るコスト分析:多施設横断研究

    福田治久, 林田賢史, 今中雄一

    病院管理   2006.8

     More details

    Language:Japanese  

  • 感染制御の経済: 感染のコストと予防への投資.

    福田 治久, 今中 雄一

    臨床検査   2005.6

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • 感染制御活動の経済性の評価.

    福田 治久, 今中 雄一

    感染制御   2005.3

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

▼display all

Professional Memberships

  • 日本ワクチン学会

    2021.4 - Present

      More details

  • Japanese Society of Environmental Infections

  • Japan Health Economics Association

  • Japan Society for Healthcare Administration

  • Japan Society of Public Health

  • Japan Epidemiological Association

  • 医療経済学会

  • JAPANESE SOCIETY OF PUBLIC HEALTH

  • 日本医療・病院管理学会

  • 日本環境感染学会

  • 日本疫学会

      More details

  • 日本環境感染学会

      More details

  • 日本医療・病院管理学会

      More details

  • JAPANESE SOCIETY OF PUBLIC HEALTH

      More details

  • 医療経済学会

      More details

▼display all

Committee Memberships

  • 一般社団法人日本疫学会   学術委員会 疫学研究推進ワーキンググループ  

    2024.2 - 2026.1   

      More details

    Committee type:Academic society

    researchmap

  • 福岡市病院事業運営審議会 運営・施設部会   委員  

    2023.9 - Present   

      More details

  • 厚生労働省 新たな地域医療構想の在り方に関する検討会   構成員  

    2023.4 - 2024.3   

      More details

    Committee type:Government

    researchmap

  • 九州大学未来社会デザイン統括本部 医療・健康ユニット 社会変革型データサイエンスグループ   構成員  

    2022.10 - Present   

      More details

    Committee type:Other

    researchmap

  • Councilor   Domestic

    2018.1 - 2019.12   

  • 地方独立行政法人福岡市立病院機構評価委員会 副委員長  

    2017.4 - Present   

      More details

    Committee type:Municipal

    researchmap

  • Councilor   Domestic

    2014.2 - Present   

  • Executive   Domestic

    2013.4 - Present   

  • 医療福祉経営マーケティング研究会   副理事長   Domestic

    2013.4 - Present   

▼display all

Academic Activities

  • 日本医療・病院管理学会誌

    Role(s): Review, evaluation

    編集委員  2024.6 - Present

     More details

  • Asian Pacific Journal of Health Economics and Policy

    Role(s): Review, evaluation

    編集委員  2024.4 - Present

     More details

  • 医療経済研究

    Role(s): Review, evaluation

    編集委員  2024.4 - Present

     More details

  • Plos One

    Role(s): Review, evaluation

    Editor  2023.4 - Present

     More details

  • Plos One International contribution

    2023.4 - 2024.3

     More details

    Type:Academic society, research group, etc. 

  • Journal of Alzheimer's Disease International contribution

    2022.4 - 2024.3

     More details

    Type:Academic society, research group, etc. 

  • 科学研究費委員会専門委員

    Role(s): Review, evaluation

    独立行政法人日本学術振興会  2019.12 - 2020.11

     More details

    Type:Scientific advice/Review 

  • 科学研究費委員会専門委員

    Role(s): Review, evaluation

    独立行政法人日本学術振興会  2018.12 - 2019.11

     More details

    Type:Scientific advice/Review 

  • 座長(Chairmanship)

    第31回日本環境感染学会総会  ( 京都 ) 2016.2

     More details

    Type:Competition, symposium, etc. 

  • 科学研究費委員会専門委員

    Role(s): Review, evaluation

    独立行政法人日本学術振興会  2014.12 - 2016.11

     More details

    Type:Scientific advice/Review 

  • 司会(Moderator)

    第29回日本環境感染学会総会  ( 品川(国際館パミール、グランドプリンスホテル新高輪、グランドプリンスホテル高輪) ) 2014.2

     More details

    Type:Competition, symposium, etc. 

  • 日本環境感染学会雑誌

    2013.4 - 2017.3

     More details

    Type:Academic society, research group, etc. 

▼display all

Research Projects

  • リアルワールドデータ駆動型ドラッグ・リポジショニング創薬の基盤開発

    Grant number:24K21306  2024.6 - 2027.3

    科学研究費助成事業  挑戦的研究(開拓)

    福田 治久, 石黒 智恵子, 野間 久史, 上村 夕香理, 西田 基宏

      More details

    Grant type:Scientific research funding

    近年,医薬品開発は困難を極めており,データ駆動型のドラッグ・リポジショニング(DR)創薬が注目されている.しかし,基礎研究データに基づくDR創薬は臨床試験の成功確率に課題がある.本研究は,臨床現場の医薬品使用データや副作用発現状況などの診療報酬明細書データ(レセプトデータ)を用いた新たなデータベース駆動型DR創薬の基盤を開発することを目的としている.多様で複雑なレセプトデータを用い,最新の機械学習,薬剤疫学,因果推論手法を駆使することで,画期的な創薬アプローチを実現し,DR創薬研究者の増加や日本のリード,RWDでの薬事承認申請の可能性を切り拓く.

    CiNii Research

  • ビックデータを活用した降圧薬服薬アドヒアランスのエビデンス構築と保健指導への展開

    Grant number:24K14194  2024.4 - 2027.3

    科学研究費助成事業  基盤研究(C)

    後藤 健一, 福田 治久

      More details

    Grant type:Scientific research funding

    高血圧は脳心血管病の最大の危険因子であり、健康寿命の短縮を引き起こす。わが国における高血圧患者の管理状況は良好とはいえず、降圧薬服薬アドヒアランス不良が一因となっている。本研究では保健医療ビッグデータを活用し、わが国の高血圧患者の降圧薬服薬アドヒアランスの実態、降圧薬服薬アドヒアランス不良に関与する因子の解明、服薬アドヒアランスと脳心血管病発症リスクとの関連を分析し、日本人高血圧患者における降圧薬服薬アドヒアランスに関する質の高いエビデンスの創出を目指す。本研究の成果を保健指導に活用することで血圧管理不良者を減少させ、脳心血管病発症予防による健康寿命の延伸、および医療費の削減につなげたい。

    CiNii Research

  • 大規模公的医療・介護データを用いた死亡前受療行動の分析とACP普及に向けた提言作成

    Grant number:24K13505  2024.4 - 2027.3

    科学研究費助成事業  基盤研究(C)

    平山 敦士, 福田 治久, 川崎 良

      More details

    Grant type:Scientific research funding

    人口構造を反映し多死社会が到来した我が国において、Advanced Care Planning(ACP)の普及は満足度の高い人生の最終段階を迎えるために重要であるが、実際のACP実施率は40%にとどまっている。本研究ではACPの普及のきっかけとして、終末期の受療行動に注目し、まず大規模データベースを用いて死亡前の救急受診や入院、その他の受療行動を記述し、併存症・介護度・社会的特性などから関連因子を明らかにし、その示唆に基づき質的研究手法も取り入れた検証を行い、緩和ケア専門医や医療政策立案者らとの意見交換通じてACP普及・実装のためのガイドラインに資する提言を発出することを目的とする

    CiNii Research

  • 大規模リアルワールドデータに基づく降圧薬処方推移の時系列パターン分類

    Grant number:24K09914  2024.4 - 2027.3

    科学研究費助成事業  基盤研究(C)

    平田 明恵, 福田 治久, 中島 直樹

      More details

    Grant type:Scientific research funding

    本邦において患者数が多い高血圧症の診療RWDにデータマイニングと機械学習の手法を適用し、降圧薬選択・処方の時系列的パターンを分類する。一時点の特徴よりも情報が豊富な、時系列的特性に基づく集団の分類に取り組む。患者によって観察期間の長さと処方時点数が異なる一塊の処方時系列どうしの類似度を数値化し、類似度に基づき時系列をクラスタリングすることで、特異的な患者背景と関連する処方時系列パターンを分類できるかを検討する。高血圧症集団を処方時系列に表現される臨床背景に基づき分類することで、多様な臨床研究において高血圧症のバイアスをより精度高く制御できる可能性がある。

    CiNii Research

  • ビックデータを活用した降圧薬服薬アドヒアランスのエビデンス構築と保健指導への展開

    2024 - 2026

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 妊娠期から学童期を紡ぐ保健・医療統合データベース基盤開発とエビデンス創出

    Grant number:24H00659  2024 - 2026

    日本学術振興会  科学研究費助成事業  基盤研究(A)

    福田 治久, 竹内 研時, 石黒 智恵子, 上田 瑛美, 小川 浩平, 小野 玲, 上村 夕香理, 森崎 菜穂

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    本研究は,本邦の妊婦・乳幼児・学童に対して存在する”Unmet Data Needs”を解消するための保健・医療データベースを開発する.さらに,データベースを利活用することのベネフィットを社会に提示するための具体的なエビデンスを創出することを目指すものである.
    そのために,研究代表者が構築しているLIFE Studyのデータベース基盤を発展させて,新たに,母子健診,予防接種台帳,学校健診,死亡届などを個人単位で統合可能なデータベースを開発する.このデータベースを用いて,我が国のパブリック・ヘルスを支えるためのエビデンスを創出する.

    CiNii Research

  • 大規模公的医療・介護データを用いた死亡前受療行動の分析とACP普及に向けた提言作成

    2024 - 2026

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 大規模リアルワールドデータに基づく降圧薬処方推移の時系列パターン分類

    2024 - 2026

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 国内データベース基盤を用いた各種ワクチンの有効性・安全性・経済性の評価方法の検討

    2024 - 2026

    科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 自治体基盤データベースを活用したワクチンの有効性・安全性・経済性のエビデンス創出研究

    Grant number:24fk0108709  2024 - 2026

    科学研究費助成事業  AMED:新興・再興感染症に対する革新的医薬品等開発推進研究事業

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 大規模データベースを活用した承認後ワクチンの安全性評価手法に関する疫学・生物統計学的検討

    2024 - 2026

    科学研究費助成事業  AMED:医薬品等規制調和・評価研究事業

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • リアルワールドデータに基づく口腔の健康と健康関連QOLや労働生産性との関連に関する研究

    2024 - 2025

    科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 公衆衛生の向上・増進におけるデータ活用促進の要件検討

    2023.6 - 2024.3

    共同研究

      More details

    Authorship:Principal investigator  Grant type:Other funds from industry-academia collaboration

  • Comprehensive evaluation of disease burden due to influenza-like illnesses

    Grant number:23K27865  2023.4 - 2026.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • インフルエンザ様疾患による疾病負荷の包括的評価

    Grant number:23H03175  2023 - 2025

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 保健医療データベース利用による行動変容に向けたフィードバック手法の開発

    Grant number:24ek0210191  2023 - 2025

    科学研究費助成事業  AMED:循環器疾患・糖尿病等生活習慣病対策実用化研究開発事業

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 大規模コホートとリアルワールドデータを用いた口腔と全身疾患の関連についての研究

    2023 - 2024

    科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 公衆衛生の向上・増進におけるデータ活用促進の要件検討

    2022.6 - 2023.3

    共同研究

      More details

    Authorship:Principal investigator  Grant type:Other funds from industry-academia collaboration

  • Exploring evidence on the relationship between oral health, healthy life expectancy, and medical and long-term care cost reduction by utilizing big data

    Grant number:23K24557  2022.4 - 2027.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • 起立・歩行動作解析を基軸とした要介護リスク診断プラットフォームの創出

    Grant number:23K24707  2022.4 - 2026.3

    科学研究費助成事業  基盤研究(B)

    藤本 雅大, 小林 吉之, 工藤 将馬, 佐保 賢志, 長野 明紀, 福田 治久, 上村 一貴

      More details

    Grant type:Scientific research funding

    椅子からの起立や歩行に代表される日常生活動作の特徴から要介護の主要因となる転倒・認知症のリスクが推定できることから,これら動作の詳細な解析が要介護リスク因子の早期発見に効果的と考えられる.そこで本研究では,臨床や健診の現場で活用可能な小型の簡易センサを用いた遠隔計測を基軸とした動作特徴の推定手法の開発と,それを活用した要介護リスク診断プラットフォームの構築を目的とする.本研究成果の社会実装により,要介護リスクの早期発見と介入を促進する社会基盤の構築を目指す.

    CiNii Research

  • ビッグデータ活用による健康寿命延伸と医療・介護費抑制に資する口腔のエビデンス創出

    Grant number:22H03299  2022 - 2026

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 起立・歩行動作解析を基軸とした要介護リスク診断プラットフォームの創出

    Grant number:22H03449  2022 - 2025

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 地域在住高齢がんサバイバーコホートの構築:健康寿命延伸に向けて

    Grant number:22K11287  2022 - 2024

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    小野 玲, 福田 治久, 古和 久朋, 秋末 敏宏

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

    高齢社会である本邦において、悪性新生物の新規罹患の7割は65歳以上の高齢者である。高齢がん患者の増加に伴う問題点の1つに、高齢がんサバイバーの退院後における健康寿命短縮の可能性が考えられる。しかし、国内外において高齢がんサバイバーの健康寿短縮とそのプロセスについては十分に検討されておらず、高齢がんサバイバーは対策されないまま地域で日常生活を営んでいる。
    本研究の目的は、地域在住高齢がんサバイバーのコホートを構築することにより、①高齢がんサバイバーの生活習慣の現状を明らかにしてがんに罹患していない高齢者と比較し、②高齢がんサバイバーのリハビリテーションニーズを患者の立場から明らかにすることである。

    CiNii Research

  • 高血圧発症予防に向けた先制保健介入モデルの開発

    Grant number:23ek0210174  2022 - 2024

    科学研究費助成事業  AMED(循環器疾患・糖尿病等生活習慣病対策実用化研究開発事業)

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 新型コロナウイルス感染に起因すると考えられる精神症状に関する疫学的検討と支援策の検討に資する研究

    2022 - 2024

    科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 新型コロナウイルス感染症罹患後に精神症状が出現した者に関する実態調査

    2022

    科学研究費助成事業  障害者総合福祉推進事業費補助金

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • LIFE Study(100自治体・20年間のコホート研究)による医療・介護・予防データのデータベース化と活用

    2021.4 - 2026.3

    受託研究

      More details

    Authorship:Principal investigator  Grant type:Other funds from industry-academia collaboration

  • 指定難病と医療介護データの統合による経時的解析可能な難病データベース基盤の開発

    Grant number:23K21502  2021.4 - 2026.3

    科学研究費助成事業  基盤研究(B)

    佐藤 大介, 福田 治久, 桑木 光太郎, 野田 龍也, 沼沢 祥行

      More details

    Grant type:Scientific research funding

    本研究の主要な目的は、難病患者の治療経過を辿る様々な公的データベースを用いて、制度や臨
    床的理由から複雑に格納されているデータ構造を紐解き、エビデンスを創出することにある。
    ①小児から成人へ移行する場合の疾病定義の変更や、重症度によって格納されるデータベースが異なっても追跡可能なデータベース連結手法を開発し、臨床研究に活用できるデータ分析処理プロセスを標準化する。
    ②上記データベースを用いて、専門医の臨床疑問に基づく臨床疫学、医療経済学に関する研究を行う。
    本研究成果を通じて指定難病に係る治療や負担に苦しむ患者に対し、より効果的で安全な治療に
    活かすエビデンスを創出するデータベース研究を発展させる

    CiNii Research

  • Data-driven high-performance medicine for stroke

    Grant number:23K21506  2021.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • 健康データ創発的多地域コホート研究基盤の構築

    2021 - 2027

    科学研究費助成事業  JST(創発的研究支援事業)

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 指定難病と医療介護データの統合による経時的解析可能な難病データベース基盤の開発

    Grant number:21H03158  2021 - 2025

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 脳卒中疾病負荷軽減のためのデータ駆動型最適化医療の構築

    Grant number:21H03165  2021 - 2024

    日本学術振興会  科学研究費助成事業  基盤研究(B)

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

  • 保健・医療・介護・行政データを統合した大規模データベースを活用したワクチンの有効性・安全性の検証に資する研究開発

    Grant number:21nf0101635  2021 - 2023

    科学研究費助成事業  AMED(ワクチン開発推進事業)

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • リアルワールドデータを活用した新型コロナワクチンの安全性評価研究およびワクチンの有用性・安全性評価のためのモニタリングシステム開発の検討

    2021 - 2023

    国立国際医療研究センター:国際医療研究開発事業

      More details

    Authorship:Coinvestigator(s)  Grant type:Contract research

  • レセプトデータを基軸としたデータ駆動型臨床疫学研究の基盤開発

    Grant number:20H00563  2020 - 2023

    日本学術振興会  科学研究費助成事業  基盤研究(A)

    福田 治久, 能登 真一, 東 尚弘, 石黒 智恵子, 北村 哲久, 戸高 浩司, 小野 玲, 中島 直樹, 船越 公太, 土井 剛彦, 鴨打 正浩, 後藤 温, 井手 友美, 熊谷 成将

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    本研究の目的は,臨床的・政策的に真に貢献可能なエビデンスを創出できるデータ駆動型臨床疫学研究の基盤を構築することである.そのために,研究代表者が自治体と共同研究をしているLongevity Improvement & Fair Evidence Study(LIFE Study)において収集しているレセプトデータを基軸に,行政・学会・医療施設が保有する詳細な患者レジストリデータをリンケージしたデータベースを開発する.それにより各DBが相補的・相乗的な効果を発揮し,かつてない規模の臨床疫学研究が実施可能になり,将来の国家的データベース事業へ昇華させるためのモデルケースを確立する.

    CiNii Research

  • ICTプラットホーム構築による介護予防サービスの実証フィールドの開発研究

    Grant number:21dk0110041  2020 - 2022

    科学研究費助成事業  AMED(長寿科学研究開発事業)

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 脳卒中・循環器病の次世代医療研究基盤の構築に関する研究

    2020 - 2022

    国立循環器病研究センター:循環器病研究開発費

      More details

    Authorship:Coinvestigator(s)  Grant type:Contract research

  • 肺炎球菌感染症の疾病負担の推定

    2019.11 - 2021.6

    受託研究

      More details

    Authorship:Principal investigator  Grant type:Other funds from industry-academia collaboration

  • 住民の健康改善に資するエビデンス創出を目指した多地域コホート研究:LIFE Study

    2019.4 - 2031.12

    九州大学 

      More details

    Authorship:Principal investigator 

    本プロジェクトは,自治体が保有する保健・医療・介護・行政等の健康関連データを住民単位で統合したデータベース(LIFE DB)を構築し,今後20年間に渡り追跡評価することで,ライフコース健康学を創出するものである.健康の関連要因・健康の波及効果の解明,データサイエンスに立脚したEvidence-Based Health Policyの変革,ヘルスケア産業における開発プロセス革新などを通じて,健康寿命延伸と健康格差解消に向けた創発的研究成果を産出することをめざす.

  • Development of a Health Evaluation Platform for Local Residents and Verification of the Effectiveness of Preventive Healthcare and Long-term Care Services

    Grant number:19K21590  2019 - 2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Challenging Research(Exploratory)

    Fukuda Haruhisa

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    This study developed a platform capable of linking, at the individual resident level, various types of data owned by local governments, such as healthcare claims data, long-term care claims data, health examination data, and lists of implementers of preventive healthcare and long-term care services. As a result, we were able to construct a database of approximately 2 trillion records covering 7 years for 2.5 million people across 27 municipalities. Given that the data held by the m